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ABSTRACT 
 
Nucleic acid aptamers are a group of molecules which emerge from large random sequence pools 
through in vitro selection, a process called Systematic Evolution of Ligands by EXponential 
enrichment (SELEX). These recognition molecules are a potential alternative to antibodies and 
offer a greater thermal stability, robustness and chemical versatility. The first part of this thesis 
describes the selection of an aptamer against acetylcholinesterase (AChE) using conventional in 
vitro selection process. The pool enrichment was observed during 15 rounds of selection and a 
chosen aptamer, R15/19, was characterized. The R15/19 binds with dissociation constant of 
55±8pM but does not inhibit the enzyme. This aptamer can be used as a part of immobilization 
mediator. However, this manual in vitro selection procedure is time consuming as it needs 
multiple rounds of selection. Therefore, a novel aptamer selection method has been developed 
that is aimed at shortening selection times. Taking an advantage of multiple interactions, it is 
possible to generate a single sequence that contains two binding sites through a single selection 
process. The approach is adopted from proximity dependent DNA ligation assay (PLA) and called 
‘proximity ligation selection’ (PLS). Instead of using one random pool for selection, with PLS, we 
use two. These two starting pools were designed to contain different additional sequences, apart 
from the primer and random regions, at either the 5’ or the 3’ end. The basis of this method is 
only in the presence of target protein molecules, is there a close proximity of pairs of bound 
sequences. And only if those pairs are in an appropriate orientation in which the 3’ hydroxyl 
terminal of one sequence is sufficiently close to the 5’-phosphate terminal of the other sequence, 
are the extended free ends of each member of the proximity oligonucleotide pairs were brought 
closely by base-pairing to subsequently added connector oligonucleotide. The hybridized 
complexes are then joined using a DNA ligase, allowing the formation of a ligated product that 
contains a dual binding site on the target. Thrombin and lysozyme were used as model targets. 
For thrombin, none of the PLS products showed a G-quadruplex signature in CD spectroscopy. 
Using the SPR, the Kd of the aptamer dimer 2/19-5 (from F and R pool) and 4/19-7 (from 
TBA29plus and R pool) are 1.6M and 1.2M, respectively. The ELONA test was used to measure 
a Kd for each monomer and there was no binding observed from each monomer of the aptamer 
against thrombin. In the case of lysozyme, the SPR and ELONA revealed the Kd of the aptamer 
dimer (from two starting pools) of 8.7M and 9nM, respectively. The Kd of each constitute of anti-
lysozyme aptamer dimer using ELONA showed the Kd of 35.5 and 51.5nM. The Kd obtained from 
SPR was high, suggesting a low binding affinity. We assume that the aptamer molecule can freely 
fold into a favored structure once it meets the target and thus can perform binding better than in 
the SPR. Although we did not succeed in generating aptamer dimers that had higher affinity than 
monomers, there are several steps in the procedure that need to be further improved. 
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the images resulted from the biotin modification in one strand. ……………………………………………………. 
 
 
 
 
 
108 
Figure 3.5 Optimum conditions for AChE adsorption. Different concentrations of AChE diluted 
in 10mM sodium acetate pH 5.2 or 10mM PBS pH 7.4 were immobilized on microtiter plates. The 
activity was tested using the Ellman assay. In PBS pH 7.4, 10nM AChE showed the highest activity. 
This adsorption condition was subsequently used in ELONA assay……………………………………………….. 
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Figure 3.6 Enrichment of anti-AChE aptamers.  Pool affinity enrichment was performed using 
the ELONA assay. The 96-well plate was coated with 10nM AChE and incubated with 20nM ssDNA 
pools from round 3, 5, 7, 9, 12, 15 and unselected DNA pool. The binding signal was measured at 
absorbance 450nm from the reaction of HRP and TMB. The assay for AChE-aptamer binding was 
performed in triplicate and duplicate for BSA……………………………………………………………………………….. 
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Figure 3.7 Sequence of anti-AChE aptamers from round 15. Only random regions were aligned. 
A highly conserved sequenced emerged. The two dominant sequences R15/19 and R15/22, were 
found in 44% and 9%, respectively, of chosen clones……………………………………………………………………. 
 
 
115 
Figure 3.8 Supermotif alignment and Logos for selected aptamer pool from round 15. Five 
local supermotifs that show high similarity are shown here. The sequences in supermotif 3 and 4 
are also found as a part in the supermotif 1. The highlighted sequences (R15/19 and R15/22) were 
chosen for further characterization……………………………………………………………………………………………….. 
 
 
 
116 
Figure 3.9 Possible secondary structures of the R15/19, predicted using Mfold. Two possible 
conformations of the R15/19 are shown to have very similar structures. They are difference in the 
ring size and the shift in a position of the second stem loop near the 5’ end. Less structure variation 
suggests a unique fold with a good stability at the folded state……………………………………………………….. 
 
 
 
119 
Figure 3.10 The predicted secondary structure of R15/22. Four possible secondary structures 
of the R15/22 are shown to have free energy from -3 to -2kcal.mol-1. Diverse secondary structure 
may imply less stable structures…………………………………………………………………………………………………… 
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Figure 3.11 Binding curve for the round 15 DNA pool. Following the 15 rounds of selection, 
various concentrations of R15 pool and starting pool were incubated with AChE coated on 
microtiter plate. Fitting the data to a Langmuir isotherm resulted in a Kd of 0.21nM and 0.26nM 
from two independent experiments for the affinity of R15 pool aptamer for the AChE. The binding 
signal from unselected pool shows no significant increase. Each data point was assayed in 
triplicate………………………………………………………………………………………………………………………………………. 
 
 
 
 
 
122 
Figure 3.12 Dissociation constant of chosen aptamers, R15/19 and R15/22 from Round 15. 
(a) Two sequences were chosen for binding affinity assay based on the enrichment found. (b) 
Various concentrations of each aptamer (0-10nM) were incubated with AChE coated on microtiter 
plate. The Kd of the R15/19, fitting the data to a Langmuir isotherm, was calculated to be 49pM and 
60pM from two independent experiment. No binding affinity was observed for R15/22. Each data 
point was assayed in triplicate………………………………………………………………………………………………………. 
 
 
 
 
 
123 
Figure 3.13 The model represents the effect of protein orientation once adsorption onto a 
solid support to the binding efficiency and signal intensity in an ELONA assay. Due to the 
multiple binding site of target, aptamer pool can bind to different sites on the molecule. In contrast 
the individual sequence specifically binds to only single site on the target. This specific binding 
would lead to the reduction of signal intensity which partly depends on the interaction between 
aptamer and protein…………………………………………………………………………………………………………………….. 
 
 
 
 
 
124 
Figure 3.14 Initial rate velocity of AChE at different concentrations. The reaction mixture 
contained 1mM of ATCh, 2.5mM of DTNB in selection buffer (1 PBS supplemented with 1mM 
MgCl2). The hydrolysis started by adding AChE solution. The formation of yellow color product of 
the thiolate dianion of DTNB was immediately monitored at room temperature at absorbance 
412nm…………………………………………………………………………………………………………………………………………. 
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Figure 3.15 Relative activity of AChE in the presence of aptamer pool from different round 
(a) and R15/19 aptamer (b). Fixed amount of aptamer pool was incubated with AChE solution 
and the AChE activity was assayed by followed its initial velocity using Ellman’s colorimetric 
method. The difference of activity of AChE incubating with each pool or R15/19 was considered to 
be not significant…………………………………………………………………………………………………………………………. 
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Figure 3.16 A diagram shows the experimental strategy for assaying the effect of 
immobilization method and the degree of enzyme loading capacity. AChE was immobilized by 
two methods (1) affinity capture by aptamer and (2) physical adsorption. Blocking and washing 
step were applied as in ELONA method. AChE activity was assayed by followed ATCh hydrolyzed 
rate using Ellman’s reagent. The measurement was performed at A412……………………………………………. 
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Figure 3.17 R15/19 as a capture molecule for AChE. Two different formats of enzyme captured 
to PS were tested including the affinity capture by immobilized aptamer and the adsorption of 
AChE to PS surface. The AChE was retained on PS surface at a limited amount comparing to AChE 
that captured by aptamer R15/19 at the same concentration (5-20nM). Further increase in AChE 
concentration to 50nM, the curve started to saturate. This suggested the higher efficiency of 
aptamer capture than direct protein adsorption. Each data point was assayed in triplicate……………... 
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Figure 4.1 The X-ray crystallographic of thrombin (Protein Data Bank ID 1HUT) a) Thrombin 
catalytic triad contains Ser, His and Asp residues (in red side chains). Two significant binding sites 
related to aptamer interactions are shown; on the right of the figure for fibrinogen whilst amino 
acids involved in heparin binding are shown on the left. This image is created using Weblab 
ViewerLite program; b) Thrombin possesses charged residues that are not evenly distributed over 
the whole molecule. The coulombic surface of thrombin created using Chimera. The negatively 
charged residues (in red) are clustered around the active site. Two positive patches of fibrinogen 
and heparin binding exosites, indicated by arrows, are shown in blue (Bode et al., 1992; 
Padmanabhan et al., 1993)..………………………………………………………………………………………………………….. 
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Figure 4.2 Structure of the anti-thrombin aptamer (TBA15) and the binding of TBA15 with 
thrombin at fibrinogen binding exosite (PDB ID: 1HUT). a) Tertiary structure of 15-mer TBA is 
shown in a stick model; b) The stacking of the two quartets, Q1 (G1-G6-G10-G15) and Q2 (G2-G5-G11-
G14). The G8 of the TGT loop stacks with the Q1-quartet while T4 and T13 tend to form TT base pair 
and are part of base stacking; c) The interaction of TBA15 with thrombin at fibrinogen binding 
exosite (Padmanabhan et al., 1993). The image created using WebLab ViewerLite program.…………… 
 
 
 
 
 
137 
Figure 4.3 The principle of proximity ligation assay. a) In the presence of target molecule, 
aptamer probe pairs bind two epitopes of the same target molecule which would then bring the 
free ends of aptamers into close proximity orientation. Target quantification is accomplished 
through the rising of measurable signals of ligated DNA sequences from PCR amplification; b) 
Probes that fail to bind target molecules or in the absence of target molecules would hybridize with 
the excess amount of oligonucleotide connector, which would further block ligation and 
amplification………………………………………………………………………………………………………………………………… 
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Figure 4.4 Diagram of aptamer-based proximity probe pairs bound to its homodimer PDGF-
BB target.  The sequence in black is the aptamer specific for the PDGF B-chain. The sequence 
extensions from either the 3’ or the 5’ direction of aptamer are primer regions for PCR 
amplification (shown in red) and the hybridization region (shown in grey) to the connector 
oligonucleotides (shown in green) which would help to facilitate the ligation of two sequences once 
align in a close proximity orientation. (The Figure was modified from Fredriksson et al.,2002 and 
PDGF-BB molecule was obtained from Protein Data Bank, ID 1PDG (Oefner et al., 1992))……………….. 
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Figure 4.5 Application of proximity ligation assay as a detection technique for wide variety of 
targets such as (a) bacterial spore (Pai, et al., 2005) and (b) cell membrane antigens (Pai and 
Ellington, 2009). …………………………………………………………………………………………………………………………. 
 
 
142 
Figure 4.6 The PLA for measuring proteins in nuclear extracts. Two probes, dsDNA and 
antibody that recognize the same protein at different binding site can be used in the PLA for 
measuring specific targets with high sensitivity and specificity even in the nuclear extracts. The 
modification of the probes with a ssDNA extension would facilitate the proximity ligation and 
subsequently generates signal through PCR amplification.……………………………………………………….. 
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Figure 4.7 Designed bivalent aptamer obtained by linking 15-mer TBA and 29-mer TBA. 
Linkers can be poly-dA (Müller et al., 2007), poly-dT (Hasegawa et al., 2008) or non-nucleotide 
linker such as spacer phosphoramidite (Kim et al., 2008).……………………………………………………………… 
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Figure 4.8 The equilibrium of binding reaction of thrombin binding aptamer. a) The 
equilibrium between free and complex state of 15mer TBA and thrombin. After dissociation, 15mer 
TBA diffuses into bulk solution instantly whereas (b) the binding equilibrium of bivalent ligands 
tends to shift to the left. When one of linked-aptamer leaves the binding pocket, the other still binds 
to its binding site so that the leaving one can make a quick return back to the binding site after 
dissociation (Adapted from Kim et al., 2008).………………………………………………………………………………… 
 
 
 
 
 
145 
Figure 4.9 A sample of a dual-function aptamer that can simultaneously bind and inhibit NS3 
protease and helicase activities of HCV. Two aptamers are conjugated via 50-mer poly U spacer. 
The G9-II aptamer binds specifically to the protease domain, whilst the #5Δ interacts with a cleft in 
the NS3 helicase domain. The secondary structure from the original publication was predicted 
using the Mulfold program (Umehara et al., 2005).  ……………………………………………………………………… 
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Figure 4.10 A schematic structure of anti-HCV IRES aptamer monomers and their 
conjugation. The aptamers 2-02 and 3-07 target against HCV IRES domain II and III-IV, 
respectively. These two aptamers inhibit IRES-dependent translation. The newly constructed 
aptamer by conjugating the two generates a more efficient inhibitory activity aptamer than that of 
the parental aptamers. The secondary structure from the original publication was predicted using 
the Mulfold program (Kikuchi et al., 2009).……………………………………………………………………………………. 
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Figure 4.11 The flowchart of the working principles of proximity ligation selection. In the 
presence of target, two aptamers would be able to bind simultaneously to their target. The aptamer 
pairs that are in an appropriate orientation and are close enough can be ligated. The ligation 
products are then separate from unbound sequences for further characterization.…………………………. 
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Figure 4.12 3% (w/v) Agarose gel electrophoresis image showing the PCR products of 
various cycles in the presence and absence of thrombin. PCR course of the product from 
proximity ligation selection a) F pool and R pool in the presence and absence of thrombin. The 
product size (marked by arrows) showed on agarose gel should be 142 bp of dimer ssDNA; b) The 
negative ‘no thrombin’ and positive experiment using TBA29plus and R pool. The PCR product size 
of the dimer (marked by arrows) should be 132 bp. Each lane represents different PCR cycles from 
5 to 35 cycles. The ladder (25 bp-500 bp) shows on the right hand side of each set of 
experiments.………………………………………………………………………………………………………………………………… 
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Figure 4.13 Random sequences analysis from the PLS products against thrombin. The 
selection was performed using TBA29plus and R pool. Only random region from R pool were 
aligned.………………………………………………………………………………………………………………………………………… 
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Figure 4.14 Logos of the PLS product from the TBA29plus and R pool set of experiment. Two 
local supermotifs are shown here. There is no other significant consensus among others.……………… 
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Figure 4.15 Proximity ligated sequences alignment. 18 sequences from PLS between F- and R 
pool selected against thrombin were analyzed in order to identify common sequence motif 
using ClustalW2 program. The random region of each connected monomers together with the 
constant region in the middle were aligned without the primer regions. The constant region in the 
middle, consisted of 26 nucleotides (ATTTGGGCTGCTCTCGTGGCGTAATA), is the region where 
ligation occurs by the aid of the oligonucleotide connector and the T4 DNA ligase. There is one 
repeated sequence from clone ID 2/19-10 and 2-19-18 but shows no other significant common 
motif.…………………………………………………………………………………………………………………………………………… 
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Figure 4.16 Logos of the PLS product from the F pool and R pool set of experiment. Three local 
supermotifs are shown here. The sequence ID 2/19-10 and 2/19-18 represent twice in the 
sequenced pool. The sequence ID 2/19-3 and 2/19-7 share a short consensus with those two 
repeated sequences.………………………………………………………………………………………………………….. 
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Figure 4.17 CD spectrum of 3M thrombin in thrombin binding buffer. Spectrum was recorded 
at 20°C from 320nm to 200nm. The CD spectrum in far UV region reveals the composition of -
sheet and -helix in thrombin molecule.……………………………………………………………………………………….. 
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Figure 4.18 CD spectrum of TBA15. a) The sequence of TBA15; b) 5M TBA15 in thrombin 
binding buffer was measured at 4°C and 20°C. The spectrum shows positive bands at 293nm and 
246nm and a negative band at 266nm; c) in the presence of different concentration of thrombin (0-
5M), TBA15 shows the same characteristic peaks as in the absence of thrombin........................................ 
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Figure 4.19 CD spectrum of TBA29. a) The sequence of TBA29; b) CD spectra of 5M of TBA29 in 
thrombin binding buffer measured at 4°C and 20°C; c) Titration of thrombin to 5M TBA29 shows 
positive bands at 260nm and 210nm. The dashed-green line in each graph represents the CD 
signature of TBA15 in thrombin binding buffer, which is measured at 20°C. The G-quadruplex 
structure of TBA15 is used as a standard for other samples. ................................................................................... 
 
 
 
 
166 
Figure 4.20 TBA29 in buffer containing 20mM Tris-acetate, 140mM NaCl, 1mM MgCl2, 1mM 
CaCl2 and different concentrations of KCl. The pattern of CD spectrum of TBA29 in the presence 
of 50mM KCl is measured at 20°C and it is similar to the spectrum performed at 4°C. The dashed-
green line represents a CD signature of G-quadruplex from the folding of TBA15 at 20°C. ………………. 
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Figure 4.21 CD spectrum of a mixture of 5M starting pool and 5M thrombin in thrombin 
binding buffer. a) The sequence of a starting pool. The pool is N40 pool, which contains 40 random 
nucleotides flanking by constants region at both the 5’ and the 3’ end; b) The spectrum reveals 
unstructured DNA molecules in solution. The dashed-green line represents a CD signature of G-
quadruplex from the folding of TBA15. The experiment is carried out at 20°C.……………………………… 
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Figure 4.22 CD spectra of TBA15plus in the presence and absence of thrombin. a) The 
sequence of TBA15plus; b) CD spectrum of the 5M of TBA15plus was diluted in thrombin binding 
buffer in the absence of thrombin. The experiment was performed at 4°C and 20°C; c) Titrating 
thrombin of various concentrations (0, 1, 3 and 5M) to 5M TBA15plus. The dashed-green line in 
each graph represents a CD signature of G-quadruplex from the folding of TBA15. The experiment is 
carried out at 20°C.…………………………………………………………………………………………………. 
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Figure 4.23 CD spectra of TBA29plus in the presence and absence of thrombin. a) The 
sequence of TBA29plus; b) 5M of TBA29plus was prepared in thrombin binding buffer. Without 
thrombin present, the CD spectrum was measured at 4°C and 20°C; c) Titrating thrombin of various 
concentrations (0, 1, 3 and 5M) to 5M TBA29plus. The dashed-green line in each graph 
represents a CD signature of G-quadruplex from the folding of TBA15. The experiment is carried 
out at 20°C.………………………………………………………………………………………………………………………………… 
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Figure 4.24 CD spectra of 2/19-5 monomer2 in the presence and absence of thrombin. a) The 
sequence of 2/19-5 monomer2 which is obtained from the PLS between F pool and R pool; b) CD 
spectrum of 5M of 2/19-5 monomer2 in thrombin binding buffer in the absence of thrombin, 
performing at 4°C and 20°C; c) Titrating thrombin of various concentrations (0, 1, 3 and 5M) to 
5M 2/19-5 monomer2. The dashed-green line in each graph represents a CD signature of G-
quadruplex from the folding of TBA15. The experiment is carried out at 20°C.……………………………… 
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Figure 4.25 CD spectra 4/19-7 monomer2 in the presence and absence of thrombin. a) The 
sequence of 4/19-7 monomer2. This sequence is obtained from the PLS between TBA29plus and R 
pool; b) CD of 5M of 4/19-7 monomer2 in the absence of thrombin, measured at 4°C and 20°C; c) 
Titrating thrombin of various concentrations (0, 1, 3 and 5M) to 5M 4/19-7 monomer2. The 
dashed-green line in each graph represents a CD signature of G-quadruplex from the folding of 
TBA15. The experiment is carried out at 20°C.……………………………………………………………………………….. 
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Figure 4.26 Sequences and CD spectra of short.2/19-5 and short.4/19-7. a) The sequence of 
short.2/19-5 and; b) the sequence of short.4/19-7. These sequences are part of full length 
sequences 2/19-5 and 4/19-7, respectively. The sequences are cut short to show only the repeated 
guanine; c) The CD spectrum of short.2/19-5 is shown to have characteristic peaks of G-quadruplex 
in the presence and absence of thrombin; d) There is no G-quadruplex signatures observed in 
short.4/19-7 neither with nor without thrombin. The dashed-green line in each graph represents a 
standard CD signature of G-quadruplex from the folding of TBA15.The experiment was performed 
in thrombin binding buffer at 20°C.………………………………………………………………………………………………. 
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Figure 4.27 Schematic diagram of ELONA assays. Protein targets are adsorbed onto microtiter 
plate. The assay format depends on an oligonucleotide of interest. The oligonucleotides in (a) is 
modified with biotin. This modified sequence can be directly measured by adding SA-HRP. Whilst 
the sequence in (b) doesn’t contain any modification, the assay can be performed by adding the 
biotinylated 5’ probe that can hybridize at the 5’ end of the sequence before adding SA-HRP.…………. 
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Figure 4.28 The binding curve of TBA15 and TBA15plus. a) The sequence of TBA15 and b) The 
sequence of TBA15plus; The binding curves of TBA15 (c) and TBA15plus (d) were obtained by 
ELONA or ELONA Probe method. The dissociation constant (Kd) of each aptamer against thrombin 
was calculated by fitting the curve with nonlinear curve fitting program, Origin 8.6. Each data point 
was performed in triplicate.………………………………………………………………………………………………………… 
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Figure 4.29 The binding curve of TBA29 and TBA29plus. a) The sequence of TBA29 and b) The 
sequence of TBA29plus; The binding curves of TBA29 (c) and TBA29plus (d) were obtained by 
ELONA or ELONA Probe method. The dissociation constant (Kd) of each aptamer against thrombin 
was calculated by fitting the curve with nonlinear curve fitting program, Origin 8.6. Each data point 
was performed in triplicate.………………………………………………………………………………………………………… 
 
 
 
 
177 
Figure 4.30 The binding curve DNA starting pool.  Binding curves were obtained by ELONA or 
ELONA probe method. The dissociation constant (Kd) of DNA starting pool against thrombin was 
calculated by fitting the curve with nonlinear curve fitting program, Origin 8.6. Each data point was 
performed in triplicate.…………………………………………………………………………………………………………………. 
 
 
 
178 
Figure 4.31 The binding curve of 2/19-5.monomer1. The binding did not reach saturation and 
displayed in dose-dependent manner which would suggest it is binding to the protein target with 
low binding affinity………………………………………………………………………………………………………………………. 
 
 
179 
Figure 4.32 A schematic diagram of the quadruplex/druplex structure of TBA29. The core 15-
mer G-quadruplex is labeled with number. The duplex part also plays a role in the high binding 
affinity (Tasset et al., 1997).…………………………………………………………………………………………………………. 
 
 
181 
Figure 4.33 SPR flow cell cross section. (a) The cross section of flow cell (b) SPR intensity 
curve……………………………………………………………………………………………………………………………………………. 
 
184 
Figure 4.34 A typical immobilization procedure using EDC/NHS crosslinking reaction. 
Streptavidin (or other proteins) is immobilized on SAM-COOH surface. Immobilization is carried 
out through EDC/NHS coupling reaction. Amine-reactive surface reacts with primary amine of 
protein (lysine residues) forming covalent amide bond. ………………………………………………………………… 
 
 
 
185 
Figure 4.35 Immobilization of streptavidin on a sensor chip. Reactive succinimide ester group 
was introduced to the surface via EDC/NHS coupling chemistry. Streptavidin which was diluted in 
10mM sodium acetate (NaOAc) buffer pH 5.0 was then covalently linked to the surface on both 
channels. Surface blocking for any active residues was performed using 1M ethanolamine-HCl pH 
8.5 that converted active –COOH group to –CONHCH2CH2OH group. Nonspecifically bound 
streptavidin was washed from the surface using 10mM HCl before ligand injection. 10mM 
Phosphate buffer saline (PBS) was used as a running buffer for all chip preparation steps.……………… 
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Figure 4.36 Immobilization of biotinylated aptamer on a streptavidin coated sensor chip. 
Biotinylated DNA aptamer was diluted to a range of 0.2M-1M in 10mM PBS. The immobilization 
of aptamer on a sensor chip was performed by injecting the ligand to the left channel at a flow rate 
of 10L/min for 25 min 10mM PBS was flown through the right channel as it was kept as a 
reference with no DNA aptamer. The amount of DNA immobilized through biotin-streptavidin 
interaction was calculated from the raise of signal from the base line. TBA15 around 1pmol (or 
~350RIU) was attached to the streptavidin surface on the left channel. There was no signal shift 
on the right channel since it was only buffer run through.………………………………………………………………. 
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Figure 4.37 a) Sensorgram demonstrating the binding of TBA15 to thrombin. b) TBA15 
binding curve. The Kd for TBA15 was calculated to be 53nM.………………………………………………………... 
 
188 
Figure 4.38 Determination of binding affinity of proximity ligated aptamers for thrombin 
using surface plasmon resonance. Data were obtained from the binding response from SPR and 
were fitted with nonlinear curve fitting using Origin 8.6 by assuming a 1:1 binding ratio. The 
sequence of full length 2/19-5 is shown in (a) and for 4/19-7 is shown in (b). The Kd for 2/19-5 was 
calculated to be 1.6M (c) and the Kd for 4/19-7 was calculated to be 1.2M (d).……………………………. 
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Figure 5.1 Lysozyme structure and function. a) A ribbon model of a hen-egg white lysozyme 
(PDB ID 3LYM), showing Glu35 and Asp52 in the enzyme active site; b) Notably present in human 
tears and egg white, lysozyme hydrolyzes 14 glycosidic bond between N-acetylmuramic acid 
(Mur2Ac or NAM) and N-acetylglucosamine (GlcNAc or NAG). This repeating disaccharide chain is 
crosslinked by short peptides (4-5 amino acids), forming a layer of peptidoglycan, found in the 
bacterial cell wall. ………………………………………………………………………………………………………………………… 
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Figure 5.2 A diagram shows a workflow in the preliminary study on the proximity ligation 
selection. This preliminary study is focused on the N30 DNA pool preparation and the strategy to 
obtain ligated DNA products of expected size that is then determined using gel electrophoresis.…...... 
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Figure 5.3 The PCR course of N30 DNA pool amplification. The 3% (w/v) agarose gel showed 
PCR amplification products from even cycles of amplification of the N30 pool. DNA size marker (L) 
was a 25 base-pair step ladder which ran along with the PCR product. The number of cycles is 
depicted in each lane. The expected size of DNA product is indicated by the arrow.………………………… 
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Figure 5.4 The asymmetric PCR course. The 10% (v/v) TBE-urea polyacrylamide gel showed 
ssDNA product of N30 pool from asymmetric PCR amplification which was drawn out every two 
cycles. The number of cycles is depicted in each lane. Bigger bands belonged to starting pool that 
contained the T7 promoter. The 80 bases-DNA band was expected size of our amplified pool. The 
excess primer could be seen bottom of the gel.………………………………………………………………………………. 
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Figure 5.5 Flowchart illustrating the first PLS experimental strategy. The control (no 
lysozyme) was performed along with the sample (containing lysozyme) reaction. After incubation 
for two hours, ligation and amplification reactions were carried out. In this protocol, 
ultracentrifugation was used to separate bound and ligated product from unbound/non-ligated 
sequences. The agarose gel on the right bottom shows the ligation product analysis. Lane 1 
represents DNA marker. Lane 2 and lane 3 shows the PCR products of negative control and sample, 
respectively. The gel doesn’t show a clear ligated PCR product.……………………………………………………… 
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Figure 5.6 PLS against various amount of lysozyme target. Lysozyme from 0.01nmol to 1nmol 
was incubated with 1nmol N40 DNA pool. The selection and ligation were performed in solution 
and the PCR amplification was carried out without partitioning. PCR product was analyzed on 3% 
(w/v) agarose gel. Lane 1 and 7 was DNA 25 bp step ladder, lane 2 to lane 6 were the reaction that 
contained 0nmol (control), 0.01nmol, 0.1nmol, 1nmol lysozyme and template blank PCR 
amplification, respectively. Black arrows marked the expected ligated DNA products (~152 bp). 
Unfortunately, there was no band observed at this position.…………………………………………………….......... 
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Figure 5.7 Comparison between two partitioning, centrifugation and membrane filtration. At 
a fix amount of DNA pool at 1nmol, the amount of lysozyme were varied from 0pmol (no lysozyme 
control) to 10pmol. The selections were performed in 30L total volume of incubation and 
increased to 50L after adding ligation mixture. Ultracentrifugation and membrane filtration were 
used to partition DNA unbound monomer. The PCR amplification products from these two 
partitioning method were analyzed by 3% (w/v) agarose gel electrophoresis. The expected DNA 
ligation product (~152 bp) is marked by arrow and dashed line.……………………………………………………. 
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Figure 5.8 Comparison of two pools used in the PLS. Preliminary study was carried out using 
standard pool. After PLS and amplification, aptamer monomers were dominant (a). In contrast, 
selection using F and R pool gave aptamers dimer as a majority (b).………………………………………………. 
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Figure 5.9 Schematics of the working principles of proximity ligation selection using two 
different pools, named Forward (F) and Reverse (R) pools. In the presence of target, two aptamers 
from each pool would be able to bind simultaneously to their target. And only if those pairs are in 
an appropriate orientation in which the 3’ terminal of the F pool is sufficiently close to the 5’ 
phosphate of the R pool, two DNA sequences can then ligate. The optimizations are performed in 
the incubation and ligation steps. The analysis of ligation product is carried out using gel 
electrophoresis.……………………………………………………………………………………………………………………………. 
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Figure 5.10 PLS without partitioning step. The PLS was performed by using 1nmol mix pool 
incubating with different amount of lysozyme. The partitioning step was omitted since we assumed 
that there would be less DNA monomer can be amplified. The smeared bands can be seen on the 
gel, which are due to a high concentration of DNA template for PCR amplification…………………………... 
 
 
 
209 
Figure 5.11 The PLS with membrane filtration partitioning step. The PLS was performed by 
using 1nmol mix pool incubating with 1nmol lysozyme. The partitioning step was performed after 
the ligation step. A protein-independent ligation also occurred and became the main problem of the 
PLS.……………………………………………………………………………………………………………………………………………… 
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Figure 5.12 Flowchart of PLS condition (negative experiment) optimization. The optimization 
includes ligation time, amount of T4 DNA ligase, amount of oligonucleotide connector and amount 
of lysozyme. Most experiments were carried out in the absence of lysozyme except the last 
experiment where amount of lysozyme was varied. After each experiment, the PCR product was 
analyzed on 3% (w/v) agarose gel electrophoresis.……………………………………………………………………….. 
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Figure 5.13 Optimization the proximity ligation selection condition using the negative 
experiment: ligation time. In the absence of lysozyme, the DNA mixed pools were incubated with 
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Chapter 1 
In vitro Selection of Aptamers 
 
 
 
Molecular recognition is an important part of bioanalytical assays. Finding new 
molecules for such a role has been a key development of analytical tools. Aptamers, a 
group of nucleotide-based molecules have emerged over the past two decades (Ellington 
and Szostak, 1990; Tuerk and Gold, 1990) and are a potential alternative to antibodies 
for uses in analytical, diagnostic and therapeutic applications. This chapter will provide 
a review on biorecognition aspect of established molecules before focusing on aptamers, 
which are currently of high interest. Furthermore, we will also discuss the context of 
aptamers’ discovery and their applications in sensing and therapeutic areas. Finally, 
recent progresses on aptamer selection technologies will be presented and analyzed.  
 
1.1 Biorecognition Molecules 
There are several classes of biorecognition elements that play central roles in proteomic 
and clinical research as well as biological processes in vivo and in vitro. Examples of 
classic recognition molecules include receptors, lectins, enzymes and antibodies, which 
are all protein-based molecules. Common properties shared among those recognition 
molecules are their specificity and affinity against their targets.  
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 Receptors are a class of proteins that are commonly found either on the cell 
surface or in the nucleus and serve important roles in controlling and balancing 
physiological functions through receiving or sensing the signals as well as passing them 
on to mediators that initiate cellular responses. Signals can be physical stimuli such as 
light, pressure and electrical impulse or chemical molecules such as metabolites, 
hormones, neurotransmitters, odors and inorganic ions (Koolman and Roehm, 2005).  
Lectins constitute a broad family of proteins that are found in all organisms. 
They bind to carbohydrate moieties and are responsible for many biological processes 
such as cell-cell recognition and cell adhesion as, for example, the interaction between 
the hemagglutinin of influenza virus and the eukaryotic cell surface (Weis and 
Drickamer, 1996). Purified plant lectins such as concanavalin A (Con A), which 
specifically binds to -D-mannose and -D-glucose residues, and wheat germ agglutinin, 
which binds to D-N-acetylglucosamine, are commercially available as a conjugated forms 
with resin for affinity columns and are widely used in affinity chromatography for 
polysaccharides, glycoproteins and glycolipids ligands.  
Enzymes are protein-based catalysts that accelerate the rate of biochemical 
reactions under physiological conditions. Due to the high selectivity and specificity of 
enzymes toward their substrates, coupled with the power of signal amplification 
through catalytic reactions, they have been categorized as very powerful recognition 
elements used for biosensing applications. One of the possibly most celebrated enzyme-
based biosensors was the one to measure blood’s glucose using glucose oxidase, which 
was first developed by scientists at Oxford University in 1980s (Cass et al., 1984). Since 
they came on the market, this biosensor type has served hundreds of millions of patients 
suffering from diabetes with the number increasing every year (WHO, 2012). However, 
one of the major challenges faced when employing enzymes is the limited working 
conditions due to their thermal and chemical instability.  
Antibodies are a group of globular proteins known as immunoglobulins. 
Monoclonal antibodies are generally produced by immunizing an animal (usually a 
rabbit) with the appropriate antigen and the antibody secreting lymphocytes are fused 
with myeloma cell lines forming immortal hybrid cells, hybridomas. The cloning of 
hybrid cells then generates homogeneous and specific monoclonal antibodies of choice. 
The development of recombinant DNA technologies allows the production of engineered 
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antibodies and fragments, which have desirable properties, on a large scale (Thorpe and 
Thorpe, 2000).  
Several thousand antibodies are available from commercial sources. One 
application of antibodies is their role in protein purification as immunoaffinity-captured 
molecules incorporated into a chromatographic system in immunoaffinity 
chromatography (IAC), where antibody or antibody fragment are used as a stationary 
phase. The effectiveness of single step purification using IAC has been reported (Yocum 
et al., 2005; Ichibangase et al., 2009). In clinical proteomics research, IAC has been 
utilized to remove abundant proteins (such as albumin, immunoglobulin G (IgG), 
transferin and haptoglobin) from blood samples, leaving the less abundant proteins to 
be used for protein profiling in the diagnosis of diseases. The elimination of highly 
abundant proteins reduced the range of interference allowing lower abundance proteins 
to be analyzed. However, the controversy has arisen over immunoaffinity depletion 
regarding non-selective loss of low abundance proteins, which may lead to inaccurate 
quantitative analysis of serum biomarkers (Yocum et al., 2005). Additionally, 
Ichibangase et al. (2009) demonstrated that although the immunoaffinity column 
commercially available as an avian yolk immunoglobulin (IgY), effectively eliminated 
bovine serum albumin (BSA) from protein standard mixtures, it also removed other 
proteins by 18-45%. Furthermore, they also pointed out the possibility of adsorption of 
hydrophobic high-molecular weight proteins in plasma onto the surface of the affinity 
column materials, contributed to the reduction in efficiency of immunoaffinity columns 
(Ichibangase et al., 2009).  
Various antibody-based assays have been developed for proteomic research 
(Moody et al., 2001; Knezevic et al., 2001; Schweitzer et al., 2002) and clinical 
applications (Hudson and Souriau, 2003; Scott et al., 2012). These immunoassays 
provide specific qualitative and quantitative measurements based on the antigen-
antibody interaction. Radioimmunoassay (RIA), using radioisotope-labeled antigens or 
antibodies, was largely replaced with enzymes in enzyme-linked immunosorbent assays 
(ELISA) first described in 1971 (Engvall and Perlmann, 1971). The combination of an 
enzyme that is conjugated to one reactant, typically an antibody brings several 
advantages over RIA such as ease of handling, high sensitivity and specificity and fast 
speed of detection (Clark et al., 1986). Key features of ELISA including specific 
interaction between antigen-antibody and the use of an enzyme such as horseradish 
 
31 In vitro Selection of Aptamers 
peroxidase (HRP) or alkaline phosphatase (AP) as an amplifier and signal generator. 
This makes ELISA a powerful analytical tool, which is generally applied to measure 
concentration of almost any antigen such as pathogens, toxins, drugs and hormones 
either in direct or indirect assay formats. Recently, the development of 
analysis/diagnosis in human healthcare has aimed to substitute complicated assays with 
a simple platform that is low cost, disposable, equipment-free and easy to use even in 
remote areas by less-skilled users. It would be the ultimate purpose to have healthcare 
products that are affordable to serve a wider population, specifically in developing 
world. This will require as shrinking down several thousand pounds worth of 
equipment to only tiny pieces such as microchips or paper-based sensors, particularly 
for point-of-care testing (Liu et al., 2012).  
Although antibodies are very attractive recognition molecules and their 
applications have been paramount, there are several limitations of using them, including 
the difficulty of generating specific antibodies against toxins or highly toxic substances 
that cannot be tolerated by animals, or against less immunogenic molecules. Moreover, 
to generate immunosensor chips, multiple limitations arise from the use of immobilized 
antibodies as they are prone to irreversible denaturation. Extra-modifications may also 
require in controlling orientation of proteins on the surface (Engvall, 1980; Lee et al., 
2003; Vashist et al., 2011). 
 Although the aforementioned classes of protein-based molecules have proven to 
have high affinity and specificity toward their ligands, they suffer from chemical and 
thermal denaturation as well as expensive production. These drawbacks can be 
overcome by nucleic acid-based affinity reagents, known as aptamers, which were first 
reported in 1990 and since have been extensively studied. These molecules have an 
ability to bind to various kinds of target molecules with an affinity and specificity that is 
often comparable to monoclonal antibodies (Drolet et al., 1996; Fredriksson et al., 2002; 
Nimjee et al., 2005; Keefe et al., 2010). Moreover, the ease of production, modification 
and manipulation of aptamers enhances their attractiveness and applicability. The 
potential applications in analysis and clinical diagnosis (Drolet et al., 1996; Fredriksson 
et al., 2002) as well as therapeutics (Ng et al., 2006; Keefe et al., 2010) have greatly 
contributed to the interest in development of aptamer selection methods, with the 
ultimate goal being to reduce the time and labor of the aptamer selection process. 
Specific ligand binding reactions of nucleic acid are well known to control many 
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biological processes, demonstrating that they have both the affinity and specificity 
required for this purpose. The next section briefly describes some well characterized 
nucleic acid-ligand interactions. 
 
1.2 Nucleic Acid-Ligand Interactions 
Many cellular processes are based on the interaction of nucleic acids with proteins. 
Thus, every step in the central dogma; that is replication, transcription and translation, 
requires the presence of and reactions between DNA, RNA and protein. To affect those 
processes, precisely controlled nucleic acid-protein interactions must occur. For 
example DNA-protein binding regulates the cellular levels of gene products during 
transcription and these in turn control both protein synthesis and DNA replication. In 
the following sections two illustrative examples of specific interactions between 
proteins and duplex DNA and RNA, are discussed. A fundamental understanding of these 
interactions leads to an appreciation of factors that influence synthetic nucleic acid 
(aptamer) binding affinity and specificity for their target ligands.  
 
1.2.1 Lac Repressor: An Example of DNA-Transcription Factor Interactions 
Transcription factors are the most common examples of the interactions between DNA 
and protein. In transcription initiation, DNA must be recognized by sequence-specific 
transcription factors. Structural studies of these protein-DNA complexes indicated 
factors that contributed to a specific interaction between the two partners (Chuprina et 
al., 1993; Bell and Lewis, 2000). One of these factors is a DNA binding scaffold such as a 
helix-turn-helix (HTH) or a zinc finger motif. The other factor is particular amino acid 
residues, which directly contact and form non-covalent bonds to bases, imparting 
specificity (Brennan, 1993; Aravind et al., 2005). The major groove of duplex DNA is 
wide enough to accommodate an -helix of a DNA binding domain whilst the functional 
groups of the exposed edges of base pairs provides a mechanism by which proteins can 
discriminate base pairs. Other classes of DNA-recognition motif such as -sheets and -
barrels have been discussed in the review by Rohs et al. (2010). These authors propose 
two major binding mechanisms; base readout and shape readout that reflect the ability 
of proteins to recognize either DNA bases or shapes, and by using a combination of 
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multiple readout mechanisms, achieve their specificity-determining contacts (Rohs et 
al., 2010).  
The lac repressor (Figure 1.1(a)) specifically binds to the regulatory region of 
the lac operon and inhibits the gene expression. It is a tetrameric protein that contains a 
HTH headpiece DNA-binding domain (amino acid residues 1-49). The HTH is a common 
scaffold that is found as a part of larger DNA-binding proteins (Pabo and Sauer, 1992). 
Among the three core helices of HTH domain, one is known as a recognition helix, which 
typically inserts itself into the major groove (Figure 1.1(b)). There is another short 
helical segment (residues 50-58), called the hinge-helix, which binds DNA in minor 
groove (Bell and Lewis, 2000). NMR spectroscopic studies (Chuprina et al., 1993) and X-
ray crystallographic data (Bell and Lewis, 2000) reported several interconnected sets of 
interactions among specific bases, phosphate backbone and particular amino acid side 
chains that contributed to binding specificity and stability. These set of interactions 
involve: 
 A number of direct hydrogen bonds between specific bases of the operator 
sequence and amino acid side chains in the headpiece 
 Hydrogen bonds formed between the phosphate group on DNA backbone with 
particular side chains  
 Hydrogen bonds mediated by water-bridged contacts in the major groove 
 Hydrophobic contacts involving thymine methyl groups with non-polar amino 
acid side chains  
 Hydrophobic interactions in the minor groove 
In addition, both DNA and protein conformations play a role in the sensitivity to 
effecter molecules. The repressor subdomain orientation changes in the presence of 
allosteric effectors, such as isopropyl--D-thiogalactoside (IPTG). The IPTG-bound 
conformation brings about the release of the hinge-helix from the minor groove (Bell 
and Lewis, 2000). Furthermore, the binding of the protein results in a DNA 
conformational change, which is observed as 1) the DNA forms a compressed structure 
of around the contact site with the HTH (Chuprina et al., 1993) and 2) a 40° bending of 
DNA, induced by the binding of the hinge-helix (Bell and Lewis, 2000). Overall, these 
yields the base readout through the interconnections of all specific contacts as well as 
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the shape readout through the molecular conformational changes resulting in the 
specific recognition and anchoring of the lac repressor headpiece on the operator.    
 
 
                             
                                                         (a)                                                                          (b) 
 
Figure 1.1 Helix-turn-helix motif of the lac repressor (PDB ID 1EFA). a) Structure of the dimeric lac 
repressor. (The C-terminal, which contains helices involved in tetramerization, was deleted and did not 
show in this figure.) The headpiece, containing HTH motif, specifically binds DNA in the major groove. The 
two hinge-helices, shown in green, form part of the dimer interface and contact atoms of the sugar moieties 
of nucleotides in a minor groove; b) The binding of HTH motif of the lac repressor in the major groove. The 
recognition helix, shown in red, inserts itself and forms an interface with the major groove of the DNA target 
(Bell and Lewis, 2000). The image is created using Weblab ViewerLite program. 
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1.2.2 Nucleolin: An Example of an RNA-Binding Protein 
RNA-binding proteins (RBPs) exhibit specific recognition of their RNA targets through 
either their sequence or structure (Stefl et al., 2005). The association of RBPs with RNA 
has a key role in controlling RNA metabolism, involving pre-mRNA processing as well as 
mRNA transport, localization, translation and stability (Dreyfuss et al., 2002). There are 
several classes of RNA-binding proteins, classified by a variety of protein motifs. Here in 
this section, a RNA-binding domain (RBD, also called a RNA-recognition motif (RRM)), 
which is the most common RNA interaction domain, is illustrated using nucleolin as an 
example (Allain et al., 2000; Johansson et al., 2004).  
 Nucleolin is a multifunctional protein that contains four tandem consensus RBDs 
and adopts a  fold. These multiple RBD domains facilitate cooperative binding, 
so achieving high affinity (Stefl et al., 2005). NMR spectroscopy was used to study the 
interaction between the two N-terminal domains, called RBD12, and a 22-nucleotide 
RNA stem-loop (Figure 1.2(a) and (b)), which was found by in vitro selection. The stem-
loop secondary structure shares a common UCCCGA motif with well characterized pre-
rRNA binding sites and is required for nucleolin binding (Ghisolfi-Nieto et al., 1996). 
Structure analysis revealed that each domain of nucleolin specifically interacts with two 
nucleotides in the RNA loop through the surface of the -sheets. The bases pack against 
conserved hydrophobic amino acid side-chains as shown in Figure 1.2(c) (Allain et al., 
2000). Mutagenesis at F17, Y58 and Y140 was found to decrease the binding affinity for 
the SELEX nucleolin recognition element (sNRE). Another observation was that the 
protein linker that connects two RBDs is flexible in the free form and becomes ordered 
in the complex. This would suggest it has a significant role in the protein-RNA complex. 
Further study on RBD12 with a natural RNA target (b2NRE) (Johansson et al., 2004) 
revealed specific recognition of the consensus sequences, similar to the RBD12/sNRE 
complex. However, the two interactions are different in some aspects. First, sNRE and 
b2NRE have different sequences in the non-consensus region, thus they adopt different 
folds. Second, the b2NRE undergoes conformational rearrangement upon binding to 
RBD12 to fit itself into the binding partner (also known as ‘induced-fit’ mechanism). 
Third, RBD12 has no interactions with non-consensus nucleotides, which resulted in a 
100 to 500-fold difference stability of the complex.  
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                                    (a)                                                                  (b) 
 
                                                                                        (c) 
Figure 1.2 Structure of the nucleolin RBD12/sNRE complex (Allain et al., 2000). A secondary structure 
representation of a stem-loop NRE, which was identified by in vitro selection, is shown in (a). The consensus 
NRE loop is shown in red and responsible for the interaction with proteins. The folding structure of sNRE is 
shown in (b). The RBD12 from hamster nucleolin forms complex with sNRE. The RBD 1 contacts the 3’ side 
and the RBD2 binds to the sequence on the 5’ side. The bases that are recognized by RBD12 are numbered 
and shown in yellow. Amino acid side-chains (F17, Y58, L103 and Y140) at the interaction points are shown 
in red. The inter-domain linker, shown in purple, participates in the recognition of the hairpin architecture 
(c). The image is created using Weblab ViewerLite program. 
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 A number of factors contributed to RNA-protein interactions that are related to 
primary sequence and shape recognition. It is similar to DNA-protein interactions in that 
there is no simple recognition code or one-to-one complementarily between protein and 
RNA sequences. Non-covalent interactions at multiple points are a fundamental 
requirement for a stability and specificity of a complex. In nature, high binding affinity is 
not always necessary since other constituents in the cellular environment such as 
cofactors would also affect the binding ability. Weaker interactions may be biologically 
relevant and even advantageous (Änkö et al., 2012).  This may not be the case for the in 
vitro selection where we need high binding affinity ligands for analytical and therapeutic 
purposes. Although it needs to be kept in mind that in vitro selection of aptamers is 
carried out using, mostly, pure protein in selected conditions which may be different 
from physiological conditions, the basic principles of nucleic acid-protein interactions in 
nature are also seen in aptamer-protein contacts. The interaction between RBD12 and 
sNRE is a good example of how an aptamer reacts differently from a natural nucleic acid. 
The tighter binding of sNRE might be due to its structure being similar to that of the 
bound b2NRE (Johansson et al., 2004). Ultimately, in vitro selection is usually based on a 
single property, a binding affinity. Unlike natural RNAs, aptamers do not usually trade 
off their affinity and specificity in ligand binding with other biological functions 
(Hermann and Patel, 2000).  
 
1.2.3 Nucleic Acid Aptamer-Small Molecule Interaction 
As described in the previous section, the discovery of synthetic nucleic acids that 
specifically bind proteins occurred long after that of natural protein-nucleic acid 
interactions. In contrast the discovery of natural small molecule binding RNAs happened 
a decade after the description by Ellington and Szostak (1990) of synthetic RNAs that 
could specifically bind small molecules.  
The theophylline-binding aptamer is a good example of a synthetic RNA that can 
bind to a small molecule. This RNA aptamer is highly specific for theophylline with a 
dissociation constant of ~400nM. Interestingly, it can discriminate against caffeine, 
which differs from theophylline only by the addition of a methyl group at the N7 
position (Figure 1.3(a)). The binding affinity of caffeine to the theophylline aptamer is 
10,000-fold lower than its original ligand. The key to high binding and high specificity of 
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the theophylline aptamer is a variety of factors including a network of intermolecular 
hydrogen bonding, base stacking interactions, which form a well-ordered binding 
pocket, as well as a planar structure of the theophylline that can fit into the aptamer fold 
(Figure 1.3(b) and (c)) (Zimmermann et al., 1997; Hermann and Patel, 2000).   
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Figure 1.3 Theophylline-RNA aptamer complex (PDB ID 1EHT). a) Theophylline differs from caffeine by 
a substitution of methyl group at N7 position; b) The folded structure of theophylline-RNA aptamer 
complex; c) An expanded view of the binding pocket for theophylline (Zimmermann et al., 1997). The image 
is created using Weblab ViewerLite program. 
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 As shown in the close up view in Figure 1.4, base stacking interactions and a 
network of hydrogen bonds are formed in the core of the RNA-theophylline complex. In 
the binding pocket, there is a sandwich of three base triples. The first set composes of 
U6, U23 and A28, which forms the floor of the binding pocket. The theophylline is 
included into the second triple by forming hydrogen bonds with C22 and U24. The 
hydrogen bonding between C22 and theophylline is also the key to distinguish 
theophylline from caffeine. The third triple, involving A7, C8 and G26, covers on top of 
the core of the complex. This structure is further stabilized with extensive base stacking 
( U6, A7, C21 and C22) by forming a ‘base-zipper’ on one side of the binding pocket and a 
unique ‘1-3-2’ stack, that results from the intercalation of G26 in between U24 and G25, 
on the other side. Unsurprisingly, those mentioned bases, which involve in specific intra- 
or intermolecular interactions, are conserved residues and are brought close together 
by the formation of an unusual S-turn (Zimmermann et al., 1997). 
 
 
 
Figure 1.4 The close up view of the theophylline RNA aptamer binding pocket. The unusual S-turn is 
formed by the folding of bases from C21 through G29 and plays as a part of binding pocket. All labeled 
residues are conserved and require for binding and structural stability. The binding pocket contains a 
sandwich of base triples, which stack to one another. The bases shown in pink and aqua green formed the 
top and bottom floor of the pocket. The C22 and U24 (in orange) form hydrogen bonding (green dash) with 
the theophylline and insert themselves between the above and below floor (Zimmermann et al., 1997). The 
image is created using Weblab ViewerLite program. 
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 A conformational rearrangement of nucleic acid structure upon binding to 
protein or its small ligand also makes a contribution to binding affinity and specificity as 
can be seen in the case of nucleolin/b2NRE complex (Johansson et al., 2004). The 
theophylline binding aptamer also undergoes conformational rearrangement upon 
binding of its ligand as it was observed by monitoring changes in the imino proton NMR 
spectrum of complex and unbound form of the RNA (Zimmermann et al., 1997). Similar 
conformational changes have been observed with DNA aptamers, for example Bishop et 
al. (2007) described an L-argininamide binding DNA aptamer that is partially disordered 
in the absence of the ligand and undergoes an induced-fit upon binding. It was further 
suggested (Bishop et al., 2007) that this induced-fit model is applicable to DNA aptamers 
as had been previously observed in RNA-protein interactions (Leulliot and Varani, 
2001). 
 In conclusion, the interactions of both natural and synthetic nucleic acids with 
proteins and small molecule share common features. A number of structural studies 
suggested the high binding affinity and specificity is a result of different contributions 
including hydrogen bonding, electrostatic interactions, hydrophobic interactions and 
base stacking. Structural rearrangement to an optimized conformation of both partners 
also plays a role in forming the complex. These contributions do not work in isolation 
but they are cooperative. In-depth studies of molecular interactions reveal a better 
understanding at the cellular level and during in vitro selection, it helps to design 
aptamers with a desire functions for particular applications.  
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1.3 Aptamer: A Recognition Molecule 
Aptamers are synthetic functional oligonucleotides (ssDNA or RNA). They first emerged 
from two independent studies in 1990 (Ellington and Szostak, 1990; Tuerk and Gold, 
1990). The term ‘Systematic Evolution of Ligands by EXponential enrichment (SELEX)’ 
was introduced by Tuerk and Gold at Colorado University (1990) where they described 
the use of the SELEX procedure to select RNA molecules from a randomized pool that 
interact with T4 DNA polymerase. In parallel, the work of Ellington and Szostak at 
Harvard (1990) described the selection of RNA molecules from a large population of 
random RNA sequences that bound specifically to a variety of organic dyes and they 
coined such binding species ‘aptamers’. A great number of aptamers have since been 
selected to bind a variety of targets, whether complex (such as cell surfaces), or small 
(such as organic dyes, antibiotics, cofactors) using the same SELEX procedure 
(Reviewed by Stoltenburg et al., 2007; Keefe et al., 2010; McKeague and DeRosa, 2012). 
 Understandably, aptamers are not only characterized as binding molecules but 
also offer excellent applicability in diagnostic and therapeutic applications. The affinity 
of aptamers for their targets, which typically ranges from M to pM in dissociation 
constants, is credited to the aptamers’ capability to fold into three dimensional 
structures upon association with their target. NMR spectroscopy and X-ray 
crystallography have been used to determine the three-dimensional structures of 
aptamer-ligand complexes that revealed a key molecular recognition process which 
governs the specificity between the pair. Intermolecular contribution is attributed to the 
combined force of different events including hydrogen bonding, electrostatic 
interactions, hydrophobic interactions, shape complementarities, and base stacking 
(Hermann and Patel, 2000). The high stability of aptamers along with their easy 
production via automated DNA synthesis has lead to them being considered as 
alternatives to antibodies. Table 1.1 shows the comparison of aptamer and antibody 
properties.  
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Table 1.1 Summary of a comparison of aptamer and antibody properties (Nimjee et al., 
2005; Keefe et al., 2010) 
Properties Aptamer Antibody 
Binding affinity  M to pM range  M to pM range 
Production process  Chemically synthesizable/ scalable 
 Require iterative rounds of 
selection against known target to 
select specific aptamers 
 Typically obtained for almost any 
desired target 
 Cost effective 
 Production requires a biological 
system 
 Contamination from 
manufacturing process may affect 
product quality 
 Difficult to raise antibody to toxic 
substances which cannot tolerated 
by animals 
 Non-immunogenic target needs to 
be modified 
Immunogenicity  Non-immunogenic  Significant immunogenicity 
Batch-to-batch variation  Uniform activity regardless of 
batch synthesis 
 May show high variation from 
batch-to-batch 
Stability  Heat tolerant  
 Returns to its original 
conformation after temperature rise 
 Stable over repeated cycle of 
denaturation/ renaturation 
 Nuclease sensitive 
 Temperature sensitive 
 Undergoes irreversible 
denaturation under harsh condition  
 
 
 Not susceptible to nuclease 
degradation 
Shelf-life  Easy storage as lyophilized 
powder or keep as solution in -20°C 
indefinitely 
 Limited shelf-life 
Conformation  Predominantly unstructured in 
solution then folded into 3D 
structure upon binding 
 Contains defined structure even in 
absence of ligands 
Site specific chemical 
modification 
 Easy to modify 
 Labeling/ conjugation chemistries 
are readily introduced either during 
synthesis or post-synthetically 
 Limited modifications of molecules 
Immobilization  Simple immobilization on either 
the 5’ or the 3’ end 
 Random orientation is usually 
observed 
Size  Small size allows more efficient 
entry to biological compartment but 
susceptible to renal filtration/ needs 
further modification such as 
PEGylation 
 Large size prevents renal filtration 
but may limit bioavailability or 
prevents access to many biological 
compartments 
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1.4 Applications of Aptamers 
The development in aptamer screening methods has permitted the identification of a 
great number of specific RNA/DNA aptamers against their target molecules. 
Additionally, aptamers have been proved to be equal or even superior to other 
recognition molecules in many ways. All of these attractive properties have highlighted 
the potential of aptamers as new alternatives to play important roles in bioanalytical 
research, diagnostics and therapeutics.  
 This section will cover some of the analytical applications in which aptamers 
have been employed in recent years and also covers the aptamers that have been used 
as therapeutic agents, which are currently available in the market or at the clinical trial 
stages. 
 
1.4.1 Aptamers in Analysis 
Several studies have focused on using aptamers as recognition elements in analytical 
tools including affinity chromatography, capillary electrophoresis (CE), microfluidic 
technology and biosensors. In almost all types of applications, aptamers are immobilized 
on a variety of supports. Coupling aptamers to different detectors or transducers allow 
appropriate analytical signals to be obtained. 
In column chromatography, the basic principle of systems relies on the 
interaction of analytes in the mobile phase, which flows over or through the stationary 
phase, which may be solid, gel, liquid or solid/liquid, packed in a column. The 
compounds are then differentially retained in the column and can therefore be 
separated. In terms of affinity chromatography, the separation and subsequent 
purification of compounds of interest are achieved in a single step relying on the affinity 
of a compound to an immobilized ligand (Figure 1.5(a)). Aptamers have been used as 
immobilized capture molecules in the stationary phase and have proved to be very 
stable and highly selective. CE is another technique which has broad applications for 
separating biological molecules including amino acids, peptides, proteins, DNA 
fragments and nucleic acids and organic molecule such as drugs (Walker, 2000; Zhang et 
al., 2009). This technique has several attractive features including small sample volume 
requirement, low reagent consumption, short analysis time and high separation 
performances and the possibility of automation. The key concept to achieve efficient 
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separation is the different electrophoretic mobility of the aptamer-target complex and 
the free ligand (Figure 1.5(b)).  
 
 
 
Figure 1.5 Aptamers as recognition elements in analytical tools. a) Aptamers have been used as capture 
molecules in affinity column chromatography to purify and/or pre-concentrate analytes; b) CE has been 
used to separate and detect the amount of analyte that forms a stable complex with the aptamer.  
For the past few years, micro- and nanofluidic technology has been increasingly 
important as several analytical platforms such as sample preparation, reaction, 
separation and detection can be integrated within a single chip. The attractive features 
of microfluidics seem to be common to CE with a few additional advantages of being 
simplicity, high throughput and portability. Real-time monitoring of the sample of 
interest is also possible (Swensen et al., 2009). The excellent promise of analytical 
applications of aptamers in affinity separation and detection are shown in Table 1.2.  
(a) 
(b) 
Table 1.2 Examples of aptamers in analytical tools as affinity capture molecules 
Target Analytical Technique Method involved Description 
Selected 
Reference(s) 
D-Vasopresin  Chiral molecules 
separation based on 
stereoselectivity  
 High Performance 
Liquid Chromatography 
(HPLC) 
 Immobilized biotinylated DNA aptamer on POROS streptavidin column 
(2.1x30mm)  
 Separation at 20°C using low ioinic strength mobile phase at flow rate of 
150L/min and analysis time around 15 min enhanced the separation 
where L-enantiomer eluted in the void volume. 
 The separation factor is in the same order of magnitude as obtained using 
stereoselective monoclonal antibody. 
Michaud et al., 
2003; Williams 
et al., 1997 
Human L-
selectin 
receptor 
globulin      
(LS-Rg) 
 Protein purification using 
affinity chromatography 
 HPLC  Purified recombinant human LS-RG fusion protein from Chinese hamster 
ovary cell using aptamer affinity column (5x50mm) packed with 
biotinylated DNA aptamer immobilized to streptavidin rasin  
 Elution with EDTA gradient or NaCl gradient while retaining protein 
native structure 
 Purity increases 1500-fold with 83% recovery yield in a single step 
Romig et al., 
1999 
17-estradiol 
(E2) 
 Sample preparation/ 
Preconcentration 
 Detection of 
preconcentrated sample 
using HPLC 
 Replace non-selective hydrophobic solid phase extraction generally used 
in preconcentration-sample preparation step with anti-E2 aptamer-
anchored glass microbeads. 
 Tested on spike water samples show recovery yield ~27%. 
 Reusable 
Huy et al., 
2011 
Leukemia cell 
line 
 Cancer cell enrichment 
 Capture and detect cancer 
cells in blood samples 
 Simple square capillary-
based cell affinity 
chromatography 
 Cell imaging system, 
confocal microscope 
 Immobilized sgc8, aptamer that selectively recognized leukemia cell lines 
with reported Kd of 0.8nM, along the inner chamber of capillary by 
interaction with avidin. 
 >90% capture efficiency 
 Fluorescently labeled aptamer probe can be used to image cell captured 
on the square capillary surface. 
 Relatively efficient to aptamer-based microfluidic detection device but 
simpler 
Martin et al., 
2011: 
Shangguan et 
al., 2006 
  4
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Table 1.2 Examples of aptamers in analytical tools as affinity capture molecules (Continued) 
Target Analytical Technique Method involved Description 
Selected 
Reference(s) 
Human 
immunodefici-
ency virus 
type 1 reverse 
transcriptase 
(HIV-1 RT) 
 aptamer as affinity probe  Affinity probe capillary 
electrophoresis/laser-
induced fluorescence 
(APCE/LIF) 
 Linear range of detection up to 50nM (6g/mL) 
 Highly specific (using aptamer), simple procedure and fast but not 
suitable for direct determination of HIV-1 RT activities in whole blood or 
serum because the range of HIV-1 RT concentrations in the sera appear to 
be a lot lower than analytical working range 
 Proof the improvement of APCE/LIF over antibody-based method 
Pavski and Le, 
2001 
Platelet 
derived 
growth factor 
(PDGF) isomer 
 Separation and detection   Tunable aptamer 
capillary electrophoresis  
 Separation and detection of PDGF isomers in diluted serum samples 
 Kd for B chain ~1nM, for A chain >100nM 
 Aptamer specific to B chain so different electrophoretic mobilities 
obtained among PDGF BB, AB and AA dimers 
Zhang et al., 
2009 
Thrombin  Protein detection    Silver nanoclusters     
(Ag NCs) 
 Using two thrombin binding aptamers that were modified by adding 
additional sequences, one of which contains G-rich overhang 
 The binding of two aptamers to thrombin induced DNA hybridization and 
bring the G-rich overhang to close proximity to Ag NCs,  then turn on the 
fluorescence signal of Ag NCs  
 Assay achieve in single step, no washing and separation require 
 Limit of detection 1nM, linear range 5nM -2M 
Li et al., 2012 
Leukemia cell 
line 
 An aptamer enriches rare 
cells for subsequent 
detection  
 Microfluidic device 
 Confocal Microscope 
 Immobilized biotinylated sgc8 aptamers on the surface of microchannel 
through biotin-avidin interaction and visualized cell capture using 
microscope where target cell stained red and control cell stained green.  
 Enrichment purity > 97% with > 80% capture efficiency 
 Technique was not yet optimized for patient samples. 
Phillips et al., 
2009; 
Shangguan et 
al., 2006 
Leukemia cell 
line 
 Cell capture and detection  Micropillar-based 
microfluidic device 
 
 
 Incorporate micropillars to enhance surface areas and capture efficiency 
 Selectively isolate cancer cells from unprocessed whole blood 
 Enrichment purity ~ 81% with ~ 95% capture efficiency 
 Processing 1mL of blood within 28 min 
Sheng et al., 
2012 
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Although, the traditional immunoassay techniques such as ELISA have shown 
exceptional sensitivity and specificity, using antibodies as capture or detection 
molecules has certain limitations. An alternative enzyme-linked oligonucleotide assay, 
called ELONA, has been developed based on the same principle as in traditional ELISA 
method but employs aptamers instead. The combination of the technique and the use of 
either aptamer alone or with antibody has broadened the applicability of ELONA as one 
of a rapid and high throughput assay.  
 A sandwich-type ELONA has been developed to quantify vascular endothelial 
growth factor (VEGF) levels in human serum as first reported by Drolet et al. (1996). In 
this model assay, anti-VEGF monoclonal antibody was used as a capture molecule and a 
human-VEGF binding aptamer (Green et al., 1995) was used as a detecting ligand. The 
aptamer was labeled with fluorescein and could be detected by alkaline phosphatase 
conjugated anti-fluorescein antibody fragments (Figure 1.6(a)). It was reported that the 
accuracy, precision and specificity of ELONA fell in good agreement with the limits of the 
ELISA technique. To take advantage of two-site assays, an aptamer can function as a 
capture molecule in pair with a detection ligand, which can be either an aptamer or 
antibody as shown in Figure 1.6(b) (Daniels et al., 2003; Gong et al., 2012). Furthermore, 
ELONA was also described as a tool to monitor DNA enrichments during a SELEX 
process (Cheng et al., 2008; Nadal et al., 2012) by directly immobilizing an analyte (or 
antigen) to the well’s surface and detected by adding a specific aptamer (Figure 1.6(c)). 
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Figure 1.6 Scheme of various assays which have been used in enzyme-linked oligonucleotide assays 
(ELONA) on microtiter plate. The assays have been classified depending on the steps, capture and 
detection molecules involve. Protein target can be directly adsorbed onto the surface or captured by 
antibody or aptamer. Reporter enzymes (horseradish peroxidase (HRP) or alkaline phosphatase (AP)) may 
label to antibody or conjugated with streptavidin. The protein target concentration is proportional to the 
chemiluminescence signal obtained from the labeled enzyme reaction. 
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 Where direct binding of the aptamer is not sufficiently sensitive, other assay 
formats have been used, one of them is the proximity ligation assay. This was first 
reported by Fredriksson et al (2002), and is an innovative approach for highly sensitive 
analysis of protein targets in vitro. By taking advantage of two aptamer probes that 
recognize different epitopes on the same target molecule, such as thrombin, or to the 
same epitope in a homodimer, such as PDGF-BB, a pair of aptamers then come into close 
proximity upon binding and can joined to each other through a ligation reaction. The 
ligation product can then be amplified through PCR so that even very low 
concentrations of the target molecules (down to zeptamole) were detectable by this 
technique (Fredriksson et al., 2002). More details of this proximity ligation assay will be 
described in Chapter 4 where it is used as the basis for selection.  
Another example of an aptamer as an analytical tool was reported by the 
Heemstra group recently, where they developed the use of a DNA split aptamer-based 
sensor with standard colorimetric readout to detect cocaine as shown in a diagram in 
Figure 1.7 (Sharma et al., 2012). Although split aptamer-formats have been used with 
different readouts such as through electrochemical and optical signals, none of them 
gave good dynamic ranges especially for human blood samples. This group, however, 
demonstrated the detection of cocaine at concentration of 100nM-100M in buffer and 
1-100M in blood serum. Covalent ligation trapping of the two split aptamers could 
therefore be a key to increase the detection sensitivity. 
 
 
Figure 1.7 The detection of enzyme-linked cocaine detection using the DNA split aptamer. An 
aptamer is immobilized to DNA-BIND plate through NHS-chemistry. In the presence of cocaine, it induces 
the assembly of two fragments of a DNA split aptamer and promotes a ligation reaction between azide and 
cyclooctyne group in a dose-dependent manner. Biotin, which is attached to one end of a DNA fragment, is 
detected by SA-HRP and HRP substrate. 
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In recent years, there has been a great demand for biosensor devices. However, 
the desired biosensor properties, which are easy, fast and inexpensive, are the final 
products of many difficult steps, especially fabrication which is the rate limiting factor in 
sensor development. Typically, biosensors contain two basic compositions, which are a 
biological recognition unit and a transducer. Biosensors developed today have employed 
aptamers as a recognition element with an effort to generate simple-to-operate 
analytical devices. Several aptamers have been incorporated to devices, namely 
aptasensors, where their sensitivity is greatly influenced by the transducer. Recent 
examples of aptamers used in a sensing format are summarized in Table 1.3. 
 
1.4.2 Therapeutic Aptamers 
Several aptamers have been developed that possess potential therapeutic use. The first 
aptamer-based drug approved by the US Food and Drug Association (FDA) in 2004 (Ng 
et al., 2006) is ‘Pegaptanib’, which is used for the treatment of age-related macular 
degeneration (AMD). This drug, also known as Macugen™, is a modified version of an 
RNA aptamer selected against vascular endothelial growth factor (VEGF). An anti-
thrombin aptamer is another example of therapeutic use, which is currently on clinical 
phase II study for anticoagulation in patients undergoing coronary artery bypass graft 
surgery (ARCA Biopharma Inc., 2011).   
 Unmodified therapeutic oligonucleotide classes have generally encountered 
several obstacles to their use in vivo; they are susceptible to nuclease degradation, rapid 
renal filtration and rapid biodistribution from the plasma compartment into the tissues 
(Bouchard et al., 2010; Kole et al., 2012). To improve their drug-like qualities, 
therapeutic aptamer candidates, after selection, are subjected to chemical modifications. 
For example, polyethylene glycol (PEG) of various sizes can be conjugated to a given 
aptamer at one (5’) or both (5’ and 3’) ends in order to reduce clearance (Ng et al., 2006; 
Keefe et al., 2010; Bouchard et al., 2010). Furthermore, in order to prevent aptamers 
from nuclease degradation, RNA molecules can be modified by adding 2’-O-methyl 
derivatives, however, this post-selection approach can cause a structural change and 
may result in altering binding property/activity of modified aptamers (Green et al., 
1995; Pagratis et al., 1997).  
 
Table 1.3 Examples of aptamers in biosensor applications  
Target Transduction Mechanism Description 
Selected 
Reference 
-Interferon (IFN-)  Electrochemical detection  Attached methylene blue tagged IFN--binding aptamer on gold electrodes  
 Signal obtained upon binding when electro-active reporters move away from the surface 
changing in redox current 
 Limit of detection 0.06nM, linear response up to 10nM  
Liu et al., 2010 
Arsenic (III)  Colorimetric detection 
 Resonance scattering (RS) 
assay 
 Apply to detect arsenic in drinking water (no more than 10ppb) 
 Adding hexadecyl trimethylammonium bromide (CTAB), a cationic surfactant, to function as 
competitive binding to aptamers and control the aggregation of aptamer-gold nanoparticle 
(AuNPs) in the presence/absence of As(III) 
 Limit of detection 0.6ppb using machine and 40ppb for naked eye, linear range 1-100ppb 
Wu et al., 2012 
Cocaine  Mass-sensitive detection 
(Micromechanical 
cantilever) 
 The detection relies on resolving surface stress changes due to the binding of a ligand on a 
sensitized surface. 
 The lowest detection for the cocaine concentration is estimated to be 5M. 
Kang et al., 
2011 
Adenosine  Electrochemical detection  Self-powered paper-based sensor  
 Using adenosine binding aptamer hybridized to DNA sequence which attached to microbeads 
and loaded into one channel instead of direct immobilized aptamer to a paper surface 
 In the presence of adenosine, glucose oxidase catalyzes the oxidation of glucose which in turn 
results in conversion of [Fe(CN)6]3- to  [Fe(CN)6]4- in one half cell generating readable voltage. 
 Using digital multimeter (DMM) to read-out the signal, the current increase with increasing 
adenosine concentration  
 Encapsulate the whole system by laminate with plastic to reduce the fluid evaporation 
problem. 
Liu et al., 2012 
VEGF165  Aptamer-based surface-
enhanced fluorescent 
optical detection/AuNPs 
 Single step assay. Less than 10L of sample needed. Linear detection from 1.25pM to 1.25M 
 Cost per test ~70 times lesser than multiwall ELISA kit 
 High specificity with VEGF165. No significant signal changes from other cancer-related proteins 
but highly abundant nonspecific protein serum albumin strongly gave a false-positive signal 
Cho et al., 2012 
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Alternatively, more resilient RNA molecules can be selected de novo by 
employing modified nucleoside triphosphates. A selection can perform directly using 
starting pools of modified RNA containing 2’-amino and 2’-fluoro-deoxypyrimidine and 
2’-methoxy purines (Beigelman et al., 1995; Burmeister et al., 2005; Ng et al., 2006; 
Bouchard et al., 2010). Moreover, oxygen in sugar ribose ring can be substituted by thiol 
group, generating 4’-thioribonucleoside 5’-triphosphates such as 4’-thiouridine (4’-
thioUTP) and 4’-thiocytidine (4’-thioCTP) (Kato et al., 2005). All of their reported 
modified nucleoside triphosphates can be incorporated by evolved T7 RNA 
polymerases. Further investigation over the activity of these T7 RNA polymerases 
reported that thioUTP and thioCTP are better substrates than 2’-amino and 2’-fluoro-
deoxypyrimidine nucleoside triphosphate. Further stability studies of an RNA template 
(RNA59) toward RNase A revealed that its half-life was less than half an hour, but a 
longer half-life of around 20 hrs, was found for thioRNA59 and aminoRNA59 showed no 
degradation under the same condition during the whole range of incubation (Kato et al., 
2005). Figure 1.8 summarizes chemical modifications introduced into RNA aptamers. 
Examples of therapeutic aptamers in clinical development are shown in Table 1.4. 
 
 
 
 
Figure 1.8 Examples of chemical modifications introduced into RNA aptamers especially on the 2’ 
position of ribose sugar, which can be substituted by fluoro-, amino- and methoxy group. 
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Table 1.4 Examples of therapeutic aptamers in clinical use or clinical development  
Compound 
ID 
Therapeutic 
Target 
Kd 
(nM) 
Medical Conditions Clinical Phasea 
Related 
References 
MacugenTM 
(Pegaptanib 
sodium) 
Vascular 
endothelial 
growth factor 
(VEGF) 
0.05-
0.15 
Age related macular 
degeneration 
On the Market Ruckman et 
al., 1998; 
Green et al., 
1995 
ARC1779 von Willebrand 
factor (vWF) 
2 vWF related platelet 
function disorders 
Completed phase II Diener et al., 
2009 
ARC1905 Complement 
factor 5 
2-5 Age related macular 
degeneration 
Completed phase I Biesecker et 
al., 1999 
ARC19499 Tissue factor 
pathway 
inhibitor (TFPI) 
2.8 Hemophilia Phase II Waters et al., 
2011 
AS1411 Nucleolin 400 Acute myelogenous 
leukemia 
Completed phase II Bates et al., 
1999; 
Soundararajan 
et al., 2008 
E10030 Platelet derived 
growth factor B 
chain (PDGE-B) 
0.1 Age related macular 
degeneration 
Completed phase II Green et al., 
1996 
REG1b  Factor IXa 0.6 Coronary artery 
disease 
Completed phase II Rusconi et al., 
2002 
NU172 Thrombin 25-200 Coronary artery 
bypass 
Phase II Bock et al., 
1992 
NOX-A12 
(L-RNA)c  
CXCL12d < 1 
 
Multiple myeloma and 
non-Hodgkin’s 
lymphoma 
Phase IIa Darisipudi et 
al., 2011; 
Keefe et al., 
2010 
NOX-E36 
(L-RNA) 
CCL2e 0.15 Type 2 diabetes, 
diabetic nephropathy 
Phase IIa Darisipudi et 
al., 2011; 
Keefe et al., 
2010 
a  source: clinicaltrials.gov (as of November 2012) 
b  REG-1 anticoagulation system comprises of RB006 aptamer and its complementary active control 
oligonucleotides RB007. 
c L-RNA: Spiegelmer technology has been used to identify mirror image L configuration-RNA aptamer 
through SELEX screening process.   
d CXCL12: Chemokine (C-X-C motif) ligand 12 (also known as SDF-1)  
e CCL2: Chemokine (C-C motif) ligand 2 (also known as MCP1)  
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1.5 The SELEX Process  
SELEX is an in vitro selection process for producing high specificity and affinity nucleic 
acid aptamers against a target of choice. The general selection process begins with a 
synthetic random ssDNA or RNA pool and aim at the enrichment of binding sequences. 
In a complete random pool, one of the parameters that determined the number of 
different representatives is the length of the random region. In theory, a longer random 
sequence space can generate more complex structures, however, the overall yield of the 
longer pools falls off quickly and one may argue that longer random sequence results in 
less complete coverage of sequence space than shorter random sequence tracts. The 
advantage of minimizing the aptamer to the smallest possible size is that it is important 
for downstream ease of solid-phase synthesis and to limit costs associated with 
manufacture of the resultant aptamer. In general, pools used for the in vitro selection 
span less than 100 nucleotides in random sequence positions with a diversity of up to 
1016 different molecules (Conrad et al., 1996; Pollard et al., 2000). In most cases of 
selection against proteins, which are not normally thought to bind to nucleic acids, 
completely random sequence pools are useful for the isolation of novel binding species 
without prior knowledge of functional nucleic acid sequences or structural motifs.  
 Figure 1.9 shows nucleic acid pools used for in vitro selection experiments. Each 
oligonucleotide composes of a core random sequence flanked by defined constant 
sequences at the 5’ and the 3’ end, which are necessary for polymerase chain reaction 
amplification. An RNA pool can be generated from DNA template through the 
transcription process if the T7 RNA polymerase promoter is included in the primer.           
                                           
         Primer containing T7 Promoter 
              5’-AAGCATCCGCTGGTTGAC---N40---GATCTTGGACCCTGCGAA-3’ DNA template 
                                                    Reverse primer 
     Forward primer 
5’-AAGCATCCGCTTGAC---N40---GATCTTGGACCCTGCGAA-3’ 
                         Reverse primer 
 
Figure 1.9 Examples of N40 pool. The T7 RNA polymerase promoter (delineated in bold) is 
incorporated in a primer necessary for reverse transcription process. It is possible to add enzyme 
restriction sites in the primer region to facilitate the cloning. 
CTAGAACCTGGGACGCTT-5’ 
CTAGAACCTGGGACGCTT-5’ 
5’-GCTAATACGACTCACTATAAAGCATCCGCTGGTTGAC 
 
5’-AAGCATCCGCTTGAC 
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Conventional SELEX for DNA aptamer selection (Figure 1.10) involves the 
repetition of five steps:  
 Binding of oligonucleotides to targets 
 Partition involving the separation of ligands that bind to targets from an 
unbound oligonucleotide pool 
 Elution of bound oligonucleotides  
 PCR amplification in which the number of binding sequences will be increased  
 Generation of ssDNA or RNA which is necessary for the next round of SELEX 
process  
The number of rounds needed for the manual selection of high affinity and high 
selectivity aptamers are typically more than ten rounds. Each round takes 
approximately a day or two.  
 
 
Figure 1.10 The conventional in vitro aptamer selection. Nucleic acid starting pools are as large as 1016 
unique sequences. Iterative round of selection are carried out aiming at an enrichment of specific and tight 
binding aptamers to their molecular targets. 
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 To start the selection, the pool of nucleic acids is incubated with the molecule of 
interest. The target can be immobilized or free in solution. In an initial round, a long 
incubation time and less stringent conditions, especially a higher protein to 
oligonucleotide ratio, are applied to the selection. This is necessary to reduce the risk of 
eliminating low abundance strong binders in the early rounds (He et al., 1996). More 
stringent conditions, such as decreasing the protein to oligonucleotide ratio, changing 
the buffer, reaction volume and incubation time, are required as the number of rounds 
increase. Following incubation, the partitioning of non-binding sequences from bound 
sequences can be achieved by separation procedures. This is one of the most crucial 
steps as separation efficiency is a key factor in selection performance. The poorer the 
separation efficiency, the larger the number of repeated selection operations required, 
making conventional aptamer screening a time and labor consuming process. Several 
separation techniques used in SELEX include nitrocellulose membrane filtration (Tuerk 
and Gold, 1990; Morris et al., 1998; Pileur et al., 2003; Noma and Ikebukuro, 2006), 
affinity chromatography (Ellington and Szostak, 1990; Cheng et al., 2008), magnetic 
separation (including Ni-NTA and streptavidin coated magnetic beads) (Murphy et al., 
2003; Stoltenburg et al., 2005; Barton et al., 2009; Bing et al., 2010a; Gong et al., 2012), 
electrophoresis (mobility shift and CE) (Tsai and Reed, 1998; Mosing et al., 2005; Li et 
al., 2007) or simply through centrifugation in case of cell-SELEX (Sefah et al., 2010).  
 After the separation step, bound oligonucleotides are recovered by eluting them 
from the target molecules and then amplifying to increase the copy number of recovered 
pool for subsequent selection rounds. Using the optimum number of PCR cycles helps to 
reduce the formation of PCR artifacts due to self-internal priming and over-
amplification. Following amplification where dsDNA products are generated, ssDNA is 
prepared by removing the antisense strand, for example, by  exonuclease digestion. 
In case of RNA aptamers, an additional step is required to reverse transcribed 
RNA to cDNA. The cDNA sequences were then used as templates for PCR amplification 
and then were transcribed back into an RNA pool for the next round. By iterative rounds 
of selection, partition and amplification, groups of sequences having high affinity and 
selectivity are enriched while non-specific sequences or weak binders are removed. 
Cloning and sequencing of the enriched pool is then performed in order to generate 
individual sequences for further investigation of their binding ability.  
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 A negative selection can be applied to remove any non-specific binding aptamers 
that bind the solid support material in the absence of target. This process will sieve non-
target dependent binding molecules from the population where their accumulation 
would be problematic by overrunning a selected population (Jhaveri and Ellington, 
2000).  
 The repetitive rounds of selection are a time and labor consuming process and 
this is an obstacle to generating aptamers. The requirement to increase the throughput 
and speed of selection is challenging. Therefore, an automated platform has been 
developed to achieve fast, reproducible and parallelized selection of multiple targets 
under multiple conditions (Cox et al., 1998; Cox and Ellington, 2001; Eulberg et al., 
2005)   
 The first automatic system for in vitro selection was set up in the Ellington lab 
aiming at the selection of anti-protein aptamers. Their first platform was used to select 
RNA sequences that bound oligo-dT captured on magnetic beads using Beckman Biomek 
2000 pipetting robot. Integration of magnetic-based separation to several devices to 
assist the automation and performing the selection under optimized biological methods 
yielded RNA that contained repeated adenosine sequences in the random region (Cox et 
al., 1998). The system was then adapted to the selection of RNA aptamers that bound 
hen-egg white lysozyme (Cox and Ellington, 2001). Several modifications were carried 
out from the previous platform in order to efficiently recover the highest affinity 
aptamers, the most important of which was the use of membrane filtration for the 
partitioning rather than magnetic bead capture. Some other modifications such as direct 
amplification of bead-bound nucleic acids, progressive reduction of thermal cycler 
numbers (rather than programmed as a constant number) and providing appropriate 
conditions for anti-protein selection by omitting some chemicals which may interfere 
with the binding were carried out. The anti-lysozyme aptamer obtained from 12 rounds 
in 2 days of automated selection formed a complex with lysozyme that had a 
dissociation constant of 31nM and also inhibited its catalytic activity. Although the rate 
of throughput exceeds that of manual selection by a factor of 10-100 and also shows the 
ability to run parallel selection, the authors commented that other proteins may not be 
as easy a target as lysozyme and leaving out the quality control step routinely used in 
manual selection, such as size selection of the products, may result in the accumulation 
of artifacts, which could lead to selection failure (Cox and Ellington, 2001).   
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 The accumulation of artifacts rarely occurs in well-executed manual selections in 
which important factors including choice of selection buffer, partitioning stringency, 
amplification and monitoring enrichment can be adjustable. At some point during 
selection, the experimenter needs to make a decision of when to increase stringency 
using which methods and when to stop the selection, for example. Those inputs affect 
the efficiency and outcome of selection and therefore are considered as advantages of 
the manual selection. To mimic manual selection, the automatic system must be more 
flexible. Eulberg and his colleague (2005) designed a flexible automatic selection 
protocol that offered the flexibility to adjust selection stringency and allowed online 
monitoring. However, they presented partial automation for the whole selection process 
by running the first three rounds manually. The reason for starting the selection 
manually was to assure that the selection process started with all possible sequences in 
the pool. The first significant improvement from the Cox’s platform was the 
development of fully automated semi-quantitative PCR protocol which allowed the user 
to monitor the status of the selection, to prevent over-amplification and thus to allow for 
optimal adjustment of selection parameters for the subsequent rounds. The second 
improvement was the development of automation in RNA purification using 
ultracentrifugation in order to purify nucleic acid and allow buffer change. This robotic 
system performed more slowly than the previous platform. However, the improvement 
of flexibility would provide more successful opportunity of selection (Eulberg et al., 
2005).  
In recent years, not only have automatic systems for aptamer selection been 
developed but also many modified SELEX methods have gained huge interest for 
generating new approaches to selection (Stoltenberg et al. 2007; McKeague and DeRosa, 
2012). All of these variants aimed to reduce the number of selection rounds needed to 
generate high affinity ligands or to change aptamer properties. The consequences of 
performing selection for only a few rounds are then economically relevant where we can 
obviously save time, reagent and energy while still having a great opportunity to achieve 
the selection. Although automated systems have been developed to the point of having 
flexibility and versatility, every single step necessary for repetitive cycles remains 
unchanged. Examples of alternatives and new variants of SELEX are described in the 
next section.   
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1.6 Alternative Approaches to SELEX 
Since the first discovery of in vitro selection or SELEX in 1990 (Ellington and Szostak, 
1990; Tuerk and Gold, 1990), several modifications have been made on original SELEX 
process to meet the increasing demand for their use and to speed up the production of 
aptamers (Cox and Ellington, 2001; Mendonsa and Bowser, 2004; Lou et al., 2009; Cho et 
al., 2010) or aiming to get ‘designer aptamers’ having certain properties of particular 
interest (Klussmann et al., 1996; Rajendran and Ellington, 2008). These modifications 
have been carried on in many directions including: 
 Improving the qualities/properties of random pools 
 Improving aptamer qualities for in vivo applications 
 Improving partitioning method using modern technologies 
 Reducing selection time 
 Reducing number of steps needed for the whole processes from selection to 
characterization into probably a single step 
 Improving data analysis especially bioinformatics  
We then define the variants to SELEX that are modified SELEX from the classic 
protocol and define the alternatives that are aptamer selections with attempts not to use 
an amplification step, such as Non-SELEX, or single round selection such as MonoLEX. A 
number of examples for alternatives and variants to SELEX are summarized in Figure 
1.11. Modification of SELEX methods have been reviewed by Stoltenberg et al. (2007) 
and McKeague and DeRosa (2012). Some of the variants developed recently are 
discussed in more details later in this section.   
The following paragraphs discuss particularly recent SELEX modifications with 
modern technologies including CE-SELEX, non-SELEX (NECEEM), AFM SELEX, MonoLEX, 
M-SELEX and Next-Generation SELEX, as well as a report on the latest selection method, 
called MAI-SELEX, using modified selection modules for the efficient selection of 
aptamer pairs for a given target. 
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Figure 1.11 Several classes of modified SELEXs at different stages (show in blue box) giving 
advantages over classic SELEX especially leading to increasing aptamer affinity, selectivity, and stability 
and also shortening selection times. 
 
 
1.6.1 Capillary Electrophoresis SELEX (CE-SELEX) 
CE-SELEX has been introduced to improve the efficiency of partition by giving rise to a 
mobility shift under applied voltage induced by complex formation. Once sample is 
injected onto the capillary, free DNA migrates with the same speed, regardless of size or 
sequence, showing as a single band but the complex migrates at a different rate. Altering 
the mobility of free versus complexed nucleic acid molecules allows the separation of 
strong binders from the whole DNA population (Mendonsa and Bowser, 2004). 
CE-SELEX has several advantages over conventional SELEX. Firstly, binding 
occurs in free solution thus eliminates a shielding bias of potential binding sites resulted 
from target modification. Secondly, the poor kinetics of eluting strong binders does not 
effect the separation on CE, unlike the mechanism used in affinity chromatography. 
Thirdly, due to the high speed and great resolving power of CE-based separation, the 
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number of selection rounds reduces significantly with less non-specific background 
interactions. Finally, only small volumes of reagents are needed for the run. However, 
one might be concerned by the volume issue which becomes a drawback of the 
technique where only a small proportion of the complex mixture is injected (Mendonsa 
and Bowser, 2004; Mosing et al., 2005). Moreover, CE running conditions for any given 
target need to be optimized since high salt often used in the binding buffer has an 
adverse effect on CE resolution.   
Mendonsa and Bowser (2004) demonstrated the isolation of aptamers that 
recognize human IgE within only four rounds using CE-SELEX. The average dissociation 
constant in the fourth rounds’ DNA pool was 29±6nM. In the first round of selection, 
only unbound DNAs were observed in the electropherogram during the 10 min of 
applied voltage. The DNA-IgE complex was eluted off the capillary afterwards, but the 
peak of the complex cannot be seen. This was due to the concentration of complex being 
below the detection limit of the UV detector. Too high a concentration of DNA pool gives 
rise to a broad peak; conversely too low concentration reduces the pool complexity. PCR 
amplification became a critical step for CE-SELEX due to the small amount of protein 
entering the separation, so that optimization of low-copy number PCR was needed. A 
year later, Mosing et al. (2005) successfully carried out the selection of a DNA aptamer 
against HIV-1 reverse transcriptase (HIVRT) having a Kd as low as 180pM after four 
rounds of selection. The affinity of aptamers isolated by CE was higher than those 
obtained from conventional SELEX with reported Kd value as low as 1nM after 15 rounds 
of selection (Schneider et al., 1995). One difficulty found in using CE was the injection 
size which affected the peak shape and the resolution between unbound and bound 
sequences. Although CE-SELEX offers a high selection speed and the ability to determine 
the bulk Kd, many parameters need to be optimized by experienced users.  
 
1.6.2 Non- SELEX  
Non-SELEX is a variant of CE-SELEX in which binding and partitioning are repetitively 
carried on without amplification. Berezovski et al. (2005) introduced non-SELEX 
method termed non-equilibrium capillary electrophoresis of equilibrium mixtures 
(NECEEM). This method provides information of binding parameters of the aptamer-
target interaction including Kd, Kon and Koff. Moreover, problems that occur due to the 
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bias related to differences in PCR amplification efficiency were excluded. Furthermore, a 
parameter that defined the aptamer collection window can be pre-determined for upper 
and lower boundaries. The complexes migrate in between this region. The efficiency of 
the method depends on how good the separation between complex and free DNA is. 
From a proof-of-principle work by Berezovski et al. (2005), the low nanomolar Kd 
(0.5nM for the best one) of aptamer against protein farnesyltransferase (PFTase) can be 
obtained in only a single step within 1 hr. Selection against human Ras protein, only 
three steps of NECEEM can improve bulk affinity by more than four orders of magnitude 
(Berezovski et al. 2006). 
   
1.6.3 Atomic Force Microscopy SELEX (AFM-SELEX) 
Atomic force microscopy (AFM) is a high resolution type of scanning probe (a 
cantilever) microscopy used for imaging, measuring and manipulating sample surface at 
a resolution in nanometers scale. Peng et al. (2007) introduced a novel microscopic 
technique as an alternative SELEX that combined atomic force microscope (AFM) and 
fluorescence microscope to select individual target-binding aptamer species from the 
starting pool in single step.  
The target molecules (thrombin in this case) need to be coated on substrate 
(modified glass cover slip) and aptamers were modified by attaching a bead on one end 
and a fluorophore on the other end. In this experiment, two DNA pools, containing 
thrombin binding aptamer and non-related oligonucleotides, has been used in 1 to 1 
ratio. Fluorescence and AFM images gave information on the location where the binding 
event occurred. Individual sequence would then be picked out using an AFM tip to drag 
out the aptamer from the complex. This proof-of-principle experiment was achieved as 
the selection was specific enough to pick out aptamer sequences. Amplification and 
sequencing revealed the sequence exactly matched the thrombin binding aptamer. No 
cloning and plasmid preparation was required. AFM-coupled SELEX is a very interesting 
tool for aptamer selection; however, the feasibility of the method for real applications 
still needs to be developed. There are two questions to be considered, which are firstly 
how to apply this AFM to the real SELEX using huge diverse oligonucleotide pools and 
how to easily pick out many candidate sequences using an AFM microcantilever tip. 
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1.6.4 MonoLEX 
MonoLEX is an affinity chromatography-based alternative SELEX that requires only one 
step to complete the selection for high-affinity DNA aptamers. Developed by Nitsche et 
al. in 2007, MonoLEX was tested for applicability to aptamer selection against Vaccinia 
virus (VACV). The random pool used in this experiment was a segmental random pool 
containing 20 oligonucleotides in total oriented as 5’-N7-A-N7-A-N6-3’ where N6 and N7 
are the number of six and seven random nucleotides in the random region. Counter-
SELEX was performed on proteins from virus-free cell culture supernatant. The 
unbound DNA pool was then applied to the column of resin-bound VACV particle. 
Following the separation in affinity column, the resin of the affinity column was 
physically segmented into slices and sequential elution and amplification were 
performed to generate polyclonal aptamers. The selection resulted in an aptamer that 
can recognize orthopoxvirus family members and inhibit in vitro infection. Overall, it can 
be said that MonoLEX provides an improvement for the selection of high affinity 
aptamers by taking advantage of affinity chromatography, which facilitates the 
separation and also reduces the problematic issue of PCR efficiency during repetitive 
selection. However, a complication may appear after the binding step, where several 
quantitative PCRs need to be performed for each resin segment. There was also the 
possibility of obtaining more than one species per column segment, which then led to 
polyclonal aptamers being generated, instead of monoclonal aptamers.  
 
1.6.5 Microfluidic-SELEX (M-SELEX) 
For the past few years, increasing efforts have been made to couple aptamers with 
microfluidics for analytical and aptamer selection purposes. The advantage of this 
technique is that it allows the integration of several molecular biology methods such as 
sequence selection, separation, PCR amplification and transcription onto a chip-based 
device. This provides significant improvement in terms of increased speed, reduced 
reagent consumption, reduced cost, and simplicity. Furthermore, a microfluidic platform 
can be automatically operated as reported in a microfluidic SELEX prototype by 
Hybarger et al. (2006).  
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 Immobilization of the protein target on magnetic beads provides the advantages 
of easy handling and efficient separation of bound and unbound ssDNA. However, the 
efficiency of magnetic separation is significantly lower than CE. In this matter, Soh’s 
group (2009) developed micromagnetic selection of aptamers in microfluidic channels 
by combining magnetic bead assisted SELEX with a microfluidic device. This formed a 
robust novel SELEX technology, named M-SELEX. To demonstrate the efficiency of M-
SELEX, the light chain of recombinant Botulinum neurotoxin type A (BoNT/A-rLc) was 
selected as a target immobilized on carboxylic acid-functionalized magnetic beads via 
EDC/NHS coupling chemistry. Only a small amount of the protein target was used in the 
experiment; as low as ~2 x 1010 molecules. This high stringency applied to the selection 
through the high molar ratios between the DNA starting pool and protein targets 
enhanced the efficiency of selection and significantly reduced the number of rounds 
needed for selection. This fact is also true for the CE-SELEX. The equilibrium mixture of 
oligonucleotide pools and BoNT/A-rLc-coated magnetic beads was separated in the 
microchannel precisely controlled by the magnetic field gradients generated by 
ferromagnetic patterns imbedded in the microfluidic channel.  The selection and 
separation was successful in a single step giving low nanomolar dissociation constants 
for the selected pool. One concern related to M-SELEX is the use of immobilized targets 
since the active binding sites may be shielded due to the modification (Lou et al., 2009). 
 
1.6.6 Next-Generation SELEX 
In SELEX approach, after obtaining enriched pool of nucleic acid, individual sequences in 
the pool need to be identified for further characterization. The method generally used to 
separate individual species is to insert the sequence into a vector and transform into 
competent bacterial cells, typically Escherichia coli. Numbers of colonies are randomly 
picked and sequenced. Although this step may only take one week, it is labor intensive. 
The other limitation is that only a handful of aptamer clones represent the whole 
enriched pool and an even smaller portion of sequences are enabled for sampling, thus 
one might miss potential candidates. To overcome such problems, newly developed 
sequencing technology, called next-generation sequencing or high throughput 
sequencing, has been introduced offering the ability to process millions of sequence 
reads in parallel.    
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 A particularly interesting aptamer selection approach was introduced by Soh 
and coworkers (2010), who also developed M-SELEX. They coupled high throughput 
sequencing technology with their aptamer selection platform and called this novel 
method a quantitative selection of aptamers through sequencing (QSAS).  The special 
character of this technique is the capability to track the copy number of individual 
sequences in the pool to the order of millions throughout the selection process. 
Moreover, by comparing the ratio of copy numbers between two selection rounds, they 
can then identify high affinity sequences from the ranking of fold enrichment of each 
sequence. Interestingly, the fold enrichment represents true data of high affinity 
sequences but copy number does not. The non-correlation between copy number and 
fold enrichment can be explained by the overrepresentation of some sequences as a 
result of bias during pool synthesis or PCR amplification (Cho et al., 2010). 
 
1.6.7 Multivalent Aptamer Isolation SELEX (MAI-SELEX) 
Using probe pairs that recognize two regions on the same molecule generally increases 
specificity and efficiency as shown in antibody-sandwich type ELISA. Recently, nucleic 
acid probe pairs, such as thrombin binding aptamers, have shown their applicability in 
proximity ligation assays. Although capture and detection antibody pairs are widely 
used, only a few aptamer pairs are known. The lack of specific methods of selection for 
suitable pairs is limiting further development.   
Multivalent aptamer isolation SELEX or MAI-SELEX is one variant of 
conventional SELEX that has been developed for the selection for aptamer pairs that 
bind to different sites of target proteins (Gong et al., 2012). The interesting feature of 
this SELEX is the way they have used two different modules, affinity and specificity 
modules, which then generated an aptamer pair with the desired properties. In this 
study, Gong et al. (2012) demonstrated the selection of 2’-fluoro-modified RNA aptamer 
pairs that bind to different binding sites of the V or 3 subunits of the integrin. To start 
the selection, the affinity module was used for the selection for five rounds in order to 
enrich the target-binding molecules as in conventional SELEX. Next, the specificity 
module was employed to separate aptamer families that bind to V from those that bind 
to 3. In this step, the aptamer pool was incubated with a decoy protein,IIb3, sharing 
the 3 subunit with the original target. The binding sequences were separated as an 
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aptamer family that binds to 3. The remaining unbound sequences were further 
employed in an additional round of selection with the original target V3 obtaining a 
pool of V subunit binders. The diagram of MAI-SELEX is shown in Figure 1.12. A cross 
check on specificity was carried out using the ELISA and ELONA methods, where each 
subunit specific binder was tested in comparison with V3, V6, and IIb3. The 
results indicated that both aptamers bind exclusively to their specific target subunit. 
One limitation of this SELEX may be the choice of decoy protein required for the 
specificity module (Gong et al., 2012). 
 
 
 
Figure 1.12 MAI-SELEX scheme. Two modules were used to select for an aptamer pair. The affinity 
selection was performed to generate a pool that bound to V3 protein. In specificity selection, the binders 
were selectively incubated with a decoy protein containing the 3 subunit. Decoy binders were separated 
and represented as a 3 binder pool. Unbound oligonucleotides were used to perform a second selection 
with V3 and then collected as the V binder pool. 
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1.7 Summary 
It has been over 20 years since SELEX or in vitro selection of nucleic acids introduced 
novel biorecognition molecules, named aptamers, which play important roles as a part 
of analytical, diagnostic and therapeutic areas. Long before that antibodies dominated in 
this area and antibody-based detections are considered to be the standard and a well 
establish approach in clinical analysis. Aptamers offer potential advantages over 
antibodies as described in Table 1.1. 
One major obstacle is the relatively inadequate availability of aptamers, thus 
several SELEX variants have been continuously developed, which were reviewed earlier 
in this chapter. Furthermore, taking advantage of a wider range of targets, the numbers 
of newly discovered aptamers increase rapidly each year. In July 2011, ‘Aptamer Base’ 
(http://aptamerbase.semanticscience.org/), an online forum for aptamer-related 
discussion reported interactions involving 328 DNA aptamers and 577 RNA aptamers 
for 131 targets, mainly proteins (58%) (Cruz-Toledo et al., 2012; McKeague et al., 2012).  
As the aptamer field progresses, we would expect the emergence of more new 
aptamers in biomarker discovery, advancing early stage disease diagnosis, drug delivery 
and drug discovery, which would definitely bring many more therapeutic aptamers into 
the market.   
 
 
  
Chapter 2 
Materials and Methods 
 
 
2.1 Materials 
2.1.1 Reagents 
Acetylthiocholine (ATCh):  Sigma 
5-Bromo-4-chloro-3-indolyl--D-galactopyranoside (X-Gal): Promega 
Deoxynucleotide solution mix (dNTP mix): New England Biolabs 
5,5’-Dithiobis-(2-nitrobenzoic acid) (DTNB): Sigma 
Isopropyl--D-thiogalactopyranoside (IPTG): Sigma 
Linear polyacrylamide: Ambion 
pCR®2.1 vector:  Invitrogen  
PCR purification kit (minElute): QIAgen 
Plasmid preparation kit (Miniprep): QIAgen 
30% Polyacrylamide-bisacrylamide (29:1): Sigma 
DNA ladders: Promega 
Streptavidin MagneSphere paramagnetic particles: Promega 
SYBR gold gel staining solution: Invitrogen 
3,3’,5,5’-Tetramethylbenzidine (TMB): Sigma 
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N, N, N’, N’-Tetramethylethylenediamine (TEMED): Fluka 
Common chemicals used were reagent grade or molecular biology grade from 
Sigma unless otherwise stated. All solutions used in experiments were prepared with 
deionized water purified by a MilliQ system (Millipore). Media was sterilized by 
autoclaving at 121°C for 15 min. Buffers and other reagents were sterilized by filtering 
through 0.2m membrane (Sartorious).  
 
2.1.2 Enzymes 
Electric eel acetylcholinesterase (AChE) (Type VI-S) was purchased from Sigma. OneTaq 
DNA polymerase and lambda () exonuclease were obtained from New England Biolabs. 
Hen egg-white lysozyme was purchased from Fluka. Streptavidin (SA)-horseradish 
peroxidase (HRP) conjugate was supplied by Pierce. T4 DNA ligase and thrombin were 
purchased from Invitrogen and Haematologic Technologies, respectively. 
 
2.2 General Molecular Biology Methods 
2.2.1 DNA Quantification 
DNA concentration was quantified on a NanoDrop 1000 spectrophotometer (Thermo 
Scientific). The working volume of DNA needed for the measurement was 1.5 to 2L, 
which was sufficient to form a liquid column where the light path was completely 
covered. DNA concentration was calculated using the molar extinction coefficient of 
double-stranded DNA (dsDNA) or single-stranded DNA (ssDNA) and the values were 
calculated based on a conventional 10mm light path with preferences that at 260nm. An 
absorbance value of 1 is equal to 50g/mL (dsDNA) or 33g/mL (ssDNA). All 
calculations were performed automatically on the instrument software.    
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2.2.2 Ethanol Precipitation 
Ethanol precipitation is a conventional method used to precipitate nucleic acids and can 
be also used to purify PCR products. A 400L aliquot of DNA was concentrated by 
adding one-tenth volume of 3M Sodium acetate (NaOAc) pH 5.2 (0.3M at final 
concentration), 20-25g of linear polyacrylamide and 2.5 volumes of absolute ethanol. 
The solution was thoroughly mixed and kept at -20°C overnight. The DNA pellet was 
then collected by centrifuging samples at 20,000 g at 4°C for 1 hr. The pellet was 
washed once with ice cooled 70% (v/v) ethanol and left to dry at room temperature 
before re-suspension in water. The obtained DNA was stored at -20°C until used.  
 
2.2.3 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is generally used to determine DNA quality. Agarose gel 
electrophoresis was carried out with 3% (w/v) in 1 TAE buffer gels. The gels were 
prepared in a 12cm gel tray. Each gel was made by adding 2.1g of agarose to 70mL of 
TAE buffer followed by heating in a microwave oven until the agarose fully melted. 
Hand-warm melted gel was poured into the tray. After the gel was set, it was then 
submerged in 800mL TAE buffer. DNA samples were mixed with 6 loading buffer (30% 
(v/v) glycerol, 0.025% (w/v) each of bromophenol blue, orange G and xylene cyanol) 
before loaded to gel wells. Electrophoresis was performed at a constant voltage of 120V 
for approximately 1.5 hrs. The running DNA samples were tracked from the moving of 
the blue dye front. A DNA marker (a 25 base-pair step ladder) was also run alongside 
the samples to identify their size. SYBR® Gold was then used as the gel staining reagent 
to visualize DNA bands under UV light. The gel images were captured by the Diversity 
(Syngene).  
 
2.2.4 Nondenaturing Polyacrylamide Gel Electrophoresis (Native PAGE) 
Polyacrylamide gel electrophoresis was performed using X-Cell SureLockTM Mini-Cell 
system (Invitrogen). To determine dsDNA with 70-80 nucleotides in length, 10% (v/v) 
TBE polyacrylamide gels were used. A gel was prepared in a plastic gel cassette 
(Invitrogen) by adding 3.3mL of 30% polyacrylamide-bisacrylamide (29:1), 1mL of 10 
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TBE, 5.6mL of filtered water, 100L of 10% (w/v) ammonium persulfate and 4L of 
TEMED. Gel was formed by polymerization at room temperature for 2 hrs before use. 
Sample loading buffer was described in Section 2.2.3. The gel was run at a constant 
voltage of 200V until the dye front reached two-third of the way down the gel (30 min 
run time).  
 
2.2.5 Denaturing Polyacrylamide Gel Electrophoresis (Denaturing PAGE) 
Denaturing PAGE was prepared according to the protocol described in Section 2.2.4 but 
supplemented with 7M urea. Before starting the polymerization, a gel solution 
containing urea, acrylamide/bis-acrylamide, buffer and water was put under running 
hot tap water until urea was fully dissolved. After that the solution was allowed to cool 
down to room temperature before adding ammonium persulfate and TEMED.  
Denaturing 10% (v/v) TBE-Urea gel was used to determine/purify ssDNA fragments. 
ssDNA samples were mixed with an equal volume of 2 loading dye (95% (v/v) 
formamide, 18mM EDTA and 0.025% (w/v) each of SDS, xylene cyanol and 
bromophenol blue) and heated at 95°C for 5 min. Prior to sample loading, urea was 
thoroughly rinsed out from the wells using a micropipette. Samples were loaded into the 
wells and run with a constant voltage of 180V for 45 min. 
 
2.2.6 DNA Purification Using Polyacrylamide Gel Electrophoresis 
DNA purification using polyacrylamide gel electrophoresis was performed using the 
crush and soak method (Sambrook and Russell, 2001) with minor modifications. After 
electrophoresis, without staining, the gel was taken out from the cassette and placed on 
a fluorescent TLC plate wrapped in a transparent plastic film. The gel was then exposed 
to a UV radiation at 254nm. DNA bands appeared as dark bands of UV shadows against a 
fluorescent background. Gel slices were cut out, transferred to microcentrifuge tubes 
and crushed against the side of the tubes using a pipette tip. Next, 500l of elution buffer 
(10mM Tris-HCl pH 7 and 1mM EDTA) was added to the crushed gel before incubation 
at -80°C for 20-30 min. The frozen sample tubes were quickly melted at 95°C using a 
heat block. The temperature cycle process was repeated a few times to enhance the 
release of the DNA into the solution. To collect the DNA, the sample tubes were 
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centrifuged and the DNA supernatant was carefully drawn out. The solution was pooled 
and concentrated using ethanol precipitation (Section 2.2.2). 
 
2.2.7 DNA Amplification 
DNA amplification was performed in a thermocycler (Eppendorf). The 100L of reaction 
mixture for PCR contained 1 PCR buffer supplied by the enzyme manufacturer (80mM 
Tris-SO4, 2mM MgSO4, 20mM (NH4)2SO4, 5% (v/v) glycerol, 5% (v/v) DMSO, 0.06% 
(v/v) IGEPAL® CA-630 and 0.05% (v/v) Tween 20, pH 9.2), 0.2mM dNTP mix, 1M of 
each primer and 2.5U of Taq DNA polymerase, purified water and DNA template. The 
PCR programmed was performed as follows: the sample was pre-denatured by heating 
at 95°C for 2 min followed by repeated temperature profile of 94°C for 30 sec, 51°C for 1 
min and 72°C for 1 min. The final extension step was allowed to proceed for 10 min to 
ensure that all templates were completely double-strand and fully extend. 
 A PCR master mix was prepared in 2mL preparative scale by excluding the Taq 
DNA polymerase. The optimum number of PCR cycle needed for large scale 
amplification was determined by following the PCR course on a small scale. An aliquot of 
99.5L was then taken and thoroughly mixed with 0.5L (2.5U) of Taq DNA polymerase. 
The PCR mixture was then divided into individual thin-wall PCR tubes and performed an 
amplification using the protocol described above for 14 cycles. PCR product from every 
two cycles was analyzed using electrophoresis with 3% (w/v) agarose gels. The optimal 
PCR cycle number was selected from a cycle number that gave a bright band without 
nonspecific amplicons. A 9.5L Taq DNA polymerase was then added to the large scale 
PCR solution and mixed well before being divided into either 100L aliquots of 
individual thin-wall tubes or 50L aliquots in a 96-well PCR plate. The PCR reaction was 
performed as described above at the optimum number of amplification cycles. After the 
completion of the amplification, the PCR products were pooled together. This amplified 
pool was used to prepare ssDNA pool for in vitro selection. 
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2.2.8 Phenol-Chloroform Extraction 
Organic extraction using saturated phenol-chloroform-isoamyl alcohol (25:24:1) 
(Sigma) was performed to remove proteins from DNA solution. An equal volume of DNA 
solution and phenol-chloroform-isoamyl alcohol was vigorously mixed until milky 
solution was formed. The mixture was then centrifuged at 10,000 g for 3-5 min to 
establish the extraction phases. After that, the aqueous layer (the top layer) was 
transferred to a new tube. Chloroform was added and mixed at equal volume and 
centrifuged again. The top layer of the aqueous phase was then transferred to a new 
tube to carry out ethanol precipitation as described in Section 2.2.2.  
 
2.3 General Methods Related to DNA Cloning 
2.3.1 Plasmid and Bacterial Strain 
Linearized plasmid vector pCR®2.1 (Invitrogen) shown in Figure 2.1 was used to 
prepare recombinant plasmid where PCR amplified products was directly inserted into 
the vector through a TA cloning strategy. Recombinant plasmids were then transformed 
into competent Escherichia coli (E. coli) cells (strain DH5 [F’-Φ80lacZΔ M15 Δ(lacZYA-
argF) U169 recA1 endA1 hsdR17 (rK-, mK+) phoA supE44-thi-1 gyrA96 relA1]). This 
bacterial strain was used as the general cloning host cell throughout this thesis. 
 
2.3.2 Bacterial Growth Media 
The bacterial strain was cultured aerobically in Lauria-Bertani (LB) medium composed 
of 1% (w/v) bacto tryptone, 0.5% (w/v) NaCl and 0.5% (w/v) yeast extract, pH 7.4. For 
solid agar plates, the media was supplemented with 1.5% (w/v) agar. Premixed dried LB 
and Miller LB agar (Merck) was also used with the same compositions. The media were 
autoclaved using a 2100 Classic Autoclave (Prestige Medical). 
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2.3.3 Antibiotic Selection and Blue-White Screening 
To select the positive colonies, antibiotic resistant selection was used. As shown in 
Figure 2.1, Vector pCR®2.1 contained both ampicillin and kanamycin resistant genes. 
Either of these antibiotics can be employed by adding antibiotic solutions to the liquid 
media and LB agar. The final concentration is 100g/mL ampicillin (Sigma) and 
50g/mL kanamycin (Gibco® Invitrogen).  
Amplicillin was prepared at 100mg/mL stock solution (a 1,000 dilution when 
use). It was sterilized by filtering through 0.2m membrane filter. Kanamycin was 
supplied as a sterile 100 stock solution containing 10mg/mL kanamycin sulfate. All 
aliquots were stored at -20°C until use.  
 
 
Figure 2.1 pCR®2.1 vector map a) The map of the linearized vector pCR®2.1 showed antibiotic resistance 
genes and cloning site at the lacZ gene; b) The concept of TA cloning. A single deoxyadenosine (dA) was 
added to the 3’ end of PCR product during amplification by Taq DNA polymerase. The inserts were 
efficiently ligated with the vector that contained T-overhangs forming a close circular plasmid. Primers 
region shown above were used for DNA sequencing. (Adopted from TA Cloning® user manual, Invitrogen, 
2004) 
(a) 
(b) M13 Reverse primer 
M13 Forward primer 
T7 Promoter 
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Screening of transformants that carried a successful ligated-plasmid construct 
was also performed using blue-white screening technique (Sambrook and Russell, 
2001). Using X-Gal in conjunction with IPTG allowed a detection of recombinant clones. 
Before pouring LB agar, IPTG and X-Gal at the same final concentration of 50g/mL and 
the antibiotic were added. IPTG was prepared as a 100mg/mL stock concentration in 
purified water. The solution was filter-sterilized and stored in aliquots at -20°C. 
 
2.3.4 Bacterial Storage 
E. coli (strain DH5) was grown in 2mL LB broth at 37°C with 200rpm shaking 
overnight. Bacterial stock was then prepared by transferred 0.8mL of cell culture to a 
sterile cryovial, and then added 0.2mL of sterile glycerol to make a 20% (v/v) glycerol 
stock culture. This culture was stored at -80°C. When needed, only a little scratch using 
an inoculation loop can successfully transfer bacterial cells to LB medium. The other 
1mL of overnight-grown cells was inoculated into a 100mL of a new LB medium 
prepared in a 250mL Erlenmeyer flask. This culture was used to prepare competent 
cells as describe in a following section (Section 2.3.5). 
 
2.3.5 Preparation of Competent Cells  
E. coli competent cells were prepared according to rubidium chloride method. As 
mentioned in Section 2.3.4, the starter bacteria were inoculated into 100mL of LB 
medium. The culture was then grown in incubator shaker at 37°C, 200rpm until the 
turbidity of growing culture at 600nm reached 0.3-0.5. This process would take 
approximately 3-4 hrs. After that, the cell suspension was aliquot to pre-chilled falcon 
tubes, 50mL each. The tubes were placed on ice for another 5 min. The cells were then 
collected by centrifuging (ALC PK 120R) the tubes at 3,200 g at 4°C for 10 min. The cell 
pellets were gently resuspended in 20mL ice cold transformation buffer I solution (TFB 
I; 30mM potassium acetate, pH 5.8, 100mM rubidium chloride, 10mM calcium chloride, 
50mM manganese chloride and 15% (v/v) glycerol) and kept on ice for 5 min. The cells 
were collected as previously described and subjected to resuspend in 2mL ice cold 
transformation buffer II (TFB II; 10mM PIPES, pH 6.5, 75mM calcium chloride, 10mM 
rubidium chloride and 15% (v/v) glycerol) which were then continually stay on ice for 
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15 min. The chemically-treated competent E. coli cells were divided into 100L to pre-
chilled sterile 1.5mL microcentrifuge tubes. The competent cells were quickly frozen in 
liquid nitrogen and immediately transferred to -80°C for storage. Once needed, the cells 
were thawed on ice before continue the transformation. Freeze-thaw repeatedly of the 
competent cells should be avoided since it has reduced competent cell efficiency of 
transformation.  
 
2.3.6 Preparation of Recombinant Plasmids 
A selected ssDNA pool from the successive round of selection was a subject to be 
analyzed. To start the cloning, DNA pool were reamplified in 100L PCR reaction. DNA 
amplification was performed as described in Section 2.2.7 using 4L of DNA template. 
The amount of template to be sampled was calculated based on the fact that at least one 
copy of each DNA should represent in the reamplification reaction. The amplification 
was carried out for 8-10 cycles to avoid the formation of larger amplicons or PCR 
artifacts. The PCR product was further purified using Minelute PCR purification kit 
(QIAgen).  
The purified DNA products were then cloned into pCR®2.1 TA-cloning vector. 
Before starting, vector to insert molar ratio had been calculated using the following 
equation (2.1):  
 
 
 
 
Where X ng was the amount of the PCR product which was Y base pair in length and the 
factor 3900 was a round up number of the vector size in base pair.  
To insert PCR product to the TA cloning site, the ligation reaction was set up to 
give a ratio of 1:3 (vector to insert) as follows: in 10L volume reaction containing 5.5ng 
of fresh PCR product, 1L of 10 ligation buffer, 2L of 25ng/L pCR2.1 vector, sterile 
X ng of PCR 
product 
(Y bp of PCR inserts)(50ng of pCR®2.1 vector) 
3900 
(2.1) = 
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water to a total volume of 9.2L and added 0.8mL of 5U/L T4 DNA ligase to initiate the 
ligation reaction which was performed at 14°C overnight.  
 
2.3.7 Heat-Shocked Transformation of Bacterial Cells 
Vials of 100L of frozen competent cells were slowly thawed on ice which would take 
around 20 min. From 10L product of ligation reaction (Section 2.3.6), duplicate 
transformation was carried out by pipette 5L (25ng) of insert-containing plasmids 
directly to each vial of competent E. coli and mixed by gently tapping the vials before 
continued the incubation on ice for 30 min. The cells were then heat-shocked by 
incubation in a 42°C control temperature heat block for 1 min. Immediately following 
the heat-shock, the vials were placed on ice for 2 min before adding 1mL of pre-warmed 
LB medium supplemented with 20mM MgSO4 and 0.2% (w/v) glucose. After that, the 
vials were incubated at 37°C for 1 hr at 200rpm in an incubator shaker. Next 100-300L 
of the transformed cultures was spread on different LB agar plates containing 1 
kanamycin sulfate (Section 2.3.3). All the plates were inverted (agar on the top position) 
and incubated at 37°C overnight (14-16 hrs). 
There would be 3-4 LB agar plates obtained from one transformed cultures. 
Higher concentration of cultured can also be performed by collecting the cells using 
centrifugation, and then removed some media before resuspended the cells in 100-
200L media and plated on LB agar. However, from the experiment, the direct apply of 
200-300L culture has already given well spaced colonies and the volumes were 
convenience enough to allow an even spreading.  
 
2.3.8 Performing Control Experiment of Cloning, Transformation Efficiency 
Determination and Plasmid Self-Ligation Reaction 
Positive control experiment of cloning was performed using pUC19 plasmid 
(Invitrogen). Transformation efficiency also calculated from this experiment. By 
following the experiment 2.3.7 (heat shock), 10pg of pUC19 plasmid was incubated with 
competent E. coli on ice before carrying out the heat-shocked transformation. Cells were 
plated onto LB agar plate supplemented with ampicillin. The overnight incubated 
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colonies were then counted and calculated from the following equation (2.2) (TA 
Cloning® user manual, Invitrogen, 2004).  
Transformation efficiency = 
 
 
 
 Negative control experiment was carried out by replace plasmid with sterile 
water in which the result of overnight incubation plates should show no colony.  
False-white positive colonies can occur resulted from the degradation of the 3’- 
T-overhangs of the vector, causing a blunt-end self-ligation of the vector. To perform the 
self-ligation reaction, the solution as mentioned in Section 2.3.6 was prepared except 
that sterile water was used instead of PCR product. 50L of cell suspension was plated 
onto LB agar plate containing X-gal, IPTG and either ampicillin or kanamycin sulfate 
antibiotic. After incubating the plate overnight at 37°C, white colonies resulting from a 
supercoiled pCR®2.1 vector were counted. One should expect of less than 5% of white 
colonies presenting on the plate (TA Cloning® user manual, Invitrogen, 2004). 
 
2.3.9 Purification of Plasmid DNA Containing Isolated Sequences 
Bacteria plasmids harboring inserts were grown as white or light blue colonies. By 
picking up each single white colony of E. coli, the transformant was inoculated into 5mL 
LB broth supplemented with 1 kanamycin sulfate. The cell cultures were grown 
overnight in an incubator shaker at 37°C with vigorous shaking at 200rpm. Then, 
bacteria cells were harvested by centrifugation at 5,000 g for 3 min at room 
temperature. Plasmid extraction and purification was performed using QIAprep® Spin 
Miniprep kit (QIAgen), according to the manufacturer’s protocol.  
In detail, cell pellets were resuspended in 250L of resuspension buffer (Buffer 
P1) containing RNase A and transferred to a new sterile microcentrifuge tube. Then, a 
cell lysis started by adding 250L of alkaline buffer (Buffer P2) containing NaOH and 
SDS. The tube was gently inverted 4-6 times followed by the addition of 350L of 
Number of 
Colonies 
Transformation 
Volume (L) 
10pg pUC19 
x
  
106pg 
g 
x
  Volume Plated 
(L) 
Dilution 
Factor 
x
  
(2.2)  
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neutralized buffer (Buffer N3) containing guanidine hydrochloride and acetic acid, 
immediately mixed the solution thoroughly by inversion the tube. The tubes were then 
centrifuged at 10,000 g for 10 min. Next the supernatant was applied to the silica-
based spin column and further centrifuged for 1 min. The column was washed once with 
750L of buffer PE, containing ethanol. Recentrifugation for additional 1-2 min after 
buffer PE-wash was necessary to remove residue of ethanol. After washing, plasmid 
DNA was eluted using low salt concentration buffer, elution buffer EB (10mM Tris-HCl, 
pH 8.5) supplied by QIAgen. In our cases where sequencing was later required, sterile 
water was used instead so that 50L of water was loaded at the center of the silica 
column, let the column stand for 1 min and then centrifuged for 1 min to collect the 
eluate. In 5mL culture, 5-15g of plasmid was obtained. The DNA concentration was 
measured using the NanoDrop 1000. 
 
2.3.10 DNA Sequencing 
Individual DNA plasmid was sequenced using the service from GATC Biotech. To 
sequence the insert in pCR®2.1, the M13 reverse primer (5’-CAGGAAACAGCTATGACC-3’) 
was used. The M13 forward primer (5’-TGTAAAACGACGGCCAGT-3’) and T7 promoter (5’-
TAATACGACTCACTATAGGG-3’) also can be used referred to Figure 2.1. The sequencing 
service from GATC Biotech required 20L of purified plasmid DNA at minimum 
concentration of 30ng/L. All three universal primers were supplied by sequencing 
company.  
DNA sequences data were analyzed using ClustalW2 multiple alignment 
program (http://www.ebi.ac.uk/Tools/msa/clustalw2/). The Genebee program 
(http://www.genebee.msu.su) was used to identify supermotifs within the selected 
regions and then the Weblogo program (http://weblogo.berkeley.edu/logo.cgi) was 
used to draw a graphical illustration of each sequence supermotifs. Predicted secondary 
structures of the obtained sequences were all obtained through Mfold program (Zuker, 
2003). 
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2.4 Oligonucleotides and ssDNA Pools 
Synthetic ssDNA pools and all other DNA sequences (i.e. primers and aptamer 
candidates) were obtained from Integrated DNA technologies (IDT). The pools used in 
each experiment were explained in more detailed in the following section.  
 
2.4.1 Forward and Reverse starting DNA Pools 
Two starting pools, a forward and a reverse, were used for proximity ligation selection 
(PLS) instead of using one in order to facilitate amplification of ligated products. Each 
pool contained 40 random nucleotides flanked by different extension at both the 5’ end 
and the 3’ end. The forward (F) pool was extended at the 5’ end with forward primer 
and at the 3’ end with 13 additional nucleotides. The reverse (R) pool was flanked by 
reverse primer complementary sequence at the 3’ end and additional 13 nucleotides 
extension at the 5’ end. The R pool sequences were modified by phosphate group at the 
5’ end. The schematic diagram of sequences of F and R pools was shown in Figure 2.2. 
Concentration of oligonucleotides was determined by the NanoDrop 1000. DNA pools 
were dissolved in filtered water at a concentration of 1nmol/L (1mM) and kept as 
aliquots at -20°C.  
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a) Forward pool (F pool) 
 
 
b) Reverse pool (R pool) 
 
 
Figure 2.2 Schematic diagrams shows two starting pools used in PLS, instead of single pool. a) The F 
pool template (71 bases) and b) The R pool template (71 bases). Primers are shown above and below the 
sequence of each pool. At either the 5’ or the 3’ end, DNA sequences were extended by additional sequence 
elements which can hybridize to different half of oligonucleotide connector, allowing the T4 DNA ligase to 
be able to join the two ends together. 
 
2.4.2 The Starting DNA Pool for the Selection of Anti-Acetylcholinesterase 
Aptamers 
The starting pool was 76-mer oligonucleotides composed of 40 randomized sequences 
flanked by 18 nucleotides primer hybridization sites as shown in Figure 2.3. 
Oligonucleotides were dissolved in sterile MilliQ water to desired concentrations 
without further purification. Concentration of oligonucleotides was determined by the 
NanoDrop 1000. After dissolved, all oligonucleotides were aliquot into a smaller volume 
and stored at -20°C until use. The starting synthesized pool contained approximately 
1014 sequences. 
 
 
 
Forward Primer 
Oligonucleotide 
connector 
Oligonucleotide 
connector 
Reverse Primer 
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Figure 2.3 An example of an ssDNA pool used in in vitro selection against AChE. The DNA pool 
contained a center cored of 40 random nucleotides, flanked by constant primer binding sites at the 5’ and 
the 3’ ends. Primer sequences are shown above and below the sequence of the pool. 
 
 
2.5 Preparation of ssDNA 
2.5.1 Preparation of ssDNA Pools Based on Biotin-Streptavidin Separation 
Preparation of ssDNA from dsDNA was a critical step during the SELEX process. For this 
purpose, large scale PCR amplification (i.e. 2mL, Section 2.2.7) was carried out using 
unmodified forward and biotinylated reverse primers that allowed strand separation 
using streptavidin-coated paramagnetic particles (SA-PMPs). SA-PMPs were washed 3 
times with bead buffer (20mM Tris-HCl, 5mM EDTA and 2M NaCl, pH 7.4) and 
resuspended in 1.9mL of bead buffer. Then the bead slurry was mixed with an equal 
volume of PCR product (1.9mL) and incubated for 30 min on a rotator at room 
temperature. Following this, bead-DNA complexes were washed twice with washing 
buffer (20mM Tris-HCl, 5mM EDTA and 0.2M NaCl, pH 7.4) followed by an alkaline 
elution step. The alkaline denaturation was perfomed twice with 200L of 0.2M NaOH 
for 5 min. The eluate was neutralized with 3M NaOAc pH 5.2 and once again put on a 
magnetic stand in order to capture magnetic beads. The ssDNA was then concentrated 
by ethanol precipitation (Section 2.2.2). Figure 2.4 summarizes the preparation of 
ssDNA from the biotinylated PCR product.  
 
Forward primer 
Reverse primer 
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Figure 2.4 Diagram of ssDNA generation from biotinylated PCR product. dsDNAs were captured via the 
interaction between biotin and the streptavidin coated magnetic beads. Interruption of hydrogen bonding 
between complementary strands can then release unmodified strands while the other strand was still 
immobilized. 
 
2.5.2 Preparation of ssDNA Using  Exonuclease 
The other method of ssDNA preparation was performed using exonuclease activity. The 
 exonuclease is a highly processive enzyme catalyzing the digestion from the 5’ to 3’ 
direction of one strand of the dsDNA containing 5’-phosphate (Figure 2.5). The 
exonuclease reaction was performed as described by Citartan et al. (2010) with minor 
modifications. The digestion was performed in 50L for every 2g of purified dsDNA in 
1 exonuclease reaction buffer (67mM glycine-KOH pH 9.4, 2.5mM MgCl2 and 
50g/mL BSA) and 10 units of the enzyme. The reaction mixture was then incubated at 
37°C for 45-60 min followed by heating the solution at 75°C for 10 min to stop the 
reaction. In the aptamer selection experiment, after the heat inactivation step, the 
mixture was then extracted using phenol-chloroform extraction (Section 2.2.8) followed 
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by ethanol precipitation (Section 2.2.2). An aliquot of the final  exonuclease mixture 
was analyzed by electrophoresis on either a 3% (w/v) agarose gel or a 10% (v/v) 
polyacrylamide gel (Section 2.2.3-2.2.5) to ensure complete digestion prior to 
performing subsequent experiments. By using this method, biotinylated modification of 
ssDNA can also be generated. 
 
 
 
2.6 Proximity Ligation Selection (PLS) 
2.6.1 Proximity Ligation Aptamer Selection against Lysozyme 
Lysozyme from hen egg-white was used as a model target for PLS. It was prepared as a 
stock solution at 0.5mM in 1 lysozyme binding buffer (20mm Tris-HCl pH 7.5, 100mM 
NaCl and 5mM MgCl2). This binding buffer condition was previously used by the 
Ellington group when they used this lysozyme as the model target to select an aptamer 
through an automation system (Cox and Ellington, 2001). A mixture of 0.5nmol of each 
of the F and the R pools were diluted in 50L of 1 lysozyme binding buffer, heat 
denatured at 90°C for 5 min and then allowed to cool down to room temperature for 30 
min. Lysozyme was also diluted in the binding buffer. 100pmol (1M) of lysozyme was 
Figure 2.5 Schematic representation of  
exonuclease that selectively digests the 
phosphorylated strand of dsDNA from the 5’ to 
the 3’ end. The digestion is performed at optimum 
temperature (37°C) and optimum incubation time. 
Complete digestion thus leaves non-phosphorylated 
ssDNA as a product.  
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then incubated with 1nmol (10M) of pool mixture in a total volume of 100L. 
Incubation was carried out for two hours at room temperature with continuous mixing. 
The binding solution was then applied to a 0.45m nitrocellulose filter membrane 
(Millipore) and subsequently washed twice with 200L of selection buffer. After that 
100L of ligation mixture containing 1 ligation buffer (50mM Tris-HCl pH 7.6, 10mM 
MgCl2, 1mM ATP, 1mM DTT and 5% (w/v) polyethylene glycol-8000), 0.25U of T4 DNA 
ligase (Invitrogen) and 0.005nmol oligoconnector (0.05M) was added to the 
membrane and incubated at room temperature for 5 min. The ligation reaction was 
stopped by filtering the solution and washed 5 times with binding buffer. The DNA pool 
was extracted by heating the filter twice at 95°C for 10 min in purified water. All DNA 
solutions collected from the membrane extraction were then used as templates for the 
1st PCR amplification in 1mL reactions for 10 cycles. The 2nd PCR was then carried out in 
a time course fashion in order to monitor the presence of ligated product. The PLS was 
performed in parallel with a ‘no protein’ negative control. The quality of the proximity 
ligation product was determined by gel electrophoresis as described in Section 2.2.3. 
Selected aptamers were cloned and sequenced for further study (Section 2.3).The PLS 
workflow is shown in Figure 2.6.   
 
2.6.2 A Positive Test of Proximity Ligation Selection against Thrombin  
A positive experiment was performed by using a pair of well known thrombin binding 
aptamers (TBA), TBA15 and TBA29. The two TBA sequences were modified to mimic 
the starting pool used in PLS (see the diagram in Figure 2.2) by adding primer 
sequences (highlighted) and oligonucleotide connector hybridization sequences 
(italicized). The TBA15plus sequence was 5’-phos-TCGTGGCGTAATATGGTTGGTGTGGTTGG 
GATCTTGGACCCTGCGAA-3’ and the TBA29plus sequence was 5’-AAGCATCCGCTGGTTGAC 
CAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTC-3’. Binding buffer was used as 
reported in Bock et al. (1992) which contained 20mM Tris-acetate pH 7.4, 140mM NaCl, 
5mM KCl, 1mM CaCl2, 1mM MgCl2. The TBAs were diluted in TBA binding buffer and 
heat denatured at 90°C for 5 min then allowed the DNA solution to cool down to room 
temperature for 30 min. Human -thrombin was also diluted in binding buffer. Next, 
270pM of thrombin was incubated with 15pM TBA29 and 20pM TBA15 in a total 
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volume of 100L. Experimental procedures were identical to PLS against lysozyme 
described in Section 2.6.1. 
 
100pmol Lysozyme in selection 
buffer
1nmol ssDNA pool mixture 
(F and R pools)
Incubate at TR  for 2 hr                  
(Total volume ~ 100L)
Heat 90 C for 5 min and leave at TR for 30 min
Pipette the binding reaction directly onto the pretreated filter 
membrane, equilibrate for another 10 min
Wash membrane twice with 200L of selection buffer
Add 100L of ligation mixture and incubate at TR for 5 min
Wash the filter 5 times with binding buffer
Remove the filter from the holder and heat in water for 10 min at 
95 C to elute DNA molecules
1st PCR amplification in 1mL, for 10 cycles
2nd PCR amplification, PCR cycle course
Determine corresponding size of the proximity ligation products 
using gel electrophoresis
 
Figure 2.6 Flowchart illustrates a proximity ligation selection process. The ‘no protein’ negative 
control was performed in parallel with the sample reaction. 
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2.7 In vitro Selection of Aptamer Binding to AChE 
2.7.1 In vitro Selection of Aptamer Binding to AChE 
In vitro selection of aptamer binding to AChE was started by preparing an ssDNA pool 
(Section 2.4.2) in AChE selection buffer (1 PBSM containing 137mM NaCl, 9.7mM 
phosphate, 2.7mM KCl and 1mM MgCl2). The ssDNA pool was subjected to thermal 
denaturation at 90˚C for 5 min and allowed to cool down to room temperature for 30 
min. The initial round of selection was performed by incubation of 1nmol of the ssDNA 
pool with 100pmol of AChE using a 10-fold molar excess of ssDNA to the target protein 
in a 200L of the total reaction volume. The incubation was performed at room 
temperature with rotation for 2 hrs. Protein-DNA complexes were separated from 
unbound ssDNA molecules by sieving through pretreated nitrocellulose filter (Section 
2.6.1). Bound ssDNA sequences were collected from the membrane filter as described in 
Section 2.6.1. A 100L of PCR mixture was prepared for the DNA amplification cycle 
course (Section 2.2.7). It was performed in small scale to optimize the number of 
amplification cycles (generally 2-14 cycles) needed for a large scale preparation. PCR 
sample from every two cycles was run on a 3% (w/v) agarose gel. After gel analysis, 2-
5mL scale PCR was carried out using the biotinylated reverse primer. The ssDNA pool 
was prepared as describe in Section 2.5.1. In a subsequent round of selection, 212-
280pmol of the ssDNA pool was used. The amount of AChE was also reduced. Pre-
selection was applied to remove nonspecific membrane binding species before round 2, 
3, 5, 6, 9, 12, 14 and 15. After round 10 and 15, aptamer pools were tested for their 
inhibition to AChE activity followed by cloning and sequencing as described in Section 
2.3. The experimental flowchart is summarized in Figure 2.7. 
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1nmol ssDNA pool 100pmol AChE in selection buffer
1st Round
TR, 2 hr
DNA-AChE complex
Separation through  pretreated membrane filter
DNA elution from filter
Washing
DNA amplification of selected binding species
ssDNA preparation
New pool enrichment
Pre- selection
Membrane filter
DNA Filtrate
Next Round
DNA cloning and sequencing
 
 
Figure 2.7 Flowchart illustrates in vitro selection of anti-AChE aptamer. Multiple rounds of selection 
have been carried out to enrich strong binders. Negative selection is performed to remove nonspecific 
matrix binding sequences. The amount of DNA pool and protein target used are varied as the stringency of 
selection condition is increase in later round of selection.  
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2.7.2 Enzyme Activity Assay 
 2.7.2.1 AChE Activity Assay 
Activity of AChE was assayed according to the colorimetric method of Ellman et al. 
(1961) with modifications. The reaction mixture contained 1mM of ATCh, 2.5mM of 
DTNB (final concentration) and an appropriate concentration of AChE in 0.1M 
phosphate buffer at pH 7 as an assay buffer. Reaction was initiated by the addition of the 
AChE solution. The increase in absorbance at 412nm by the formation of yellow-colored 
product of the thiolate dianion of DTNB was monitored at room temperature for 1 to 10 
min using a SpectraMAX 340PC plate reader (Molecular Device). The catalytic reaction is 
shown in equation (2.3) and (2.4). The blank solution consisted of buffer, ATCh and 
DTNB solutions (Enzyme blank).  
 
 
 
 
AChE was prepared by dissolving the lyophilized powder in 10mM phosphate 
buffered saline to a concentration 1mg/mL or higher. AChE tends to lose its activity 
faster when prepared at lower concentration solutions for long term storage at 4°C. To 
help stabilize enzyme structure during the activity assay procedure, BSA at a final 
concentration of 0.1mg/mL can be added to the assay buffer-dilution buffer where AChE 
was highly diluted. However, an AChE stock solution was prepared in contaminant-free 
phosphate buffered saline to maintain the purity of the protein for the aptamer 
selection. 
The substrate, ATCh iodide, was prepared as a 100mM stock solution in 0.1M 
PBS pH 7. It was diluted with purified water to a concentration of 10mM before use. A 
DTNB reagent was made up at 10mM stock concentration by dissolving DTNB in 0.01M 
PBS pH 7. Aliquots of each reagent were kept at -20°C. 
Enzyme activity is expressed in units in which one unit corresponds to the 
amount of enzyme which catalyzes the formation of 1mol of thiocholine per minute.  
Acetylthiocholine + H2O   Thiocholine + Acetate                 (2.3) 
 
Thiocholine + DTNB    5-thio-2-nitro-benzoic acid        (2.4) 
AChE 
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Enzyme activity was calculated from the following equation (2.5):  
 
 
The molar extinction coefficient of the yellow anion (II) measured at a 412nm 
wavelength was 13,600M-1 cm-1 originally presented by Ellman et al. (1961). A 
correction factor of 300 was applied for an assay volume (300L total reaction volume) 
and unit conversion. 
 
 2.7.2.2 Inhibition of AChE Activity Test 
The reaction was performed as described in Section 2.7.2.1 with slight modification to a 
96-well format of flat bottom microtiter plates (Corning). To test the inhibitory effect of 
the aptamer pool or selected aptamer sequences, samples were denatured at 90°C for 5 
min and then cooled down to room temperature before incubating with AChE for 2 hrs 
in a microtiter plate. The enzyme solution was diluted yielding a concentration that gave 
a linear portion of the curve during 10 min of running, typically 0.5 to 2 absorbance 
units. An enzyme to aptamer ratio was calculated and used from equal molar to excess 
amount of aptamers. The reaction started by the addition of the mixture of DTNB 
reagent and substrate. The absorbance at 412nm was measured using the microplate 
reader. The enzyme activity was calculated as described above and presented as relative 
activity compared to free enzyme (no aptamer). An ‘enzyme blank’ sample was run in 
parallel with other samples. Triplicate experiments were performed for each sample.  
 
2.7.3 Protein Content Determination by Bradford Protein Assay 
The quantitative assay for determining AChE content in a solution was performed 
according to Bio-Rad protein microassay using Bradford reagent (Bio-Rad). A standard 
curve was generated using BSA prepared by diluting standard BSA (Pierce) to 
0.1mg/mL. The reaction mixture of 1mL contained 2-10g of protein, 200L of 
concentrated Coomassie blue dye reagent (Bradford reagent) and 0.1M phosphate 
buffer. The reactions were mixed and incubated at room temperature for 30 min. The 
AChE activity (U) =  
(ΔA412/min) 
13,600  
x 300  (2.5) 
 
91 Materials and Methods 
absorbance at 595nm was then measured. Various concentrations of the standard 
protein and samples were assayed in triplicate from three independent experiments. 
The protein concentration was calculated from the standard curve of BSA (Figure 2.8).  
 
 
Figure 2.8 Calibration curve for protein determination using Bradford’s assay. BSA was used as a 
protein standard. Each data point was performed in triplicate and fitted to a linear equation. The equation 
and R-squared value of the fitting are displayed. 
 
 
2.8 Aptamer Characterization 
2.8.1 Enzyme-Linked Oligonucleotide Assay (ELONA) 
An ELISA method was modified to measure the binding of aptamers onto immobilized 
protein targets on a solid surface. The protocol was modified from the one suggested by 
Drolet et al. (1996). Relying on the hydrophobic nature of a polystyrene surface, a 
protein target was immobilized by passive adsorption. 96-well polystyrene, flat bottom, 
non-treated microtiter plates were used. The experiments were performed as described 
in the following section. 
 
 
 
92 Materials and Methods 
 2.8.1.1 Preparation of Biotinylated Aptamers Selected by PLS 
Biotinylated aptamers were prepared by using the biotinylated forward primer and the 
phosphorylated reverse primer. After amplification, PCR products were concentrated by 
ethanol precipitation and the DNA concentrations were measured using the NanoDrop 
1000. The dsDNA was then treated with  exonuclease as described in Section 2.5.2. 
Complete digestion leaves free-biotinylated ssDNA as a product. Polyacrylamide gel 
electrophoresis was used to purify ssDNA (Section 2.2.6).  
 
2.8.1.2 Preparation of Microtiter Plates 
Lysozyme was immobilized onto the microtiter plate surface by incubating 100L of 
100nM lysozyme (10pmol/well) overnight at 4°C in 10mM sodium carbonate buffer pH 
9. After incubation, the plate was washed once with 200L of PBS supplemented with 
0.05% (v/v) Tween 20 (PBST buffer) and then further incubated the plate with 100l of 
1% (w/v) BSA in PBST for 1 hr at room temperature in order to block any remaining 
active binding sites. The plate was then washed twice with 200L of PBST buffer and 
once with 200L of 1 lysozyme binding buffer (Section 2.6.1) supplemented with 0.1% 
(w/v) BSA and 0.05% (v/v) Tween 20. For AChE and thrombin, immobilization was 
carried out in PBS pH 7.4 at a concentration of 10nM AChE and 50nM thrombin.  
 
 2.8.1.3 Aptamer-Target Binding Assay Using ELONA  
To start, DNA aptamers were prepared by thermal denaturation as describe in Section 
2.6.1. They were diluted to various concentrations (0-2M) in binding buffer. Then, 
200L of biotinylated aptamer at different concentrations was added to each well and 
incubated for 1 hr at room temperature. Next, the plate was washed three times with 
PBST buffer supplemented with 0.1% (w/v) BSA (PBSTB buffer). High sensitivity SA-
HRP (1mg/mL) was used to detect bound aptamers. It was diluted 9,000 fold in PBST 
buffer containing 1% (w/v) BSA before 100L being added to each well. The incubation 
was carried out for 30 min at room temperature followed by washing four times with 
PBSTB buffer. After washing, the bound peroxidase was detected by adding 100L of 
TMB substrate (ready-to-use substrate that already contained hydrogen peroxide) to 
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the well and incubated for 30 min at room temperature in the dark. To stop the reaction, 
an equal volume of 1M sulfuric acid was added. The absorbance was measured at 
450nm using the SpectraMAX 340PC plate reader (Molecular Devices). Control 
experiments were carried out in parallel, firstly in the absence of the protein target and 
secondly in the absence of the biotinylated aptamer. The reaction of HRP is shown in 
equation (2.6) and the ELONA procedure is summarized in Figure 2.9. 
 
CH3
NH2
CH3
H3C
H2N
H3C
CH3
NH
CH3
H3C
HN
H3C
Peroxidase
+ +
H2O2 H2O
3,3',5,5'-Tetramethyl benzidine 3,3',5,5'-Tetramethyl benzidine diimine
 
 
 
 
Figure 2.9 ELONA scheme. The affinity assay was carried out using the ELONA method. Protein targets 
were adsorbed onto a microtiter plate (Step 1) then incubated with biotinylated aptamers (Step 2). The 
amount of bound aptamer was indirectly determined through the activity of a SA-HRP conjugate (Step 3). 
TMB substrate was added (Step 4) and became oxidized by HRP to produce a yellowish color after the 
reaction was stopped. 
 
(2.6) 
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 An alternative assay format was also carried out using unmodified DNA samples 
and biotinylated reporter probes. This assay format was performed with the starting 
pool in order to identify a Kd of the starting pool. One additional step was carried out 
after incubation of the aptamer with the protein. The biotinylated reporter probes were 
used in order to track the amount of bound aptamer. Two types of probes were used 
including the 5’ probe (5’-GTCAACCAGCGGATGCTTAAAAAAAA-biotin-3’) and the 3’ probe 
(5’-biotin-TTCGCAGGGTCCAAGATC-3’), depending on the aptamer sequence. Then, 5nM of 
the biotinylated probe was added to each well and incubated at room temperature for 1 
hr then the protocol was continued with the SA-HRP step as explained in Section 2.8.2.3. 
 
2.8.2 Surface Plasmon Resonance (SPR) 
 2.8.2.1 Immobilization of SA on SAM Surface 
To start, SPR system has been warmed up for at least 1.5 hrs to equilibrate the system 
and chip surface until a steady baseline is obtained. A flow rate was set at 25L/min. 
Water was first run through the system to remove any residue of ethanol and then PBS 
(pH 7.4) was used as a running buffer. Immobilization of SA on the COOH-terminated 
SPR chip surface on both channels was carried out using EDC/NHS coupling. A 1:1 
mixture of 0.4M EDC and 0.1M NHS (0.2M EDC/0.05M NHS final concentration) was 
prepared in water and flowed over the surface for 7 min in order to activate the 
carboxyl groups on the surface. Next, 1M SA (pI ~6), prepared in 10mM NaOAc pH 5, 
was injected over the surface for 10 min. After that, the excess NHS reactive esters were 
deactivated by 1M ethanolamine solution, pH 8.5 (7 min). Finally, 10mM HCl was quickly 
run over the surface for 30 sec before washing another 30 min with running buffer. 
After each injection, the system was returned to running buffer for 2 min. Solutions used 
in each step were degassed before use. 
 
2.8.2.2 Immobilization of a Protein Target on SPR Surface 
Different formats of SPR measurement can be performed by immobilizing a protein 
target and the aptamer was flown over the surface. In order to immobilize other 
proteins, a buffer which has 1 pH unit below pI of the protein is used to facilitate the 
 
95 Materials and Methods 
coupling reaction. The immobilization is carried out on the left channel only. The right 
channel flow cell is kept as a reference with no protein. Other steps of EDC/NHS surface 
activation and surface deactivation were performed as described in SA surface 
preparation. 
 
2.8.2.3 Immobilization of Biotinylated Aptamer on SA-Coated Chip 
Immobilization of biotinylated aptamer was performed based on the affinity capture 
between SA and biotin. 0.5M-1M of biotinylated aptamer was injected onto the left 
channel of SA chip at a flow rate of 10L/min for 25 min (250L injection loop size). 
After injection, running buffer was run through the system for 30 min, and then binding 
buffer (of each aptamer) was used instead. The running of binding buffer onto the chip 
was performed for roughly around 1 hr or until steady baseline was obtained.  
 
 2.8.2.4 SPR Measurement of Affinity Constants 
2.8.2.4.1 Binding Affinity Measurement on SA-Aptamer Surface 
A series of different concentrations of target protein was prepared in the binding 
buffer. The concentration used was selected from 0.1Kd to 10Kd based on ELONA assay. 
The injection of different protein concentration was performed at a flow rate 5L/min 
over a course of 40 min followed by a 20 min dissociation phase. The regeneration of the 
surface was carried out using 10mM glycine-HCl, pH 3 injected over the surface for 30 
sec at a flow rate 25L/min. 
 
2.8.2.4.2 Binding Affinity Measurement on Immobilized Protein Target Surface 
A series of different aptamer concentrations were prepared in the binding 
buffer. The aptamer solution was heated at 90°C for 5 min and then cooled down at 
room temperature for 30 min. Association, dissociation and regeneration were 
performed similarly to the injection of protein over the SA-aptamer surface.  
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 2.8.2.5 SPR Data Analysis 
The various concentrations of ligand that were flowed over the SPR surface gave 
different observed response units shown as SPR sensorgrams. The refractive index of 
buffer was subtracted from the total curve to obtain the binding curve. Data analysis 
was performed using Scrubble software. A calculation of dissociation constant was 
based on the binding at equilibrium.   
 
2.8.3 Binding Curve Analysis 
Dissociation constant (Kd) can be obtained using a plateau value fitting. The data is 
fitting to a 1:1 Langmuir isotherm by making a primary assumption that there is a fixed 
number of one parameter (e.g. protein concentration) and ligand concentrations are 
varied. The model of bimolecular interactions is described by:  
                                                                                                                
The dissociation constant at equilibrium is defined as: 
 
 
Where Kd is dissociation constant, [A] is aptamer concentration, [T] is protein 
target concentration and [AT] is complex concentration. The equation (2.2) is rearrange 
by substituting [T], which cannot be directly measured, by a term [T]total – [AT]. The 
equation (2.2) is then transformed to: 
 
 
[AT] in the equation (2.3) is a binding signal obtained upon binding and plotted 
on Y axis. When compare the equation (2.3) with a hyperbolic plot in Origin 8.6 
program, [T]total is equal to a term P1, Kd is equal to a term P2 and [A] is a DNA 
concentration, which is plotted on X axis.  
 
A    +    T AT (2.1) 
Kd = 
[A][T] 
[AT] 
(2.2) 
[AT] = 
[A][T]total 
Kd + [A] 
(2.3) 
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2.9 Circular Dichroism Spectroscopy 
Thrombin binding aptamers were analyzed using circular dichroism (CD) spectroscopy. 
CD spectra were recorded on a Jasco J-715 spectropolarimeter interfaced with a 
computer. Oligonucleotides were prepared by pre-heating at 90°C for 5 min and cooled 
down to room temperature for 30 min before starting the experiment. The experiment 
was carried out at room temperature using a quartz cuvette with 0.05cm path length. 
The CD spectrum of 5M DNA aptamers was analyzed from 320nm to 200nm. Thrombin 
was titrated to aptamer at different concentrations. The thrombin and aptamer pair was 
incubated at room temperature for 1 hr before scanning. The scan rate was 100nm/min 
and the data gathered were the average of five consecutive scans. Buffer scanning was 
subtracted from the average scan of each sample. The data collected was normalized to 
the total molar DNA concentration. Unless otherwise stated, the spectra in this 
experiment were taken at 20°C. 
 
  
Chapter 3 
In vitro Selection and 
Characterization of Anti-
Acetylcholinesterase Aptamers  
 
 
 
3.1 Introduction 
Acetylcholinesterase (AChE) (EC 3.1.1.7) is classified as a member of serine hydrolase 
super family found in many species including insects (Harel et al., 2000), marine animals 
(Sussman et al., 1991; Bourne et al., 1999) and humans (Kryger et al., 2000). In 
mammals, AChE at the neuromuscular junction is a key enzyme in controlling the 
concentration of the neurotransmitter, acetylcholine (ACh). ACh molecules are released 
from presynaptic neuron and bind to acetylcholine receptors. Their function is to initiate 
signal to open ligand-gated sodium channels resulting in depolarization of the 
postsynaptic membrane or muscle cell. The hydrolysis of ACh by AChE results in the 
decrease of ACh concentration, the dissociation of ACh from ACh-receptor complex and 
restores the resting membrane potential by closing the ion channel. Due to its critical 
role and its unique biochemical properties, AChE has become the primary target for 
therapeutic AChE inhibitors but also as a chemical warfare agent target. An alternative 
function of AChE is found in other species, such as strongly electric fish in that their 
electric organ produces a powerful discharge of current to stun their enemies and prey.  
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AChE is a very high turnover rate enzyme as reviewed in Quin (1987). The 
structure of AChE comprises a peripheral site and the catalytic active site that is buried 
at the bottom of a deep and narrow gorge, approximately 20Å in depth. The catalytic 
triad contains serine, histidine and glutamic acid instead of aspartic acid as in most 
serine protease enzymes. A theory explaining the high catalytic efficiency is that anionic 
groups dominate the surface charge and a high net negative charge on the electric eel 
AChE active site is a driving force for the rapid association of cationic substrates (Nolte 
et al., 1980). The study by Sussman et al. (1991) revealed the unusually high content of 
aromatic amino acids near the active site gorge. Modeling of the AChE-substrate 
complex showed that the binding was ionic-strength dependence and suggested that not 
only negatively charge anionic residues, but hydrophobic amino acids also take part in 
the association of its substrate by trapping ACh with a low-affinity site at the top of the 
gorge before it diffuses rapidly to the active site. The dissociation of the products, 
choline and acetate, followed the same aromatic guidance mechanism.  
Ripoll et al. (1993) and Tan et al. (1993) made theoretical calculations based on 
the crystal structure of Torpedo AChE to show that a strong negatively charge density 
moving inward facilitated the steering and accelerating the positively charged ACh 
towards the active site gorge. To evaluate the contribution of the electrostatic properties 
to the catalytic efficiency, site directed mutagenesis of human AChE was performed. The 
replacing of surface acidic residues by neutral amino acids resulted in a decrease of the 
negatively electrostatic potential. The change in surface properties, however, had no 
significant contribution to the catalytic efficiency for both cationic and neutral 
substrates (Shafferman et al., 1994). It is possible that AChE catalytic efficiency is 
contributed to by a combination of catalytic subsites. The AChE reaction scheme was 
further extended (Szegletes, et al., 1999) to include substrate binding to the peripheral 
site, which was located at the rim of active site gorge. This peripheral binding site played 
a role in initializing the catalytic pathway and was also a target for substrate inhibition 
(Szegletes, et al., 1999).  
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Figure 3.1 shows the structural model of AChE from Electrophorus electricus 
obtained by X-ray diffraction analysis (PDB ID 1C2O) (Bourne et al., 1999). In this 
particular case the electrostatic surface calculation (using the Poisson-Boltzman 
method) was used to render the surface coloring. The red, blue and white colors 
represent negative, positive and neutral charge, respectively. As can be seen in Figure 
3.1, the charges on the AChE’s surface are not evenly distributed. The negatively charged 
patches are found surrounding the catalytic site entrance whilst positively charged 
patches occurred at the other side of the molecule. AChE from this source is used 
throughout the experiment in this chapter. 
                                        
 
 
 
Figure 3.1 Structural drawing of Electrophorus electricus AChE (PDB ID 1C2O) Columbic surface of the 
monomer created using Chimera. The red color presents negative charge whilst the blue is for positive 
charge. The original structural data obtained from the X-ray diffraction with a resolution of 4.5Å of the AChE 
(Bourne et al., 1999). 
 
 
 
Entry to 
catalytic site 
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3.2 The Development of Cholinesterase Inhibitors 
Many studies have been focused on the finding of potent inhibitors that can be used in 
the treatment of Alzheimer’s disease (McGleenon et al., 1999), myasthenia gravis (Conti-
Fine et al., 2006) and glaucoma (Alward, 1998). Inhibitors exert pharmacologic effects 
by prolonging ACh activity in the presence of cholinergic neurons. The inhibitors can be 
either natural products or synthetic cationic and/or aromatic ligands, possessing 
reversible or irreversible effects. The carbamates and organophosphates used in 
agricultural industry as pesticides are among the AChE inhibitors that covalently bond 
with the active site serine. The structures of current FDA-approved cholinesterase 
inhibitors are shown in Figure 3.2.  
 
 
Galanthamine
Tacrine Donepezil
Rivastigmine
 
 
 
Figure 3.2 The FDA approved cholinesterase inhibitors. Tacrine, Galanthamine and Donepezil are 
therapeutic reversible inhibitors while Rivastigmine is a covalent inhibitor (Alzheimer’s society, 2013).  
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3.3 In vitro Selection of Aptamers that Show Inhibitory Activity 
Hundreds of aptamers have been selected against a variety of targets varying from cells 
to small inorganic molecules (Reviewed by Stoltenburg et al., 2007; Keefe et al., 2010; 
McKeague and DeRosa, 2012). An online aptamer database is also available at 
http://aptamer.freebase.com (Cruz-Toledo et al., 2012). Amongst these aptamers, 
selections were carried out in order to isolate sequences that are inhibitory against 
enzymes of interest or inhibit cell vitality. In many cases, affinity-selected aptamers that 
can inhibit the function of their cognate target proteins were obtained from iterative 
rounds of in vitro selection. Although it is generally by chance that the affinity selection 
generates aptamers that are able to inhibit enzyme activities, it has been shown that the 
folding of aptamers in a defined tertiary structure favors them fitting into pockets or 
clefts, which are often active sites, of protein targets. Hence, it is possible to identify 
aptamers that regulate protein function (Bock et al., 1992; Tuerk et al., 1992; Conrad et 
al., 1994; Tian et al., 1995; Hermann and Patel, 2000; Cox and Ellington, 2001).  
Many inhibitory aptamers play important roles in the development of 
therapeutic agents. One of the well-known examples is thrombin binding aptamer 
(TBA). The 15-nucleotide long ssDNA (TBA15) was successfully selected with five 
rounds of selection by Bock et al., (1992). TBA15 tightly binds to the fibrinogen binding 
exosite of thrombin molecule and its inhibitory potency was demonstrated with an IC50 
of 25nM. Inhibitory aptamers may be obtained by using knowledge on a ligand’s 
structure, which can facilitate the isolation of potential candidates from the whole 
selected population. For example, an RNA aptamer folded into a pseudoknot structure 
was found to bind human immunodeficiency virus type 1 reverse transcriptase (HIV-1-
RT) with a Kd of 5nM and specifically inhibited HIV-1-RT but not other RTs (Tuerk et al., 
1992). Another example showing the potential of an inhibitory aptamer for a 
commercial application was an aptamer that blocked Taq DNA polymerase activity 
(Dang and Jayasena, 1996) and was used for ‘hot start’ PCR. General affinity selection 
was performed for twelve rounds and low pM Kd of aptamers with IC50 values at low nM 
were obtained. Then, a temperature strategy was used to select the candidates whose 
function can be reversibly switched by temperature (Dang and Jayasena, 1996). This 
aptamer has been used to replace an antibody that inactivates Taq DNA polymerase at 
room temperature (NEW ENGLAND BioLabs Inc., 2013).  
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Some protein targets expressed recombinantly can be used for selection of 
promising inhibitory aptamers. For example, hemagglutinin (HA), a glycoprotein 
presented on the surface of virus envelopes, plays a key role in the initiation of viral 
infection. As a result, HA becomes a primary target for antiviral drug development. The 
recombinant HA1 protein of the H5 subtype influenza virus A was used as a target for in 
vitro DNA aptamer selection (Cheng et al., 2008). The selected aptamer was shown to 
have antiviral activity in a cell viability assay when infected with virus in the presence 
and absence of the aptamer. However, this study lacked direct evidence of HA activity 
inhibition by the aptamer and no reported binding affinity.  
 
3.4 Background and Project Objectives 
The main purpose of this work was to develop a new DNA detection method that took 
advantage of a high catalytic activity enzyme to amplify the signal. The hypothesis was 
that the aptamer also contained an additional probe sequence and in the absence of the 
DNA target, the aptamer bound tightly to and blocked the enzyme activity. Then, when a 
target sequence was added it will hybridize with the probe sequence on the aptamer. 
And the latter dissociates from the enzyme. A new equilibrium was then reached 
because some of the aptamer molecules could no longer inhibit the enzyme. Enzyme 
activity was then measured. The signal obtained should be proportional to the amount 
of DNA target. A schematic diagram of the proposed model is shown in Figure 3.3. 
To achieve this we needed to find an enzyme that could generate an easy-to-
detect signal, such as a change in color, and aptamers that can block the enzyme activity. 
We tried the thrombin binding aptamer. However, TBA15 binds at the fibrinogen exosite 
and can block blood clotting process but not the hydrolysis activity against small 
substrates such as chromogenic peptides. The next choice was one of the highest known 
turnover rate enzymes, AChE. Previously, RNA aptamers were selected to inhibit human 
red blood cell AChE (hRBC AChE) (Zhang et al., 2003). The RNA pool from round 9 was 
shown to have inhibitory activity. Although the report didn’t have all essential 
information as neither the binding affinity of individual aptamers nor the isolated 
aptamer sequences were reported, it showed however that aptamers can be selected 
against AChE. Thus, our task was to find inhibitory ligands to electric eel AChE. This 
enzyme was picked as the target because of its availability and high turnover. The 
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activity assay of this enzyme is fast and simple and the substrate is also cheap. The 
following sections describe the whole process of anti-AChE aptamer selection through 
conventional SELEX and the binding characterization of the selected sequences.  
 
 
 
Figure 3.3 A schematic diagram shows the experiment proposal. Two assay strategies are proposed. 
The assay depends on the equilibrium between the aptamer-DNA target complexes or aptamer-enzyme 
complexes and a signal is obtained as a proportion with the DNA target. 
 
3.5 Results and Discussion 
 
3.5.1 Selection of DNA Aptamers against Acetylcholinesterase 
As shown in Figure 1.4 (Chapter 1), aptamers are identified through in vitro selection 
involving five steps:  
  Binding of oligonucleotides to target molecule  
  Separation of bound from unbound oligonucleotides 
  Elution of bound oligonucleotides  
  PCR amplification in order to increase the number of binding sequences  
  Generation of ssDNA from the PCR product  
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Briefly, the DNA pool was incubated with AChE. After incubation, aptamer-AChE 
complexes were separated from the unbound oligonucleotides followed by a PCR 
amplification and ssDNA preparation. All of the processes were performed repeatedly in 
parallel with monitoring of enrichment for those oligonucleotides that recognized the 
target. The enriched pool was then cloned into bacteria and individual clones were 
picked for sequencing. Next, common sequences were grouped into families. Aptamer 
candidate sequences were picked out and either synthesized chemically or PCR 
amplified from the relevant clone and characterized against AChE in terms of their 
binding affinity and inhibitory activity. 
By following the process described above, in our selection, the DNA pool was 
estimated to have a complexity of 1014 molecules. A random region of this library 
contains 40 nucleotides flanked by 18 nucleotides complementary to a primer pair. To 
start the selection, approximately 1nmol (24g) of DNA in the first round and about 
200-280pmol of DNA in subsequent rounds of selection was incubated with 5-50pmol of 
AChE. A simple nitrocellulose membrane filtration was used to partition the DNA 
between complexed and unbound molecules. As a well-known and simple technique, 
nitrocellulose filter binding has been commonly used to study nucleic acid-protein 
interactions and as a partitioning tool in aptamer selection. Protein targets do not need 
to be modified, which is one of the advantages of using membrane filtration. The DNA-
protein complex is retained on the filter at some efficiency based on the property of 
proteins binding strongly to nitrocellulose membranes (Riggs et al., 1970) whereas the 
DNA binds weakly. We performed 15 selection rounds in total with a number of pre-
selections by passing a DNA pool through the nitrocellulose membrane in the absence of 
protein to decrease the non-specific, membrane binding species. Stringency was also 
applied differently in some rounds by increasing the number of washing steps as well as 
reducing the ratio of target protein to DNA in order to enrich the tight binders to AChE. 
The selection process was described in Section 2.7.1. The progress of selection is 
summarized in Table 3.1. 
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Table 3.1 Anti-AChE aptamer selection conditions 
Round Input DNA 
(pmol) 
Input AChE 
(pmol) 
Incubation 
volume (L) 
DNA : AChE 
ratio 
Number of 
amplification 
cycles 
needed for 
preparative 
PCR 
Washing 
condition 
Pre-selection 
1 1000 100 200 10: 1 12 5 x 200L  
2 273 50 330 5.5: 1 10 5 x 200L  
3 271 50 409 5.5: 1 10 5 x 200L  
4 270 50 200 5.4: 1 10 5 x 200L  
5 280 10 500 28: 1 13 5 x 200L  
6 241 10 644 24: 1 13 5 x 200L  
7 280 10 400 28: 1 12 5 x 200L  
8 280 10 400 28: 1 11 5 x 200L  
9 217 7.75 443 28: 1 10 5 x 200L  
10 280 5 400 56: 1 10 5 x 200L  
11 280 5 400 56: 1 8 5 x 200L  
12 250 5 400 50: 1 10 10 x 200L  
13 280 5 400 56: 1 10 10 x 200L  
14 242 5 404 48: 1 10 10 x 200L  
15 212 5 423 42: 1 10 10 x 200L  
 
 In the initial rounds, the selection was started by keeping a low ratio of DNA to 
target in order to minimize the loss of low abundant strong binders from the starting 
pool and to keep as many of potential binding species as possible. We started the first 
round by using 1nmol of ssDNA pool and 100pmol AChE. Partitioning of bound from 
unbound DNA was performed using nitrocellulose filtration. However, a certain level of 
non-specific binding to the membrane results in the accumulation of non-target binding 
DNA, which may become a problem (Irvine et al., 1991). This is because PCR 
amplification, which is a part of the selection procedure, amplifies both specific and non-
specific DNA. To minimize this effect, pre-filtration of the ssDNA pool through 
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nitrocellulose membrane in the absence of AChE was regularly performed from the 
second round onwards.  
The stringency was increased by lowering the amount of AChE used in the 
second round and further gradually reduced throughout the selection process. In later 
rounds, the ratio of DNA to protein was kept almost constant and the stringency was 
then increased through the number of washes from round 12 to the final round. The PCR 
condition optimization is a very critical part of selection because, in order to produce a 
ssDNA aptamer pool for the subsequent round, a high amount of good quality PCR 
product needs to be prepared. Amplifying heterogeneous sequences is generally more 
problematic than for a homologous sequence. This can be seen from the accumulation of 
high molecular weight DNA products during amplification. The accumulation of high 
molecular weight products and disappearance of DNA of the expected size shown in 
progressive cycles of amplification indicate over-amplification and is probably due to 
self-internal priming by the folding back of the 3’ end forming a stem loop that can be 
further amplified. This may result from the reduction in primer concentration during 
successive cycles and so there is less competition with self-priming. This PCR over-
amplification and the formation of non-specific amplicons can be avoided by, firstly, 
optimizing the number of PCR cycles and secondly, using higher primer concentrations 
(1M to 2M) than in the typical PCR conditions (Jhaveri and Ellingtion, 2000; Musheev 
and Krylov, 2006). In this work, we used the primers at 1M concentration and 
optimized the number of PCR cycles needed for 2mL preparative scale PCR 
amplification. The optimum number was determined by following the PCR course on a 
small scale. The PCR cycle number that yielded an intense band of the expected size 
without non-specific amplicons was then chosen. The other advantages of following the 
PCR course was that we can then make a rough estimation of the point where we needed 
to increase stringency and more importantly to monitor the selection progress in later 
rounds. Agarose gel electrophoresis images of selection rounds are shown in Figure 3.4. 
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Figure 3.4 Agarose gel electrophoresis images showing the progress of aptamer pool amplification in 
round 1 to round 15. In each image, the number represented in the bottom was a PCR cycle course. A 25 
base pairs DNA step ladder (Promega) was used as a DNA marker size. The ‘100’ number indicates the DNA 
band that has a size equal to 100 base pairs. The expected size of the DNA product was 76 base pairs and 
indicated by arrows. Slightly bigger band at the bottom of the images resulted from the biotin modification 
in one strand.  
 
The number of PCR cycles can be used to indicate the point at which to increase 
stringency. For example, the appearance of a DNA band at lower PCR cycle number in 
round 4 compared to round 3 indicated the accumulation of DNA species so that we 
increased stringency condition in the subsequent round to remove weak binders. By 
referring back to Table 3.1, the stringency was increased by changing the ratio of DNA to 
protein in round 5. The increase in molar ratio of the DNA input pool to AChE led to 
more competition between specific and non-specific binding events. The progress of 
 
109 In vitro Selection and Characterization of Anti-Acetylcholinesterase Aptamers 
PCR amplification in round 11 was an indicator to increase stringency in the selection 
process. From round 12, the stringency was increased by increasing the number of 
washing steps. This washing should reduce the non-specific background retention of 
DNA on the filter and enhance the dissociation of less strongly binding molecules 
without disrupting strong complexes. Observation in later selection rounds indicated no 
further enrichment from round 13 to round 15, which suggested the point where pool 
sequences should be analyzed had been reached. 
 
3.5.2 DNA Aptamer Pool Enrichment Determination 
Gel images provided only a rough estimation of pool enrichment whilst other highly 
sensitive analytical methods can provide information of the binding affinity in parallel 
with the selection. For classic in vitro selection, we determined DNA aptamer pool 
enrichment during 15 rounds of selection, more quantitatively than with gel images by 
using an enzyme-linked oligonucleotide assay (ELONA) which provides a quick and 
simple assay format for assessing aptamer enrichment.  
The principle of ELONA is similar to enzyme-linked immunosorbent assay 
(ELISA) but instead of using the specific interaction between antibody-antigen pair, an 
aptamer plays a role as a binding molecule. ELONA offers a rapid and simple procedure 
generally used for protein detection. The modified ELONA sandwich type assay has 
accuracy, precision and specificity well within the limits expected of a traditional ELISA 
as demonstrated by Drolet et al (1996). A summary of the ELONA assay format was 
shown in Figure 1.6 (Chapter 1). Having protein target immobilized on the solid surface, 
the aptamer is added and incubated to allow equilibrium to be reached. The unbound 
aptamers are then separated from the complexes (bound aptamers) through washing 
and the retained amount of bound aptamer molecules is determined. Biotinylated DNA 
was required in this assay so that the binding can be directly monitored by adding HRP 
conjugated to SA (SA-HRP) and a chromogenic substrate for HRP. In this experiment, 
firstly we optimized the pH of the buffer used for AChE adsorption and the amount of 
AChE that can be adsorbed onto a non-treated hydrophobic polystyrene (PS) microtiter 
plate. Next, the pool’s enrichment was determined by measuring the amount of bound 
DNA at fixed added DNA. 
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To start the experiment, a microtiter plate was prepared as described in Section 
2.8.1.2. Various concentration of AChE (0-50nM) were coated onto the wells in two 
different buffers, 10mM PBS, pH 7.4 and 10mM sodium acetate buffer, pH 5.2. A non-
treated PS microtiter plate is hydrophobic by nature so that a passive adsorption of 
protein is primarily due to the hydrophobic interaction between proteins and the 
surface. It was reported that protein adsorption on hydrophobic surface works best near 
the pI of the protein where the degree of structural change is minimal (Haynes et al., 
1994). Even though the reported pI of electric eel’s AChE is 5.3, two pH buffers were 
tested because AChE is an acid-labile protein and cannot tolerate low pH in solution. The 
adsorption was performed overnight at 4°C. After incubation, the plate was then washed 
several times with PBS supplemented with 0.05% (v/v) Tween 20 and 0.1% (w/v) BSA 
(PBSTB) to reduce non-specific binding before being blocked with 1% (w/v) BSA. Some 
adsorbed protein molecules may undergo rearrangement in structure, even 
denaturation. By monitoring the enzyme activity, we can determine the active fraction of 
the AChE immobilized on the surface. The AChE activity assay was carried out using 
acetylthiocholine (ATCh) and Ellman’s reagent (Section 2.7.2.1). Figure 3.5 shows the 
activity of the immobilized AChE at different concentrations and different buffers. 
The highest activity was recorded when AChE was immobilized on the surface 
using a solution of 10nM in 10mM PBS buffer, pH 7.4 and the enzyme activities gradually 
reduced at concentrations away from this (Figure 3.5). As 100L solution of the 10nM 
AChE (MW 280kDa) was used for immobilization, the solution contained 1pmol or 
280ng of the protein This amount of protein is comparable to the typical binding 
capacity of the well which was reported to be 100-200ng of IgG per square centimeter 
and the surface area covered by 100L solution is approximately 1.0cm2 (Gibbs, Corning 
ELISA Bulletin, 2001). However, this capacity also depends on the nature of each protein 
such as size and hydrophobicity. At higher AChE concentrations, the activity bound 
showed a decrease. This might be explained as in the case in ELISA where higher 
concentrations of protein during coating led to increase in protein desorption during 
incubation and washing (Engvall et al., 1980). On the other hand, the use of higher 
protein concentrations can result in higher protein loadings but this can cause the loss 
of enzyme catalytic activity due to steric hindrance in which it could prevent access of 
the substrate to the immobilized enzyme’s active sites. The concentration of AChE at 
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10nM in 10mM PBS, pH 7.4 was used as the optimal concentration for microtiter plate 
preparation in the subsequent experiments. 
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Figure 3.5 Optimum conditions for AChE adsorption. Different concentrations of AChE diluted in 10mM 
sodium acetate pH 5.2 or 10mM PBS pH 7.4 were immobilized on microtiter plates. The activity was tested 
using the Ellman assay. In PBS pH 7.4, 10nM AChE showed the highest activity. This adsorption condition 
was subsequently used in ELONA assay. 
 
The DNA pool from round 3, 5, 7, 9, 12 and 15 and the starting DNA pool were 
then tested for their binding, which reflected the aptamer enrichment for the repetitive 
rounds. We selected ELONA to monitor the progress of aptamer enrichment because it 
allows a rapid evaluation of the pool binding capacity. As described previously, 
sequences were modified by attaching biotin to the 5’ end with a biotinylated primer 
and PCR. Purified PCR products were then treated with  exonuclease for 30 min to 
generate ssDNA (Section 2.5.2) followed by phenol-chloroform extraction (Section 2.2.8) 
and ethanol precipitation (Section 2.2.2).  
Firstly, 10nM AChE was coated in the wells and kept overnight at 4°C. It is 
necessary to keep in mind that the amount of the protein added was not the actual value 
of AChE immobilized on the surface, but by treating each well the same, we assumed 
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that the same amount of protein was adsorbed on the polystyrene surface. Following the 
protein adsorption, wells were washed once with phosphate buffer saline containing 
0.05% (v/v) Tween 20 (PBST) and the remaining surface was blocked with 200L of 1% 
(w/v) BSA in PBST. The blocking step was performed at room temperature for 2 hrs. 
Blocking is one of the essential steps associated with solid-phase assays such as ELISA 
and ELONA. The blocking aims to reduce non-specific binding of newly added proteins 
or biomolecules to the wells. Incomplete blocking resulted in high background signals. 
In this experiment, 1% (w/v) BSA was used in conjunction with non-ionic detergent, 
Tween 20, in 10mM PBS pH 7.4. Both of the blockers (0.05% (v/v) Tween 20, 0.1% 
(w/v) BSA) were also included in washing buffer. Washing solutions that contain 
blockers at these concentrations showed no disruption to previously adsorbed 
molecules of interest on the surface (Engvall, 1980).  
A detection system was used to measure the amount of bound aptamer and 
composed a colorimetric enzyme assay as previously described in Chapter 1. HRP was 
used as a developing reagent. It was conjugated with SA which can then bind with a 
biotin moiety in the DNA strand. This revealed an advantage of nucleic acids in term of 
easy modification. Biotinylation can be achieved at either the 5’ or the 3’ ends or even 
more easily by using a biotinylated probe. SA-HRP is commercially available and has 
high sensitivity, low cost and long shelf life. The flexible choice of peroxidase substrates 
made SA-HRP more attractive to use in detection. Chemiluminescent, fluorescent and 
colorimetric peroxidase substrates can be used and giving a detection limit in 
femtogram to picogram range in typical ELISA. In our experiment, N,N,N’,N’-
tetramethylethylenediamine (TMB) was used due to its low background. The reaction of 
HRP that oxidizes TMB is shown in equation 2.6. HRP then converts colorless TMB into a 
soluble blue product that can be quantified with a plate reader through the absorbance 
at 655nm. In our experiment, we chose to stop HRP activity with 1M sulphuric acid 
solution in order to measure the endpoint product. In acidic conditions, the blue 
solution turned yellow, which is more sensitive to measure at 450nm. The amount of 
substrate oxidized is proportional to the amount of aptamer complex with the target.   
To start the assay, the biotinylated DNA pools were diluted to 20nM and 
incubated with immobilized AChE for 2 hrs on microtiter plate. The affinity enrichment 
was performed as described in Section 2.8.2 for ELONA assay. Figure 3.6 shows aptamer 
affinity enrichment over 15 rounds of selection.  
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Figure 3.6 Enrichment of anti-AChE aptamers.  Pool affinity enrichment was performed using the ELONA 
assay. The 96-well plate was coated with 10nM AChE and incubated with 20nM ssDNA pools from round 3, 
5, 7, 9, 12, 15 and unselected DNA pool. The binding signal was measured at absorbance 450nm from the 
reaction of HRP and TMB. The assay for AChE-aptamer binding was performed in triplicate and duplicate for 
BSA. 
 
The absorbance at A450 showed a steady increase as the selection progressed, in 
particular after 5 rounds of selection, where the binding of the enriched pool increased 
sharply and reached a maximum at round 12. The higher signal indicated an increased 
amount of binders in the pool. By contrast, no significant signal can be observed in the 
wells that were coated with BSA. This result suggested the isolation of aptamers that 
specifically bind to AChE. This result prompted the decision to clone the DNA population 
of round 15 into a vector for sequencing.  
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3.5.3 DNA Aptamer Sequence Analysis 
After 15 rounds of selection were completed, the step that was required to identify 
potential aptamer candidates is cloning and sequencing. In this experiment, cloning 
(Section 2.3.6) was performed by inserting PCR product amplified from round 15 into 
the TA cloning vector (Figure 2.1, Chapter 2). The constructs were then transformed 
into competent E. coli cells strain DH5 (Section 2.3.7). The transformation efficiency of 
these newly prepared competent cells was calculated to be around 107 using pUC19 
plasmid as a positive control. A negative control was performed by plating sterile water 
and competent cells (no vector) on an LB plate supplemented with kanamycin (or 
amplicilin), X-gal and IPTG (for blue-white screening). No colonies appeared on either 
control plates.  The second negative control was performed by plating the cells that 
carried the vector with no insert. A few blue colonies appeared on the plate which 
suggested take-up of self-ligated vectors by bacteria so that they can survive in the 
medium that contained antibiotic. Assuming that only circular plasmids can be taken up 
by bacterial cells and only plasmids that contained an inserted sequence can form the 
proper shape through TA matching, blue-white screening was performed to reduce the 
likelihood of picking up colonies that had no insert.  
Fifty of the white colonies obtained from the cloning of the enriched aptamer 
pool from round 15 were randomly picked (from triplicate sample preparations of 
transformants). Plasmids were extracted (Section 2.3.9) for sequencing. There were 47 
sequencing results obtained from 50 clones. There were two sequences that contained 
longer random regions than the original pool length. This band extension might be due 
to a nonspecific annealing between templates known as over-amplification (Cox et al., 
1998). Some sequences are shorter than 76 bases (full length), which might be a result 
from the formation of stable loops during amplification. Sequence analysis was carried 
out using a ClustalW2 program (http://www.ebi.ac.uk) for multiple alignment analysis 
that can group the sequences into families as shown in Figure 3.7. The complete 
sequences including primer regions are shown in Appendix A.  
 
 
 
 
 
115 In vitro Selection and Characterization of Anti-Acetylcholinesterase Aptamers 
 
 
 
 
F
ig
u
re
 3
.7
 S
e
q
u
e
n
ce
 o
f 
a
n
ti
-A
C
h
E
 a
p
ta
m
e
rs
 f
ro
m
 r
o
u
n
d
 1
5
. O
n
ly
 r
an
d
o
m
 r
eg
io
n
s 
w
er
e 
al
ig
n
ed
. A
 h
ig
h
ly
 c
o
n
se
rv
ed
 s
eq
u
en
ce
d
 e
m
er
ge
d
. T
h
e 
tw
o
 d
o
m
in
an
t 
se
q
u
en
ce
s 
R
1
5
/1
9
 a
n
d
 R
1
5
/2
2
, w
er
e 
fo
u
n
d
 in
 4
4
%
 a
n
d
 9
%
, r
es
p
ec
ti
v
el
y
, o
f 
ch
o
se
n
 c
lo
n
es
. 
 
 
116 In vitro Selection and Characterization of Anti-Acetylcholinesterase Aptamers 
In order to search for common motifs among representative clones, the Genebee 
program (http://www.genebee.msu.su) was used to identify common motifs within the 
selected regions. A graphical illustration of each sequence alignment was also generated 
by WebLogo program (http://weblogo.berkeley.edu/logo.cgi) and is shown under each 
supermotif alignment (Figure 3.8). The sequence logos illustrate sequence similarity in a 
form of stacks of letters (bases) and height of each letter. The overall height indicates a 
conserved base at that position, while the relative frequency of each base is shown by 
the height of letters within the stack (Crooks et al., 2004). 
 
Local supermotif 1  
R15/2       ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGG- 
R15/4       ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/6       gggggttgacTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGG- 
R15/7       ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/11      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/13      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/15      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/18      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/19      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/20      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCTGCTGTTGG- 
R15/25      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGG- 
R15/26      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/29      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGG- 
R15/30      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGG- 
R15/32      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/38      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGg 
R15/44      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGG- 
R15/45      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGG- 
R15/46      ----------TGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGt- 
R15/49      ----------TGTGGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTtg- 
                             
Local supermotif 2  
R15/9       ggcCCGGCCCAACCTATCCTCGTAACTACCTCCAGGCCCCTC 
R15/21      -GGCCGGCCCAACCTATCCTCGTAACTACCTCCAGGCCCCTC 
R15/22      -GGCCGGCCCAACCTATCCTCGTAACTACCTCCAGGCCCCTC 
R15/37      -GGCCGGCCCAACCTATCCTCGTAACTACCTCCAGGCCCCTC 
                    
Figure 3.8 Supermotif alignment and Logos for selected aptamer pool from round 15. Five local 
supermotifs that show high similarity are shown here. The sequences in supermotif 3 and 4 are also found 
as a part in the supermotif 1. The highlighted sequences (R15/19 and R15/22) were chosen for further 
characterization.   
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Local supermotif 3  
R15/1       ATGCCCCACCCCTTGCACGACGTAGACATTCGTCTTTTTGA- 
R15/39      ATGCCCCACCCCTTGCACGACGTAGACATTCGTCTTTTTGAg 
                                         
Local supermotif 4 
R15/1       ccccttgcacGACGTAGacattcgtcttttt 
R15/2       agctctggcaGACGTAGTGTGaaggtacccg 
R15/4       agctctggcaGACGTAGTGTGaaggtaccag 
R15/6       agctctggcaGACGTAGTGTGaaggtacccg 
R15/7       agctctggcaGACGTAGTGTGaaggtaccag 
R15/11      agctctggcaGACGTAGTGTGaaggtaccag 
R15/13      agctctggcaGACGTAGTGTGaaggtaccag 
R15/15      agctctggcaGACGTAGTGTGaaggtaccag 
R15/16      gtgcgtgcgacgtGTAGTGTGtggggggtgt 
R15/18      agctctggcaGACGTAGTGTGaaggtaccag 
R15/19      agctctggcaGACGTAGTGTGaaggtaccag 
R15/20      agctctggcaGACGTAGTGTGaaggtacctg 
R15/25      agctctggcaGACGTAGTGTGaaggtacccg 
R15/26      agctctggcaGACGTAGTGTGaaggtaccag 
R15/29      agctctggcaGACGTAGTGTGaaggtacccg 
R15/30      agctctggcaGACGTAGTGTGaaggtacccg 
R15/32      agctctggcaGACGTAGTGTGaaggtaccag 
R15/38      agctctggcaGACGTAGTGTGaaggtaccag 
R15/39      ccccttgcacGACGTAGacattcgtcttttt 
R15/44      agctctggcaGACGTAGTGTGaaggtaccag 
R15/45      agctctggcaGACGTAGTGTGaaggtacccg 
R15/46      agctctggcaGACGTAGTGTGaaggtaccag 
R15/49      ggctctggcaGACGTAGTGTGaaggtacccg 
                                                      
Local supermotif 5  
R15-3       CCCACCCACTCTACTGATGCGCTTACTGCTCCCACCCCTAT 
R15-5       CCCACCCACTCTACTGATGCGCTTACTGCTCCCACCCCTAT 
R15-12      CCCACCCACTCTACTGATGCGCTTACTGCTCCCGCCCCTAT 
R15-24      CCCACCCACTCTACTGATGCGCTTACTGCTCCCACCCCTAT 
                                          
Figure 3.8 (continue) Supermotif alignment and Logos for selected aptamer pool from round 15. Five 
local supermotifs that show high similarity are shown here. The sequences in supermotif 3 and 4 are also 
found as a part in the supermotif 1. The highlighted sequences (R15/19 and R15/22) were chosen for 
further characterization.   
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As shown in multiple sequence alignment in Figure 3.7 and 3.8, common motifs 
are identified. Among the five local supermotifs and logos, shown in Figure 3.8, two 
aptamers were chosen for further characterization. It was a firm choice for R15/19 to be 
chosen for further characterization since it showed high abundance in the cloned 
population. This sequence and its homologues represented 43% of the sequenced pool. 
The second one was R15/22 which was found to be 9% of the sequenced pool. The 
sequences in full length are summarized in Table 3.2.  
 
Table 3.2 Chosen sequences of anti-AChE aptamer after 15 successive rounds of 
selection. The full length of each aptamer is shown together with the number of 
sequences found out of 47 clones. 
 
Aptamer Sequences* Frequency 
R15/19 AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAG
GTACCAGCTATTGGGATCTTGGACCCTGCGAA 
20 clones (43%) 
R15/22 AAGCATCCGCTGGTTGACGGCCGGCCCAACCTATCCTCGTAACTA
CCTCCAGGCCCCTCGATCTTGGACCCTG 
4 clones (9%) 
* A random region is shown in bold and a constant region is shown in italic.  
 
The secondary structures of the selected sequences are predicted using Mfold 
software (Zuker, 2003). This software has been developed to predict suboptimal 
secondary structure of RNA and DNA based on energy minimization for folding that 
relies on thermodynamic parameters. The temperature for folding prediction was set at 
25°C and salt concentrations were used based on the selection buffer, which were 
137mM Na+ (in phosphate buffer saline) and 1mM Mg++. The secondary structure 
prediction does neglect tertiary interactions that stabilize compact three-dimensional 
structures of sequences (SantaLucia and Hicks, 2004). Thus, it needs to be born in mind 
that Mfold can only predict a folding stability and the ratio of folded state/unfolded state 
of the sequence in solution at equilibrium, but not the conformation they form when 
bound to target. It does not imply the affinity of each structure against their target in 
which a highly stable structure may not be a better binder since ‘induced fit’ is another 
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factor to be considered upon molecular interactions. The binding affinity needs to be 
experimentally determined. 
Two possible similar folding patterns of R15/19 are shown in Figure 3.9 with 
high stabilization free energy (-9.48 and -8.78kcal.mol-1). This suggests a unique fold of 
the sequence with good stability. The R15/22 is shown to have four possible folding 
structures (Figure 3.10). This implies high diversity but lower stability of the structures. 
The primer regions are parts of the secondary structure. These two selected aptamer 
sequences did not show any shared consensus region.  
  
                         
                          (a) ΔG = -9.48kcal.mol-1           (b) ΔG = -8.78kcal.mol-1 
  
 
Figure 3.9 Possible secondary structures of the R15/19, predicted using Mfold. Two possible 
conformations of the R15/19 are shown to have very similar structures. They are difference in the ring size 
and the shift in a position of the second stem loop near the 5’ end. Less structure variation suggests a unique 
fold with a good stability at the folded state.  
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(a) ΔG = -3.43kcal.mol-1    (b) ΔG = -3.02kcal.mol-1
   
           
(c)  ΔG = -2.97kcal.mol-1    (d) ΔG = -2.44kcal.mol-1
   
Figure 3.10 The predicted secondary structure of R15/22. Four possible secondary structures of the 
R15/22 are shown to have free energy from -3 to -2kcal.mol-1. Diverse secondary structure may imply less 
stable structures.  
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3.5.4 DNA Aptamer Binding Characterization: ELONA Binding Assay  
As previously described in Section 3.5.2, the ELONA method has been used to monitor 
the progress of enrichment during the aptamer selection process. This assay has also 
been proven in its applicability to determine the binding affinity. ELONA offers 
advantages in many ways including being able to avoid radioisotope labeling, 
minimizing waste production, increase throughput in a 96-well format microtiter plates, 
ease of precise quantification of the relative binding affinities (Murphy et al., 2003). We 
can reduce the cost of using light sensitive fluorescence labeling and substitute the 
fluorescence sensitivity by signal amplification through the activity of the peroxidase 
label. Various formats of ELONA (Figure 1.6) offer a flexibility of the assay format and 
provide the possibility of performing the assay in parallel so that we can speed up 
determination of binding affinity for several targets.  
In this experiment, the simplest format of assay was chosen by adsorbing 10nM 
AChE onto PS surface of 96 wells plate as previously surveyed. The washing and 
blocking steps were performed similarly to enrichment experiment. Then, various 
concentrations of aptamer were used to incubate with this fixed amount of the protein. 
In this experiment, we investigated the interaction of the enriched pool from round 15 
and the chosen sequences, R15/19 and R15/22.    
  
 3.5.4.1 Binding Affinity of Aptamer Pool from Round 15   
The equilibrium dissociation constant (Kd) of round 15 aptamer pool (R15 pool) was 
calculated using ELONA. AChE was coated on a 96-wells plate with the same condition 
as the ELONA enrichment assay. The pool sequences were reamplified using 5’-
biotinylated forward primer, thus the biotin was attached to the 5’ end. Various 
concentrations of the starting random pool and R15 pool in the range of concentration 
0-10nM were added into each well (triplicate for each data point). The amount of bound 
aptamer pool was measured by adding SA-HRP and TMB and the recorded absorbance 
value at 450nm was plotted against aptamer concentration (Figure 3.11). The Kd was 
calculated using Origin 8.6, assuming a 1:1 binding isotherm. The Kd of R15 pool was 
calculated to be 0.21nM and 0.26nM from two independent experiments. There was only 
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background signal levels obtained from the wells that the starting pool was added 
indicating negligible binding to the AChE.  
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Figure 3.11 Binding curve for the round 15 DNA pool. Following the 15 rounds of selection, various 
concentrations of R15 pool and starting pool were incubated with AChE coated on microtiter plate. Fitting 
the data to a Langmuir isotherm resulted in a Kd of 0.21nM and 0.26nM from two independent experiments 
for the affinity of R15 pool aptamer for the AChE. The binding signal from unselected pool shows no 
significant increase. Each data point was assayed in triplicate. 
 
3.5.4.2 Binding Affinity of Selected Aptamer: R15/19 and R15/22 
The two aptamers were abundant in the cloned population of the enriched pool, as can 
be seen in the sequence alignment (Figure 3.7 and Figure 3.8), were selected to be tested 
their binding affinity against AChE (Table 3.2). Consistent with the abundant 
representation, sequence R15/19 showed pM affinity by using the same ELONA format. 
The calculated Kd for the R15/19 from two independent measurement were 49pM and 
60pM using nonlinear curve fitting in Origin 8.6, assuming a 1:1 binding isotherm 
(Figure 3.12). The plateau curve and low absorbance value of the R15/22 would suggest 
negligible binding affinity (Figure 3.12). The high occurrence of the R15/22 in the 
cloned population of the enriched pool but no binding ability may be due to a sequence 
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bias in PCR amplification. It was also a possibility that the AChE molecule was not 
oriented to expose the binding site for the R15/22 when immobilized on the surface.  
 
 
(a) 
R15/19 AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGACCCTGCGAA 
R15/22 AAGCATCCGCTGGTTGACGGCCGGCCCAACCTATCCTCGTAACTACCTCCAGGCCCCTCGATCTTGGACCCTG 
 
(b) 
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Figure 3.12 Dissociation constant of chosen aptamers, R15/19 and R15/22 from Round 15. (a) Two 
sequences were chosen for binding affinity assay based on the enrichment found. (b) Various 
concentrations of each aptamer (0-10nM) were incubated with AChE coated on microtiter plate. The Kd of 
the R15/19, fitting the data to a Langmuir isotherm, was calculated to be 49pM and 60pM from two 
independent experiment. No binding affinity was observed for R15/22. Each data point was assayed in 
triplicate. 
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In general, the binding signal intensity reflects aptamer to protein interaction. 
Especially at the plateau region, the value also depends on factors such as saturation of 
the binding site (Clark et al., 1986). This might be used to explain the absorbance 
difference in binding signal derived from the assay of DNA pool round 15 and the 
R15/19 sequence. The random orientation of molecule during adsorption can cause 
some binding sites to be hidden and thus reduce the accessibility of the aptamer to its 
binding motif. Due to the multivalent recognition sites of AChE, various DNA aptamers 
found in the pool could simultaneously interact with the target but the R15/19 sequence 
would specifically bind to a certain site of the molecule. The proportion of binding of the 
R15/19-AChE could therefore be lower than that of the pool-AChE. This would be one 
limitation of using immobilized protein in some applications. Figure 3.13 describes the 
proposed model. In addition, regarding to the amounts of AChE on the surface, plate to 
plate variation could be another factor affecting the binding. In our replicate 
experiments, we may find the difference in signal intensity but this could happen in a 
proportion that would not affect the binding affinity value.  
 
 
 
 
Figure 3.13 The model represents the effect of protein orientation once adsorption onto a solid 
support to the binding efficiency and signal intensity in an ELONA assay. Due to the multiple binding 
site of target, aptamer pool can bind to different sites on the molecule. In contrast the individual sequence 
specifically binds to only single site on the target. This specific binding would lead to the reduction of signal 
intensity which partly depends on the interaction between aptamer and protein. 
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3.5.5 Inhibition Assay of AChE Binding Aptamer to AChE Activity 
AChE is classified as a member of the serine hydrolase superfamily. It is recognized as a 
high turnover rate enzyme that plays an important role at neuronal junctions in order to 
catalyze hydrolysis of neurotransmitter, ACh. As described previously, several AChE 
inhibitors including plant extracts and chemical drugs have been studied for their 
applicability in therapeutic uses. Here in this section, as we aimed to perform the 
aptamer selection against AChE using conventional SELEX, the selected aptamer was 
required to assay for its inhibitory activity once bound to AChE.  
 AChE activity was assayed by followed its initial rate velocity as explained in 
Section 2.7.2.1 using Ellman’s colorimetric method. The rate of non-enzymatic 
hydrolysis of acetylthiocholine (ATCh) was performed as a blank reaction. Free enzyme 
activity at different concentrations was first measured as shown in Figure 3.14. This 
experiment was performed in order to determine the optimum enzyme concentration 
for further analysis. In a run, the curve describing the hydrolysis was observed during 
the first few minutes where the reaction rate monitored through absorbance at 412nm 
was linear and the slope was not too high. The initial rate velocity was calculated from 
the slope (ΔA412/sec) at each enzyme concentration. The relationship of AChE 
concentration, initial rate velocity and enzyme activity is shown in Table 3.3. The 
enzyme activity was calculated as described in equation 2.5 (Section 2.7.2.1).  
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Figure 3.14 Initial rate velocity of AChE at different concentrations. The reaction mixture contained 
1mM of ATCh, 2.5mM of DTNB in selection buffer (1 PBS supplemented with 1mM MgCl2). The hydrolysis 
started by adding AChE solution. The formation of yellow color product of the thiolate dianion of DTNB was 
immediately monitored at room temperature at absorbance 412nm.  
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Table 3.3 Rates of hydrolysis of acetylthiocholine (ATCh) by different 
concentrations of AChE  
[AChE] 
(final concentration) 
ΔA412/sec 
(Slope) 
Rate (M/min) mol thiol/min 
AChE activity 
(Unit, U) 
42.5pM (3.5ng) 0.004 1.7x10-5 0.005 0.005 
85pM (7ng) 0.007 3.3x10-5 0.01 0.01 
170pM (14ng) 0.014 6.2x10-5 0.02 0.02 
 
 Due to the fast hydrolysis rate of AChE, the enzyme dilution was made from 
stock solution to give an activity in a range of 0.005-0.01U. This range was selected for 
the inhibition assay as a suitable amount of enzyme that gives not too fast an initial rate 
of reaction to monitor. This experiment was rerun each time a new batch of AChE 
solution was prepared. To evaluate the potency of inhibition, a DNA pool or selected 
aptamer was incubated with AChE with 4:1 molar ratio for 2 hrs. The initial rate velocity 
was followed and calculated as a relative activity by setting AChE activity in the absence 
of aptamer equal to 100%. Figure 3.15(a) and (b) is shown the relative activity of AChE 
in the presence of each DNA pool of round 4, 7, 10 and 15 and R15/19 aptamer. The 
initial rate velocity curves of each sample are shown in Appendix B.  Unfortunately, 
neither the DNA pool nor R15/19 showed any significant inhibitory effect against AChE. 
The difficulty of gaining the aptamers that can block the active site pocket of AChE may 
be due to the net negative charge of AChE near the active site entrance (Figure 3.1). The 
presence of strong electrostatic field appears to preferentially interact with cationic 
ligands into the active center gorge (Nolte et al., 1980) whist DNA is negatively charged 
at the working pH (pH 7.4) and therefore is repulsive to the active site of the AChE. 
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Figure 3.15 Relative activity of AChE in the presence of aptamer pool from different round (a) and 
R15/19 aptamer (b). Fixed amount of aptamer pool was incubated with AChE solution and the AChE 
activity was assayed by followed its initial velocity using Ellman’s colorimetric method. The difference of 
activity of AChE incubating with each pool or R15/19 was considered to be not significant. 
(a) 
(b) 
 
128 In vitro Selection and Characterization of Anti-Acetylcholinesterase Aptamers 
3.5.6 AChE Immobilization with High Retention of Activity through Aptamer 
Mediated Attachment 
It has been known that immobilization technology can improve enzyme stability and 
reusability for industrial and analytical applications (Cass et al., 1984; Chibata, 1986; 
Yamaguchi and Miyazaki, 2013). Several techniques have been developed to improve 
many enzyme properties compared to the corresponding soluble enzyme (Ukeda et al., 
1996; Mateo et al., 2007). Traditional approaches such as passive adsorption (Butler et 
al., 1993) and covalent binding (Paynter and Russell, 2002) often result in substantial 
loss of enzyme activity where even slightly changes in a conformation can have a major 
impact on function (Sheldon, 2007).  
 In recent years, well-established chemistries for DNA immobilization have been 
applied to aptamers by offering ease and robustness in attaching aptamers to a variety 
of surfaces without losing their function. This nucleic acid based aptamer could then be 
efficiently used to immobilize their targets with high affinity and high specificity as 
demonstrated through applications in microarrays and DNA biosensors (Sassolas et al., 
2007; Liu et al., 2010; Wu et al., 2012; Liu et al., 2012; Cho et al., 2012). The selective 
ability of aptamers to bind a particular region of their targets, especially for proteins, 
without interfering or blocking the active site(s), then offers an application of aptamers 
in affinity immobilization of the native, unmodified proteins. 
 We considered our anti-AChE aptamer (affinity in low pM range) for application 
as a mediator in AChE immobilization. AChE-based biosensors have been developed to 
monitor levels of pesticides such as carbamates and organophosphates which are used 
in agriculture. These toxic substances are found to contaminate the environment (soil 
and water) and can enter to food chain where they could be harmful to humans 
(Roepcke et al., 2010; Pundir and Chauhan, 2012). In these sensing devices, AChE was 
immobilized either by adsorption (Nguyen et al., 1998), covalent attachment (Barshan-
Tashnizi et al., 2009) or through the biotin-streptavidin interaction (Huang et al., 2008). 
One immobilization method we would like to propose here is that of using an aptamer 
mediated immobilization in order to increase loading of the active enzyme. This would 
offer a new method for the immobilization of AChE if it proved to provide a surface 
containing a higher density of active AChE than that of the other immobilization 
methods.  
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Our selected R15/19 anti-AChE aptamer showed the Kd in low pM range (Figure 
3.12) and did not inhibit AChE (Figure 3.15). This suggests that the aptamer did not bind 
at or close to the active site of the enzyme, which makes it suitable as a reagent to 
mediate AChE immobilization. To assess its validity for this purpose, it needs to be 
shown that aptamer mediated immobilization results in a high level of retention of 
activity. Two sets of experiments were performed by comparing the activity of adsorbed 
AChE on a microtiter plate with captured AChE on the R15/19 aptamer-coated surface 
as showed in the experimental diagram in Figure 3.16. 
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Figure 3.16 A diagram shows the experimental strategy for assaying the effect of immobilization 
method and the degree of enzyme loading capacity. AChE was immobilized by two methods (1) affinity 
capture by aptamer and (2) physical adsorption. Blocking and washing step were applied as in ELONA 
method. AChE activity was assayed by followed ATCh hydrolyzed rate using Ellman’s reagent. The 
measurement was performed at A412.   
 
 In the first set of experiments, the plate was first coated with 100L of 50nM SA 
in sodium acetate buffer, pH 5.0. Aptamer molecules were immobilized through SA-
biotin interaction. After blocking and washing steps, 100L of various concentrations of 
AChE (5nM -200nM) were added to each well and then the activity was assayed. The 
second set of experiments was performed by assaying enzyme activity which was 
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directly adsorbed onto PS surface at different concentrations from 5-20nM. As described 
in the ELONA experiment (Section 3.5.2), the maximum capacity of the plate is roughly 
around 100-200ng of IgG. The lowest amount of AChE used was 140ng (0.5pmol) which 
was well in the capacity range of the plate whereas the highest amount added to the well 
was calculated to be 5.6g (20pmol) of protein. AChE activity immobilized by different 
methods is shown in Figure 3.17. AChE which was captured on the R15/19 was shown 
to be 4-fold higher activities than that of the directly adsorbed molecules.  
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Figure 3.17 R15/19 as a capture molecule for AChE. Two different formats of enzyme captured to PS 
were tested including the affinity capture by immobilized aptamer and the adsorption of AChE to PS surface. 
The AChE was retained on PS surface at a limited amount comparing to AChE that captured by aptamer 
R15/19 at the same concentration (5-20nM). Further increase in AChE concentration to 50nM, the curve 
started to saturate. This suggested the higher efficiency of aptamer capture than direct protein adsorption. 
Each data point was assayed in triplicate. 
 
As shown in Figure 3.17, AChE activity became saturated and we could estimate 
the Kd of this AChE-aptamer capture interaction (half of the maximum activity) to be 
around 10nM. This estimated Kd was higher (lower affinity) than the one we obtained 
from ELONA test (55pM). This might be explained in terms of the different 
immobilization formats where in one method, AChE molecules were directly adsorbed 
and the other method, AChE molecules were captured by the immobilized aptamer.  
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The 4-fold higher activity of AChE obtained using the aptamer as an 
immobilization mediator compared to the adsorption method is consistent with the 
observation that the aptamer does not inhibit AChE activity (Figure 3.15). There are a 
number of factors that cause loss of catalytic activity when enzymes are immobilized; 
these include surface induced denaturation and aggregation (Engvall, 1980; Sharma et 
al., 2010) as well as steric hindrance of access by substrate to the active site. In the case 
of aptamer mediated immobilization it is possible that the absence of direct interaction 
between the protein and surface reduces the denaturation whilst the flexible nature of 
the ssDNA chain linking the two allows for good substrate accessibility.  
Immobilization of AChE through this mediated aptamer not only allows the 
enzyme to be attached on the surface with a uniform direction but also keep the 
enzyme’s active site away from steric hindrance to facilitate ligand access resulting in 
the higher activity. Aptamer capture strategy would therefore improve signal intensity 
and consequently sensitivity in the development of a sensing device. A further 
advantage is that no modification of AChE is required. 
 
3.6 Conclusions 
After 15 round of in vitro selection, we selected the aptamer, so-called R15/19, that 
binds to AChE with a dissociation constant in the picomolar range. The combination of 
the sensitivity of an ELISA technique with the flexibility of a DNA-based recognition 
molecule proved a great success in using ELONA to monitor the progress of selection 
and to measure the binding affinity of DNA-ligand. Although, we could not achieve the 
selection of an inhibitory aptamer, our selected aptamer can be used as a mediator for a 
new AChE immobilization strategy that does not require any additional modification of 
proteins of interest. The 4-fold increase in AChE catalytic activity of aptamer-captured 
over adsorbed enzyme represents a significant improvement in enzyme performance. 
This aptamer capture method can also be applied to 1) capture AChE in order to select 
aptamers that recognize different binding sites on a molecule; 2) capture AChE for pre-
concentration and purification purpose; 3) prevent AChE undergoing denaturation due 
to adsorption to the hydrophobic PS surface.  
  
Chapter 4 
Proximity Ligation Selection and 
Bivalent Thrombin Binding Aptamers 
 
 
There have been increasing demands for using aptamers either in therapeutic 
applications or as analytical tools. Aptamers have been selected for various targets 
through the process called SELEX (Ellington and Szostak, 1990; Tuerk and Gold, 1990). 
The entire conventional in vitro selection process however, is time-consuming, although 
picomolar affinities are achievable as shown by the results in Chapter 3. In order to 
generate aptamers that can meet the current and future demands, a number of 
alternative selection methods have been developed that were previously reviewed in 
Chapter 1.  
 This chapter will focus on proximity ligation selection (PLS) which is a 
modification of the original proximity ligation assay (PLA) reported by Fredriksson et al. 
(2002). They used two aptamer probes that can simultaneous and proximate recognize 
the homodimeric platelet-derived growth factor B-chain (PDGF-BB) and human -
thrombin. The PLA is not only a sensitive way to measure protein concentration but has 
also been shown to be valuable for protein localization (Söderberg et al., 2006). In 
recent publications, a combination of two known aptamers (also known as fusion 
aptamer, dual aptamer, bifunctional aptamer and bivalent aptamer) has been designed 
to recognize simultaneously different parts of the target molecules with improved 
functionalities over the monomer (Umehara et al., 2005; Müller et al., 2007; Hasegawa et 
al., 2008; Kim et al., 2008; Bing et al., 2010b). By adapting this PLA, a novel aptamer 
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selection method was developed aiming at bringing down the number of selection 
rounds to only a single step. An effort to shorten selection time takes advantage of 
multiple interactions that can then make it possible to generate sequences that contain 
two binding sites through rapid selection. It may also produce higher affinity binders 
based on avidity interactions. The PLS can, therefore, be used as a powerful selection 
tool for aptamers. 
 In this study, thrombin was chosen as the model target as two well-
characterized monofunctional thrombin binding aptamers (TBA15 and TBA29) are 
known. This chapter will start with a brief review on thrombin, its inhibitors and 
thrombin binding aptamers, before discussing PLS against human -thrombin. The 
selection used either two complete starting pools or the known TBA29 aptamer and a 
single starting pool. Characterization of the selected binders was performed to 
determine if they possessed G-quadruplex structures using circular dichroism 
spectroscopy and binding affinity of the selected sequences were analyzed using ELONA 
and SPR. 
 
4.1 Human -Thrombin: A Structure and Its Functions  
In response to damage occurring to the endothelial lining, the blood clotting process 
plays an important role as a part of a physiological response that stops bleeding (Stubbs 
and Bode, 1995). -Thrombin is a key serine protease that plays an important role in 
controlling the blood clotting process. Understanding thrombin structure and its 
inhibitor mechanism can therefore help to regulate the functions of thrombin and 
expand its applications to biomedical, therapeutic and diagnostic fields. Found as a 
precursor (prothrombin) in the blood stream, it is activated by a series of factors in both 
intrinsic and extrinsic pathways of the blood clotting cascade. The active thrombin then 
in turn triggers the clot formation process through the production of a fibrin network 
where specific cleavage of the negatively charged fibrinopeptides by thrombin then 
enhances the interaction of fibrin monomers to form an insoluble clot (Ng et al., 1993). 
This activation cascade also works in parallel to the adhesion of glycoproteins on the 
platelet cell membrane to the subendothelial layer, which consequently recruits more 
platelets at the site to form an aggregate. The aggregation process also needs help from 
fibrinogen in order to anchor the platelets to one another (Lieberman and Marks, 2012).  
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Like trypsin, the thrombin cleaves the C-terminal peptide bonds of arginine and 
lysine residues, but with a much higher specificity for the cleavage site on its substrate. 
In addition to the deep and narrow active site cleft and apolar subsites surrounding the 
catalytic center, thrombin’s specificity toward its substrates also involves two regions 
clustered with positively charged residues, one called the fibrinogen binding exosite at 
the base of the catalytic site and the other the heparin binding exosite, which is found 
close to the carboxy-terminal of the B-chain helix (Bode et al., 1992). These extra 
binding exosites and canyon like active site cleft contribute to the remarkable specificity 
of thrombin toward its substrates and they are also the targeting site of inhibitors. The 
structural model of thrombin is shown in Figure 4.1.  
 
4.2 Thrombin Inhibitors 
Blood coagulation needs to be controlled in a very precise fashion to prevent the 
random formation of a clot, which might block the blood vessels. In such cases where 
patients fail to control the activity of enzymes related to blood coagulation this could 
lead to the risks associated with thrombotic disorders that can cause disability and 
death (Lee and Ansell, 2011; De Caterina et al., 2012). The discovery of safe 
anticoagulant drugs is therefore challenging. To meet the requirement of safer 
anticoagulant drugs, which show little or no sign of side effects, is still the goal 
prompting continuous development, to expand several classes of anticoagulant 
molecules. To date, natural and man-made inhibitory molecules have been developed 
and can be categorized into three classes which are; 1) heparins, 2) vitamin K 
antagonists and 3) specific thrombin inhibitors (Lieberman and Marks, 2012). Thrombin 
is one of the most important proteases in the blood coagulation cascade that regulates 
many factors in that process and plays both prothrombotic and antithrombotic 
regulatory roles. Intensive studies of structure-function relationships of thrombin and 
its important roles in varieties of biological functions (Bode et al., 1992; Di Cera and 
Gruber, 2009) have made thrombin a primary target for antithrombotic drug design 
(Lee and Ansell, 2011; Figueiredo et al., 2012; De Caterina et al., 2012).  
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Figure 4.1 The X-ray crystallographic of thrombin (Protein Data Bank ID 1HUT) a) Thrombin catalytic 
triad contains Ser, His and Asp residues (in red side chains). Two significant binding sites related to aptamer 
interactions are shown; on the right of the figure for fibrinogen whilst amino acids involved in heparin 
binding are shown on the left. This image is created using Weblab ViewerLite program; b) Thrombin 
possesses charged residues that are not evenly distributed over the whole molecule. The coulombic surface 
of thrombin created using Chimera. The negatively charged residues (in red) are clustered around the active 
site. Two positive patches of fibrinogen and heparin binding exosites, indicated by arrows, are shown in 
blue (Bode et al., 1992; Padmanabhan et al., 1993) 
 
Fibrinogen binding 
exosite 
Heparin binding 
exosite 
Negative patches 
around the active site 
Region closes to the 
C-terminal  
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Serpins, serine protease inhibitors, are a group of inhibitory proteins found in 
plasma. They inhibit a specific serine protease by forming an irreversible enzyme-
inhibitor complex at the enzyme active site. The important serpin that controls the 
activity of thrombin is antithrombin III (ATIII). The binding between ATIII and thrombin 
is enhanced by heparin. Low molecular weight heparin (LMWH), obtained from the 
fractionation of high molecular weight heparin (HMWH), and synthetic 
pentasaccharides, Foundaparinux (Peters et al., 2008) has been developed as an 
alternative to HMWH. However, the lack of specificity and regular monitoring needed in 
patients on heparin and other inhibitors such as wafarin increases the demand for more 
straightforward drugs targeting only a single coagulation enzyme, thrombin. Several 
reversible direct thrombin inhibitory (DTI) drugs have been developed from hirudin 
analogs or peptidomimetic thrombin inhibitors. DTI drugs such as Lepirudin, Desirudin, 
Bivalirudin and Argatroban have been developed and already been approved by US FDA 
(Mousa, 2009; Lee and Ansell, 2011).  
 
4.3 Thrombin Binding Aptamers 
Apart from chemically synthesized DTI drugs described above, a new class of thrombin 
inhibitors based on sequence specific ssDNA aptamers has been intensively studied over 
the past two decades since the discovery of a thrombin binding aptamer (TBA) by Bock 
et al., (1992). The originally selected sequences were then tailored to 15 nucleotides in 
length and can tightly bind to the fibrinogen binding exosite of the thrombin molecule. 
The specific binding then inhibits thrombin activity in hydrolyzing fibrinogen. The G-
quadruplex structure of this 15mer TBA is a special structure produced during the 
complex formation. The structure of human -thrombin-TBA complex was solved by X-
ray crystallography (Figure 4.2) (Padmanabhan et al., 1993). Categorized into DTI class, 
TBA shows potential for being a therapeutic molecule, which has now been driven into a 
phase 2 clinical trial (compound ID: NU172) for anticoagulation in patients undergoing 
coronary artery bypass graft surgery (ARCA Biopharma Inc., 2011).   
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Figure 4.2 Structure of the anti-thrombin aptamer (TBA15) and the binding of TBA15 with thrombin 
at fibrinogen binding exosite (PDB ID: 1HUT). a) Tertiary structure of 15-mer TBA is shown in a stick 
model; b) The stacking of the two quartets, Q1 (G1-G6-G10-G15) and Q2 (G2-G5-G11-G14). The G8 of the TGT 
loop stacks with the Q1-quartet while T4 and T13 tend to form TT base pair and are part of base stacking; c) 
The interaction of TBA15 with thrombin at fibrinogen binding exosite (Padmanabhan et al., 1993). The 
image created using WebLab ViewerLite program.  
(a) (b) 
(c) 
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4.4 Proximity-Dependent Ligation Assay: A Multivalent Interaction 
Approach that Enhances Protein Detection 
Multivalent interaction (avidity) is a phenomenon that involves the binding of a 
molecule with multiple ligand binding sites that interacts with different epitopes of a 
target. Simultaneous binding of a ligand to multiple sites of the same target molecule has 
been reported to increase binding affinity based on its avidity compared with 
corresponding monomers. The potential application of multiple interactions has lead to 
the development of a protein detection method called ‘proximity ligation assay (PLA)’. It 
has been used in order to detect, quantify and localize protein targets. It was firstly 
introduced by Fredriksson et al. (2002) by using aptamer pairs with affinity for the 
cytokine PDGF-BB and for human -thrombin. 
The general strategy of this assay is based on the simultaneous and close 
recognition of two epitopes on the same target molecule by pairs of affinity probes such 
as aptamers (Fredriksson et al., 2002), peptides (Pai et al., 2005) and antibodies 
(Söderberg et al., 2006; Jarvius et al., 2007; Gustafsdottir et al., 2008; Fredrikson et al., 
2008). Binding by sets of pair-wise affinity probes to their specific target molecule or 
molecular complex raises their effective local concentrations to the point where the 
attached oligonucleotides free ends would come into close proximity and could be 
joined to each other by enzymatic DNA ligation. The formation of a new molecule from 
ligating the two aptamer sequences can then be amplified using PCR. Signals from 
probes that are not in proximity (i.e. in the absence of target molecules) would not be 
amplified and therefore undetectable, resulting in a high signal-to-noise ratio. The 
principle of PLA is shown in Figures 4.3. 
 As mentioned above, PLA has been proven to be a powerful tool for in vitro 
analysis of proteins and other macromolecules. By using the properties of amplifiable 
nucleic acids through PCR, this technique offers excellent sensitivity and specificity 
comparable to currently available methods. Here in this section, we described a process 
to develop the proximity ligation strategy for novel aptamer selection.  
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Figure 4.3 The principle of proximity ligation assay. a) In the presence of target molecule, aptamer 
probe pairs bind two epitopes of the same target molecule which would then bring the free ends of 
aptamers into close proximity orientation. Target quantification is accomplished through the rising of 
measurable signals of ligated DNA sequences from PCR amplification; b) Probes that fail to bind target 
molecules or in the absence of target molecules would hybridize with the excess amount of oligonucleotide 
connector, which would further block ligation and amplification 
 
Firstly, as proposed by Fredricksson et al. (2002), a pair of DNA aptamers that 
both recognize a homodimeric platelet derived growth factor B-chain (PDGF-BB) was 
used (Figure 4.4). Each aptamer probe was modified by extending either the 3’ end or 
the 5’ end with an oligonucleotide linker that did not interfere with the binding of the 
aptamers. In the presence of PDGF-BB, the binding of probe pairs on the same site of 
each monomer promoted the close proximity orientation of the free ends. The free ends 
were then hybridized to an oligonucleotide connector and helped to line-up the probe 
pairs for T4 DNA ligase to be able to join both ends together. The newly formed 
oligonucleotide can then be a PCR template, and real-time PCR would then be used to 
quantify the protein target whereas unligated probes remained unamplified. The assay 
conditions such as incubation time, incubation volume, the length of oligonucleotide 
(a) (b) 
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connectors and the concentration of connectors has been optimized and used to analyze 
PDGF-BB in purified form and in biological samples. The remarkable achievements of 
this technique were the reproducibility of the assay in which as few as 24,000 PDGF-BB 
molecules could be detected over the background and also the potential application in 
clinical samples such as human serum in terms of sensitivity, where it was comparable 
to ELISA. Proximity ligation can also be applied to assay a monomeric protein such as 
human -thrombin by using a pair of DNA aptamers recognizing two different binding 
sites on the same molecule.  
 
 
 
 
 
Figure 4.4 Diagram of aptamer-based proximity probe pairs bound to its homodimer PDGF-BB 
target.  The sequence in black is the aptamer specific for the PDGF B-chain. The sequence extensions from 
either the 3’ or the 5’ direction of aptamer are primer regions for PCR amplification (shown in red) and the 
hybridization region (shown in grey) to the connector oligonucleotides (shown in green) which would help 
to facilitate the ligation of two sequences once align in a close proximity orientation. (The Figure was 
modified from Fredriksson et al.,2002 and PDGF-BB molecule was obtained from Protein Data Bank, ID 
1PDG (Oefner et al., 1992)). 
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Low femtomolar detection limits arose from the advantages of dual recognition. 
However, there were some limitations of the approach which were 1) nonlinear 
amplification ability of PCR that may lead to a difficulty in correlating the amount of 
signal and the amount of target (Zhang et al., 2001), 2) the availability of probe pairs 
with high affinity and specificity, 3) the limitation in target size and 4) the efficiency of 
the ligation reaction.  
The improvements in the proximity ligation technique in protein detection by 
combining proximity ligation and PCR-signal amplification with other methods have 
been carried out to overcome some of the limitations mentioned above. Firstly, the bio-
recognition unit was not limited to only aptamers, but antibody-based probes linked to a 
DNA sequence for the signal amplification have also been used (Jarvius et al., 2007). 
Secondly, rolling circle amplification (RCA) in which a circularized DNA probe was 
linearly replicated by DNA polymerase under isothermal condition has been adopted for 
the quantification of antigens in antibody-based detection systems (Schweitzer et al., 
2000; Di Giusto, et al., 2005; Söderberg et al., 2006).  
The PLA has been used in the sensitive detection of a single bacterial spore by 
using peptide-oligonucleotide-phycoerythrin conjugates. This recognition unit can bind 
adjacent to another on the cell surface creating ligated amplicons associated with the 
number of bacterial spores of interest (Figure 4.5(a)). As few as 100 bacterial spores of 
Bacillus anthracis, 10 of B. subtilis and down to 1 of B. cereus were detected (Pai, et al., 
2005). Proximity ligation also proved its role in clinical application to detect infectious 
pathogens, the parvovirus and Lawsonia intracellularis (Gustafsdottir et al., 2006). 
Another interesting application of PLA was the usage of real-time PCR and modified RNA 
aptamers that can recognize prostate specific membrane antigen (PSMA). Although 
there were difficulties in optimization of various factors such as a concentration of the 
aptamer-probes and oligonucleotide connectors and the amount of target cells which 
needed a particular range of working concentration, the method proved to be sensitive 
enough to detect as little as 10-10,000 cells (Pai and Ellington, 2009). Figure 4.5(b) 
shows the diagram of an adaptation of anti-cell surface RNA aptamers to PLA. 
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Figure 4.5 Application of proximity ligation assay as a detection technique for wide variety of targets 
such as (a) bacterial spore (Pai, et al., 2005) and (b) cell membrane antigens (Pai and Ellington, 2009).  
 
 
Gustafsdottir et al. (2007) presented a procedure for measuring DNA-protein 
interactions in nuclear extracts based on the PLA. In this study, two probes, which 
potentially recognized the same DNA binding protein of interest, were used. One of the 
oligonucleotide probes was attached to an antibody and the other probe was a partly 
double-stranded oligonucleotide with a single-stranded extension at the 3’ end (Figure 
4.6). The transcription factors, that related to human diseases; tumor protein 53 (p53), 
hepatocyte nuclear factor 4 (HNF-4 and upstream stimulatory factor 1 (USF1), were 
analyzed. The signal-to-noise ratio for the proximity ligation was analyzed as a score 
that predicted the binding ability of the probes. The results were in a good agreement 
(a) 
(b) 
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with electrophoretic mobility shift assay (EMSA). From this study, it was concluded that 
proximity ligation is suitable for analysis of transient molecular interactions with high 
sensitivity and low reagent/sample requirements. Furthermore, the PLA has proved to 
fulfill clinical requirements, for example the development of in situ proximity ligation to 
detect stimulation-independent phosphorylation of platelet-derived growth factor 
receptor  (PDGFR) (Jarvius et al., 2007), the use of proximity ligation assay for 
monitoring the interaction of vascular endothelial growth factor A (VEGF-A) to its 
receptors (Gustafsdottir et al., 2008) and multiplex proximity ligation assay for plasma 
biomarker profiling (Fredriksson et al., 2008). 
To sum up this section, the PLA has shown outstanding properties in common to 
all applications and triggered our research by not only being highly sensitive and very 
specific to targets but also having an ability to increase the avidity of ligand and target 
interactions through multivalent binding.  
 
 
Figure 4.6 The PLA for measuring proteins in nuclear extracts. Two probes, dsDNA and antibody that 
recognize the same protein at different binding site can be used in the PLA for measuring specific targets 
with high sensitivity and specificity even in the nuclear extracts. The modification of the probes with a 
ssDNA extension would facilitate the proximity ligation and subsequently generates signal through PCR 
amplification. 
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4.5 Aptamer Dimerization: Simultaneous Ligand Binding That Enhances 
Binding Affinity and Inhibitory Effect 
The usefulness of aptamer dimerization/multimerization was not limited to only the 
proximity ligation assay. Aptamer dimerization or a combination of two selected 
aptamers is a process developed to generate a novel assembled recognition molecule 
containing bivalent binding sites. The most intensive studied aptamer pair is TBA. The 
15-mer TBA (TBA15) binds to the fibrinogen binding exosite and inactivates functions 
required for thrombin-mediated coagulation, whereas the 29-mer TBA (TBA29) binds to 
the heparin binding exosite. The dissociation constant (Kd) of TBA15 is in the range of 3-
240nM (Bock et al., 1992; Tasset et al., 1997; Berezovski et al., 2003; Baldrich et al., 
2005) and the Kd of TBA29 is 0.5nM determined by nitrocellulose filter binding (Tasset 
et al., 1997). The assembly of TBA15 to TBA29 with optimized linker and appropriate 
linker length was reported to increase binding affinity and inhibitory activity (Müller et 
al., 2007; Hasegawa et al., 2008; Kim et al., 2008). Figure 4.7 shows design strategy of 
the linked TBAs.  
 
 
 
Figure 4.7 Designed bivalent aptamer obtained by linking 15-mer TBA and 29-mer TBA. Linkers can 
be poly-dA (Müller et al., 2007), poly-dT (Hasegawa et al., 2008) or non-nucleotide linker such as spacer 
phosphoramidite (Kim et al., 2008). 
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 Several studies have confirmed the effectiveness of simultaneous binding of 
bivalent aptamers which not only increased overall binding affinity but also enhanced 
inhibition potency over that of the binding of a monovalent ligand. Kim et al. (2008) 
performed a blood clotting test in the presence of linked TBA. It achieved a 17-fold 
increase in inhibition efficiency. This result agreed with the potent anticoagulation 
property of the fusion TBA in the study of Müller et al. (2007) and Hasegawa et al. 
(2008). This improvement can be explained in terms of the binding kinetics parameter 
by performing an experiment based on FRET. It was found that there was no significant 
difference on relative kon rate between monovalent and bivalent aptamers but a much 
smaller koff rate with the bivalent one. By connecting two aptamers which can then 
recognize different parts of the same molecule simultaneously, an avidity effect 
dominated, resulting in a longer residence time on the target. This leads to an overall 
change in the binding equilibrium (Figure 4.8). 
        
Figure 4.8 The equilibrium of binding reaction of thrombin binding aptamer. a) The equilibrium 
between free and complex state of 15mer TBA and thrombin. After dissociation, 15mer TBA diffuses into 
bulk solution instantly whereas (b) the binding equilibrium of bivalent ligands tends to shift to the left. 
When one of linked-aptamer leaves the binding pocket, the other still binds to its binding site so that the 
leaving one can make a quick return back to the binding site after dissociation (Adapted from Kim et al., 
2008). 
(a) 
(b) 
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The evidence for the binding affinity enhancement through multiple domain 
interactions is not limited to protein-DNA aptamer pairs, but can be useful in the binding 
of RNA aptamers to their RNA targets. Hepatitis C virus (HCV) is a small, enveloped virus 
that carries a single-stranded positive-sense RNA genome containing a single open 
reading frame, which is predicted to encode a polyprotein of about 3,000 amino acids 
(depending on the strains). The encoded polyprotein is processed to structural domains 
encoding nucleocapsid and envelope glycoproteins followed by non-structural (NS) 
domains encoding proteins related to replication and proliferation such as NS3 which is 
related to protease and helicase activity (Cuthbert, 1994; Umehara et al., 2005). It was 
also reported that the translation initiation of HCV protein occurs at the internal 
ribosome entry site (IRES) within the 5’-untranslated region (5’-UTR) (Tsukiyama-
Kohara et al., 1992). This IRES region allows the HCV translation initiation to occur in 
the middle of mRNA sequences. Thus, both NS3 protein and IRES element become 
targets for anti-viral drugs.  
The rationally designed RNA aptamer assembly has also been developed to 
generate dual-functional aptamers and increase inhibitory potency to reach an ultimate 
goal of developing new anti-HCV drugs. The attempt has been previously performed to 
generate RNA aptamers against HCV NS3 by Umehara et al. (2005) and RNA aptamers 
against HCV IRES by Kikuchi et al. (2009). The in vitro selection of RNA aptamer 
monomers generated moderate to high-binding affinity aptamers which also contained 
inhibitory functions against both targets. In 2005, Umehara et al. constructed new RNA 
aptamers by combining known RNA aptamers that can block protease and helicase 
activities of HCV NS3. Dual-function aptamers that can simultaneously bind and inhibit 
both NS3 enzymatic activities were obtained. Figure 4.9 shows the secondary structure 
of one of the newly constructed dual-function aptamer, G925-s50, that effectively 
inhibits NS3 protease activity in living cells. This aptamer also shows inhibitory activity 
against HCV replication in vitro.  
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Figure 4.9 A sample of a dual-function aptamer that can simultaneously bind and inhibit NS3 
protease and helicase activities of HCV. Two aptamers are conjugated via 50-mer poly U spacer. The G9-II 
aptamer binds specifically to the protease domain, whilst the #5Δ interacts with a cleft in the NS3 helicase 
domain. The secondary structure from the original publication was predicted using the Mulfold program 
(Umehara et al., 2005).   
 
 
For IRES, Kikuchi et al. (2009) selected two RNA aptamers which bind to domain 
II and domain III-IV of HCV IRES. The binding affinities of these RNA aptamers to their 
target were in the low nanomolar range, however one of them showed only moderate 
inhibition of IRES-dependent translation. This group succeeded in generating a newly 
constructed RNA aptamer by assembling two RNA ligands that showed a stronger 
inhibition on IRES-dependent translation activity than the parental monomers. This can 
be explained by the cooperative function of the two binding sites in which one binding 
region facilitated binding the target whereas the other one on the conjugated aptamer 
performed its inhibition activity (Kikuchi et al., 2009). The schematic secondary 
structure of the conjugated anti-IRES aptamers is shown in Figure 4.10. 
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Figure 4.10 A schematic structure of anti-HCV IRES aptamer monomers and their conjugation. The 
aptamers 2-02 and 3-07 target against HCV IRES domain II and III-IV, respectively. These two aptamers 
inhibit IRES-dependent translation. The newly constructed aptamer by conjugating the two generates a 
more efficient inhibitory activity aptamer than that of the parental aptamers. The secondary structure from 
the original publication was predicted using the Mulfold program (Kikuchi et al., 2009). 
 
 
4.6 Proximity Ligation Selection 
We developed a new technique called ‘Proximity Ligation Selection (PLS)’ as the 
selection is based on ligation of two ssDNA sequences binding to the target protein in 
proximity from a starting DNA pool. A single round selection was carried out using non-
modified targets. An appropriate partitioning was required to separate unbound 
sequences from bound ones. The protein-dependent ligated products showed twice as 
large a size as the initial pool and was expected to be the ligated aptamers. In the PLS, 
instead of using one starting pool, two DNA pools have been used in order to obtain 
unique amplification products. These two DNA pools were designed to contain different 
additional sequences apart from the primer and random regions, at either the 5’ or the 
3’ end. The basis of this method is that only in the presence of target proteins is there a 
close proximity of pairs of bound sequences. And only if those pairs are in an 
appropriate orientation in which the 3’ terminal of one pool is sufficiently close to the 5’-
phosphate terminal of the sequence in the other pool, are the extended free ends of each 
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member of the proximity oligonucleotide pairs brought together by base-pairing to a 
subsequently added oligonucleotide connector. The DNA-hybridized complexes are then 
joined using a DNA ligase, allowing the formation of ligated products that contain a dual 
binding site of the target. The flowchart of PLS is shown in Figure 4.11.   
 
 
Starting pool Target+
Independent binding of two sequences to target
Ligation of bound sequences
Separation of target with bound ligation 
product from unbound sequence
Release of ligation product and increase 
the copy number
Sequencing
 
 
Figure 4.11 The flowchart of the working principles of proximity ligation selection. In the presence of 
target, two aptamers would be able to bind simultaneously to their target. The aptamer pairs that are in an 
appropriate orientation and are close enough can be ligated. The ligation products are then separate from 
unbound sequences for further characterization. 
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4.7 Aims of the Project 
Aptamers have been proved to be comparable to monoclonal antibodies in terms of 
affinity and specificity and offer a greater thermal stability, robustness and chemical 
versatility. Since they were first described in 1990, aptamer screening methods have 
been developed to enhance the production of these novel recognition molecules which 
can be used as powerful tools for both therapeutic and diagnostic purposes (Green et al., 
1995; Drolet et al., 1996; Ruckman et al., 1998; Fredriksson et al., 2002; Ng et al., 2006; 
Keefe et al., 2010). Being efficient in terms of shortening the selection time of repeating 
SELEX rounds, a new approach for aptamer selection was introduced in an automatic 
platform (Cox and Ellington, 2001; Eulberg et al., 2005). The development of automated 
selection by using a robotic work station would give a high-throughput rate of aptamer 
selections. However, this approach of selection was still based on conventional 
screening, where it reduced the manual labor rather than the number of selection 
rounds.   
As mentioned above, the proximity ligation assay has already been achieved by 
using two aptamers that can bind to the same epitope of a homodimer protein 
(Fredriksson et al., 2002) or two distinct epitopes of the same protein (Fredriksson et 
al., 2002; Müller et al., 2007; Hasegawa et al., 2008; Kim et al., 2008). In this study, we 
aimed to develop a novel aptamer selection method that can significantly reduce the 
number of selection rounds. The local protein concentration would bind the aptamers 
and therefore facilitate ligation. Proximity ligated aptamers would then simultaneously 
bind to their specific target based on their avidity rather than affinity. Due to the 
ultrasensitive nature of the technique, exceptional recognition properties of aptamers 
together with the basic knowledge of the proximity ligation assay and in vitro selection, 
the technique we developed can be used to improve the aptamer screening method as 
well as an aptamer property to achieve the goal of developing efficient and fast 
screening with only a single round of selection.  
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4.8 Results and Discussion 
Thrombin binding aptamers (TBAs) are among the best characterized aptamers that 
offer excellent properties for their medical and analytical applications. Those 
applications of the TBAs are based on their high specificity and high binding affinity to 
thrombin. Several methods have been tried on these two TBAs in order to generate a 
new class of TBA containing higher binding affinity. In this study, we proposed that by 
using PLS we could then generate bivalent aptamers against the target of interest. 
Thrombin is known to bind to two aptamers on different exosites of the molecule; it can 
therefore be an excellent test for our newly developed selection method. This section 
describes the PLS against thrombin using 1) Forward pool (F pool) and Reverse pool (R 
pool) and 2) the R pool and TBA29plus. TBA29plus is the 29-mer TBA that binds to the 
heparin binding exosite. It was modified by adding the extension on both the 5’ end 
(forward hybridization region) and the 3’ end (extension for oligonucleotide connector 
hybridization region). Selected products were characterized later by CD and binding 
affinity assayed using ELONA and SPR. 
 
4.8.1 Proximity Ligation Selection of Thrombin Binding Aptamers 
Two sets of PLS experiment were performed on thrombin. The first set was carried out 
using an F pool and a phosphorylated R pool. The expected PCR amplification product 
analyzed by gel electrophoresis should be 142 base pairs. The second set of experiments 
was carried out using the TBA29plus aptamer instead of F pool. We hypothesized that 
TBA29plus can bind to thrombin at the heparin binding exosite according to its original 
core sequence. Once TBA29plus occupies one exosite, the other potential binding site is 
likely to be the fibrinogen binding exosite. If in any case, the second sequence comes to 
interact with this binding site and ligation occurs, throughout the stringent washing 
step, the aptamer dimer stays attached to the target. The second sequence could also 
bind to other regions on the thrombin molecule. The orientation of two different 
monomers to form ligation products in the second set of experiment was established as 
a positive control ligation, cloning and sequencing step. The PLS was performed as 
described in Section 2.6.1. The aptamer sequence of TBA29plus and experimental detail 
are shown in Section 2.6.2.  
 
152 Proximity Ligation Selection and Bivalent Thrombin Binding Aptamers 
The selection was carried out against thrombin in thrombin binding buffer 
(TBB) containing 20mM Tris-acetate pH 7.4, 140mM NaCl, 5mM KCl, 1mM CaCl2 and 
1mM MgCl2 (Bock et al., 1992). The ratio of starting mixed pool to thrombin was 10:1. 
The reactions were prepared along with negative ‘no protein’ control as shown in Table 
4-1. The ssDNA pools were incubated with thrombin for 2 hrs before performing the 
filtration through alkaline treated mixed cellulose acetate/cellulose nitrate membrane. 
The ligation mixture was added on top of each membrane and further incubated for 5 
min at room temperature. Each membrane was thoroughly washed with 200L of TBB 
ten times. After that, bound sequences were eluted in hot water. To minimize the loss of 
bound sequences, the entire eluted pool was amplified in the 1st PCR for 10 cycles in 
1mL scale. Then in the 2nd PCR amplification, product from the 1st PCR served as a 
template to perform a PCR cycle course by withdrawing PCR product mixture every five 
cycles for 35 cycles. The number of PCR cycles should be roughly proportional to the 
amount of DNA pool that binds to target proteins (Jhaveri and Ellington, 2000). 
Therefore, the DNA pool eluted from the ‘no protein’ control needs more PCR cycles for 
full amplification than does the DNA pool selected in the presence of thrombin, suggest 
that the DNA sequences in the latter is at a higher concentration due to target binding. 
The ligated products were verified by 3% (w/v) agarose gel electrophoresis. As shown 
in Figure 4.12, we then obtained DNA that was twice as long as the starting pool. 
 
Table 4.1 Composition of solution used in the PLS against thrombin  
Reagents 
F and R pool TBA29 and R pool 
Final 
concentration 
No protein 
control (L) 
+100pmol 
thrombin (L) 
No protein 
control (L) 
+100pmol 
thrombin (L) 
25M F pool 20 20 - - 5M 
25M R pool 20 20 20 20 5M 
25M TBA29 - - 20 20 5M 
TBB 60 44.4 60 44.4 1 
   
6.4M Thrombin in 
binding buffer 
- 15.6 - 15.6 1M 
Total volume (L) 100 100 100 100  
Heat solution at 90°C for 5 min, then cool down to room temperature for 30 min 
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Starting from 71 bases of each pool, the PLS DNA PCR product appeared on the 
gel a little smaller than 150 base pairs marker. The actual size of the dimer product 
should be 142 base pair plus a dA hanging on each of the 3’ end as we used Taq DNA 
polymerase for the amplification. In the presence of thrombin, we can observe the band 
in cycle 5 of the PCR but no band shows until cycle 15 of the negative ‘no thrombin’ 
(Figure 4.12(a)). A similar pattern of bands shows on the ligated PCR product of 
TBA29plus (61 bases) and R pool. The total length of this PCR product is expected to be 
132 base pairs in length. It can be noticed that there were 5 cycles difference in the PCR 
amplification in the presence of thrombin to the negative ‘no thrombin’ control (Figure 
4.12(b)). The importance of the 2nd PCR amplification is, first, we can follow the 
amplification of both specific and nonspecific ligated product from PLS. The nonspecific 
ligated DNA sequence was the protein-independent ligation product. This type of 
nonspecific ligation can be generated even in the absence of protein target but can be 
assumed to be a much smaller amount compared to the protein-dependent ligation. 
Second, to find the optimum number of PCR cycles needed to amplify template for 
preparative PCR by determining the maximum number of PCR cycles that showed the 
DNA band on the gel in the presence of thrombin but not in the absence of thrombin. A 
repeated experiment was carried out and represented the same pattern of the bands 
analyzed on 3% (w/v) agarose gel electrophoresis. 
The accumulation of high molecular weight product appeared to be the same 
problem as shown in in vitro selection described in Chapter 3. This accumulation, as 
discussed earlier, indicates over-amplification and is probably due to self-internal 
priming by the folding back of the 3’ end forming a stem loop that can be further 
amplified. As can be seen from the gel electrophoresis (Figure 4.12), we then amplified 
our ligated product for 10-12 PCR cycles where we did not observe this higher 
molecular weight band.  
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Figure 4.12 3% (w/v) Agarose gel electrophoresis image showing the PCR products of various cycles 
in the presence and absence of thrombin. PCR course of the product from proximity ligation selection a) 
F pool and R pool in the presence and absence of thrombin. The product size (marked by arrows) showed 
on agarose gel should be 142 bp of dimer ssDNA; b) The negative ‘no thrombin’ and positive experiment 
using TBA29plus and R pool. The PCR product size of the dimer (marked by arrows) should be 132 bp. Each 
lane represents different PCR cycles from 5 to 35 cycles. The ladder (25 bp-500 bp) shows on the right hand 
side of each set of experiments. 
  
 
   
(a) 
(b) 
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4.8.2 DNA Sequence Analysis 
Following the PLS, the selected pools were reamplified in order to prepare template 
sequences for plasmid ligation, cloning and subsequent sequencing. Ten PCR cycles of 
100L PCR reaction volumes were carried out for each sample from F pool and R pool 
and TBA29plus and R pool. To remove excess primers, PCR products were then purified 
using PCR cleanup kit (Qiagen) according to the manufacturer’s protocol.  
Preparation of recombinant plasmids and cloning were performed as described 
in Section 2.3.6 and 2.3.7 for all four samples. Three negative controls were performed 
as a quality check by plating 1) sterile water and 2) E. coli cells containing only the 
vector with no insert, and 3) E. coli cells without the vector on LB plates. The controls 
showed no colonies when plated with either sterile water or E. coli without the vector. 
When an LB plate was spread with 800L of the transformed cells (≈70% of total 
volume) with vector containing no insert, less than 20 blue colonies appeared on the 
plate (the transformation efficiency of competent E. coli DH5 was around 107cfu/mL). 
By using an antibiotic selectable marker, there was reduced contamination from the 
environment and the advantage of using blue-white screening offered the ease of colony 
selection. White colonies were randomly picked for 20 clones for sequencing from each 
set of experiment.  
There were 17 clones out of 20 from the set of PLS from the TBA29plus and R 
pool that showed clear sequencing chromatograms. No contamination from monomer 
sequences was found among the selected clones as all the chosen clones showed only 
sequences containing combinations of the two starting pools. However, some of them 
had a longer sequence than the original pool (41 bases instead of 40 bases). These might 
be due to the error during PCR amplification of the random region. The sequences in the 
random region of R pool half (excluding the flanking sequences) were then aligned using 
ClustalW2 program (http://www.ebi.ac.uk) for multiple alignment analysis that can 
group the sequences into families as shown in Figure 4.13. This multiple sequence 
comparison shows no significant consensus motif. We then used the Genebee program 
(http://www.genebee.msu.su) to search for local supermotifs among representative 
clones. The Genebee program gives a greater chance of spotting the consensus region, 
which could suggest a role for these regions in binding a specific part of the target 
(Ellington and Szostak, 1992). These local supermotifs were presented as a graphical 
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illustration as sequence logos that showed sequence similarity in a form of stacks of 
letters (bases) and height of each letter generating by the WebLogo program 
(http://weblogo.berkeley.edu/logo.cgi) (Crooks et al., 2004). Unfortunately, there was 
no significant common region found among other sequences. Only two logos were 
chosen to show in Figure 4.14. The complete sequences including primer regions are 
shown in Appendix C (Table C.1). 
 
 
 
Figure 4.13 Random sequences analysis from the PLS products against thrombin. The selection was 
performed using TBA29plus and R pool. Only random region from R pool were aligned.  
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Local supermotif 1  
 
                 +     +  + ++ ++++  ++    +++++ +++      
4/19-11     (6) gcaacccgttACCAAACCCCATCtcggTAGAGACGT----- 
4/19-20     (2) tccctgggagAGCAGACCCGGTC-aatTAGAGGCGTtgaag  
                             
 
Local supermotif 2 
 
                   +    ++++++++       + + 
4/19-9      (1) cccgcaggTGATGTATtgaatgtcgc 
4/19-13     (1) ---gagcaTGATGTATcagcgtacac 
 
                                   
 
Figure 4.14 Logos of the PLS product from the TBA29plus and R pool set of experiment. Two local 
supermotifs are shown here. There is no other significant consensus among others. 
 
 
 
The second set of PLS experiment was performed using two different starting 
pools, F and R pools. Sequence analysis was carried out by randomly picked 20 white 
colonies. There were 18 clones out of 20 from this set that showed clear sequencing 
chromatograms. All the sequences were analyzed as described above. Sequence 
alignment is shown in Figure 4.15. The alignment shows the random region of each half 
from the F and the R pools connected with a constant region in the middle, which is the 
ligation region. The PLS sequence alignment of a starting pool set shows one sequence 
represented twice from clone number 10 and 18 (point by arrow). The local supermotifs 
are illustrated in Figure 4.16. One logo shows the repeated sequences (clone number 10 
and 18) and the other two logos show a short consensus within clone number 3 and 17 
that share with the repeated sequence pair. The high sequence diversity observed 
within both selections (TBA29plus and R pool’s set and starting pools’ set) may have 
resulted from performing only a single round of selection. The full length sequences 
including primer regions are shown in Appendix C (Table C.2). 
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Local supermotif 1  
        ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
2/19-10(1) CAGGAGAAAATAAACGTACTCTTATACGTTTCTCGAATATAATTTGGGCTGCTCTCGTGG 
2/19-18(1) CAGGAGAAAATAAACGTACTCTTATACGTTTCTCGAATATAATTTGGGCTGCTCTCGTGG 
       
            
 
                 ++++++++++++++++++++++++++++++++++++++++++++++++ 
2/19-10     (61) CGTAATACGATTTCACGCGTCCCCTATCATTTAGAAATGTCGACGACG 
2/19-18     (61) CGTAATACGATTTCACGCGTCCCCTATCATTTAGAAATGTCGACGACG 
                
 
Local supermotif 2 
                 +..+..+...++.+++++.+.++++++.......... 
2/19-3      (74) tggaaacacgCCATATCACTAAGAAATtggacttt-- 
2/19-10     (72) ttcacgcgtcCCCTATCATTTAGAAATgtcgacgacg 
2/19-18     (72) ttcacgcgtcCCCTATCATTTAGAAATgtcgacgacg 
                                 
 
Local supermotif 3 
                 ....+.....+++++.+++.+++.......... 
2/19-10     (26) acgtttctcgAATATAATTTGGGctgctctcgt 
2/19-17     (54) ctcgtggcgtAATATTATTCGGGtgaagaggcc 
2/19-18     (26) acgtttctcgAATATAATTTGGGctgctctcgt 
                               
 
Figure 4.16 Logos of the PLS product from the F pool and R pool set of experiment. Three local 
supermotifs are shown here. The sequence ID 2/19-10 and 2/19-18 represent twice in the sequenced pool. 
The sequence ID 2/19-3 and 2/19-7 share a short consensus with those two repeated sequences. 
 
Even though we could not identify any substantial common motif shared among 
all the sequences, we further examined the selected oligonucleotides for the presence of 
a minimum of four interspersed GG features. To test our two hypotheses mentioned 
earlier, the binding properties of the sequences were measured and among them we 
tested the possibility of the sequences forming G-quadruplex structures as we first 
assumed that thrombin may select binders that can form a stable G-quadruplex as 
reported for TBA15 and TBA29.  
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The binding affinity measurement was carried out on chosen sequences. Based 
on the strong characteristic of TBA which contain repeated guanine bases and can form 
G-quadruplex structures, we first analyzed individual sequence by looking for the 
repeated GG or GGG. As shown in Figure 4.13 and Figure 4.15, the guanine nucleotides 
are highlighted in brown. The sequence ID 4/19-7 (Figure 4.13) shows a possible G-
quadruplex motif. The PLS product between two starting pools showed one possible 
sequence, which was on the second half of sequence ID 2/19-5. These two sequences 
were then synthesized for further binding characterization to confirm the possible G-
quardruplex formation. Table 4.2 shows the sequences used for CD and binding affinity 
measurements. The random regions are shown in bold and G residues indicated in red 
represent possible G-quadruplexes. Characterization of the chosen sequences is 
described in the following section. 
 
Table 4.2 Sequences chosen for binding affinity measurement 
Aptamer ID Sequences (5’  3’) 
Starting Pool AAGCATCCGCTGGTTGAC-N40-GATCTTGGACCCTGCGAA 
TBA15 GGTTGGTGTGGTTGG 
TBA15plus TCGTGGCGTAATATGGTTGGTGTGGTTGGGATCTTGGACCCTGCGAA 
TBA29 AGTCCGTGGTAGGGCAGGTTGGGGTGACT 
TBA29plus AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTC 
2/19-5               
(full length) 
AAGCATCCGCTGGTTGACACGCCCTCACGAAGGACGTTTTGCGCTCAGGGATAAAACAAATTTGG
GCTGCTCTCGTGGCGTAATAAACCTTTGCAAGGGTCAGGTGGGGTCTAGGCTTATTAGTGGGATC
TTGGACCCTGCGAA 
2/19-5.monomer1 AAGCATCCGCTGGTTGACACGCCCTCACGAAGGACGTTTTGCGCTCAGGGATAAAACAAATTTGG
GCTGCTC 
2/19-5.monomer2 TCGTGGCGTAATAAACCTTTGCAAGGGTCAGGTGGGGTCTAGGCTTATTAGTGGGATCTTGGACC
CTGCGAA 
Short.2/19-5 AAGGGTCAGGTGGGGTCTAGG 
4/19-7               
(full length) 
AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCATTT
GGGCTGCTCTCGTGGCGTAATACGGGTACATGCGGACAATGAGGATGGAGGGGGTGCACCACAGA
TCTTGGACCCTGCGAA 
4/19-7.monomer2 ATTTGGGCTGCTCTCGTGGCGTAATACGGGTACATGCGGACAATGAGGATGGAGGGGGTGCACCA
CAGATCTTGGACCCTGCGAA 
 
Short.4/19-7 GGACAATGAGGATGGAGGGGG 
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4.8.3 Circular Dichroism Spectroscopy 
 
 4.8.3.1 Principle of Circular Dichroism 
Circular dichroism (CD) is a spectroscopic technique that measures the interaction of 
circularly polarized light with optically active molecules in solution. Optically active 
molecules are among the largest group found in biological materials such as the peptide 
group linking amino acid residues and nucleic acids. CD spectroscopy technique gives 
information of molecular conformations and interaction between ligand and target. This 
method measures the differential absorption (ΔA) by molecules of left and right 
circularly polarized light at each wavelength. Circularly polarized light is generated from 
two orthogonal plane-polarized waves that have a phase difference by one-quarter of a 
wavelength. The resultant wave is circularly polarized light of either EL or ER electric 
vector that circles about a direction of a propagation line. Once circularly polarized light 
passes through optically active molecules of interest, right and left circularly polarized 
light are absorbed to different extents, thus having different amplitudes. The sum of 
those two opposite circularly polarized light is then generated as an elliptical resultant 
wave. The amount of ellipticity can be described by the angle (θ) and can also be 
characterized by the difference in molar extinction coefficients (Δ) (Freifelder, 1976). 
According to the Beer-Lambert law, absorbance, A, is proportional to molar 
extinction coefficient, . So that the CD can be expressed in terms of Δ, which is the 
difference between  of left and right circularly polarized light (L-R). However, many 
commercially available CD instruments report CD as ellipticity calculated from the 
measurement of the angle (Ѳ) of the elliptically polarized light. Molar ellipticity [Ѳ] can 
be used to account for the effects of path length and concentration of the sample in 
solution. The relationship between ellipticity, the differential absorption and the molar 
ellipticity are defined in equations 4.1 and 4.2, respectively. The plot of ellipticity against 
wavelength gives a curve called the CD spectrum (Woody, 1995).  
 
 
 
Ѳ = 32.98 ΔA (4.1) 
[Ѳ] = 
100.Ѳ 
l.c 
= 3298 Δ (4.2) 
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 The unit of molar ellipticity is degrees.cm2/dmol where the l and c in equation 
4.2 represent path length (cm) of sample cell and concentration (M) of sample, 
respectively. The number 100 is the conversion factor that converts the path length in 
centimeters to meters. 
 
 4.8.3.2 CD spectra of the Thrombin Binding Aptamers 
CD is a sensitive and relatively straightforward technique to study the structures of G-
quadruplexes which show a unique CD spectrum. Single stranded G-rich nucleic acid 
sequences have long been recognized for their ability to form intermolecular or 
intramolecular quadruplex structures and many of them have biological functions in 
vivo (reviewed in Lipps and Rhodes, 2009). One of the most intensively studied 
synthetic oligonucleotides that can from a quadruplex structure is the TBA. The first 
TBA discovered through the in vitro selection by Bock et al. (1992) revealed an essential 
15 base sequence for binding (TBA15). Later, in 1997, Tasset et al. selected the TBA29 
that binds to the heparin exosite on thrombin. The TBA15 has been well characterized 
and is used as G-quadruplex standard for CD assignment of other samples.  
  
 4.8.3.2.1) CD Spectrum of Human-Thrombin 
The CD spectra of nucleic acids and proteins overlap to some extent. However, 
strong CD bands of DNA and RNA are observed in the near UV region above 240nm, 
whereas protein CD is observed primarily in the far UV region around 230-200nm 
(Woody, 1995). The secondary structures (-helix, -pleated sheet, -turn) of globular 
proteins contribute to the CD spectrum and the overall CD spectrum of a native protein 
consists of a combination of each component spectrum (Brahms and Brahms, 1980). In 
order to study the conformational change of TBA due to the interaction with thrombin, 
we firstly measured the thrombin CD spectrum in the same range of wavelength as used 
for DNA (320 to 200nm) at 20°C. It was found that the shape of far UV CD spectrum, 
after subtraction of the thrombin binding buffer (TBB) (20mM Tris-acetate pH 7.5, 
140mM NaCl, 5mM KCl, 1mM MgCl2 and 1mM CaCl2), contained a strong negative band 
at around 225-210nm characteristic of regular secondary structure as shown in Figure 
4.17. X-ray crystallography of thrombin (Padmanabhan et al., 1993) revealed that the 
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thrombin B-chain is composed of 28% -strands and 10% -helix. There are no 
significant bands above 240nm that are normally contributed by the aromatic side 
chains of phenylalanine, tyrosine and tryptophan residues. The intensity of the CD in 
this region is environment dependent and also depends on the number of aromatic 
amino acid residues, especially tryptophan which has by far the most intense transition 
(Rodger and Ismail, 2000). In our study conditions, the CD spectrum in Figure 4.17 
shows that 3M thrombin in TBB has no significant CD bands in the region above 
240nm which might interfere with the identification of G-quadruplex CD signatures.  
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Figure 4.17 CD spectrum of 3M thrombin in thrombin binding buffer. Spectrum was recorded at 20°C 
from 320nm to 200nm. The CD spectrum in far UV region reveals the composition of -sheet and -helix in 
thrombin molecule.  
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4.8.3.2.2) CD Spectra of Thrombin Binding Aptamers and the Starting PLS Pool in 
the Presence and Absence of Thrombin 
 The three dimensional structure of TBA15 complexed with thrombin has been 
determined by X-ray crystallography (Padmanabhan et al., 1993) and NMR spectroscopy 
(Schultze et al., 1994), which reported the folding of TBA15 into a compact antiparallel 
G-quadruplex in the presence of potassium ions or thrombin. The characteristic CD 
spectrum of TBA15 has been reported in the literature as containing positive bands at 
around 290-295nm and 248nm and a negative band at 265nm which are signatures for 
an antiparallel quadruplex (Smirnov and Shafer, 2000; Hamaguchi et al., 2001;  Fialová 
et al., 2006; Nagatoishi et al., 2007; Gray et al., 2008). CD spectra (Section 2.9) of 5M 
TBA15 in thrombin binding buffer were obtained by taking the average of five scans at 
4°C and 20°C as shown in Figure 4.18(b). The CD profile showed positive maxima at 
293nm and 246nm and negative band at 266nm. This is consistent with the formation of 
the intramolecular antiparallel G-quadruplex in the absence of thrombin, but with a 
stabilizing cation present. Several studies have shown that metal cation such as Na+, K+ 
and Sr+ can stabilize the quadruplex structure (Padmanabhan et al., 1993; Macaya et al., 
1993; Kankia and Marky, 2001) especially for K+, which is necessary for maximum 
inhibitory activity of the TBA on thrombin (Tsiang et al., 1995). Temperature can also 
play a role in stabilizing the G-quadruplex structure even in the absence of ligands. This 
is shown in Figure 4.18(b) where the G-quadruplex signature is observed at both 4°C 
and 20°C with potassium ions in the buffer. We further investigated the CD spectrum of 
TBA15 in the presence of various concentration of thrombin. The CD spectra were 
obtained as previously described at 20°C. The spectra of TBA15 exhibited the same 
characteristic bands as presented in the absence of thrombin above 240nm (Figure 
4.18(c)). Due to the formation of the G-quadruplex structure even in the absence of 
thrombin, there was no significant difference in the CD spectra above 240nm in the 
presence or absence of thrombin. The negative signal below 240nm is clearly due to 
thrombin. 
 
 
 
 
165 Proximity Ligation Selection and Bivalent Thrombin Binding Aptamers 
 
GGTTGGTGTGGTTGG 
200 220 240 260 280 300 320
-2
0
2
4
6
8
10
12
 4oC
 20oC
266nm
293nm
246nm
[
] 
x1
0
-5
 (
d
eg
re
es
.c
m
2
.d
m
o
l-1
)
Wavelength (nm)
 
 
200 220 240 260 280 300 320
-10
-5
0
5
10
 TBA15 + 0M Thrombin
 TBA15 + 1M Thrombin
 TBA15 + 3M Thrombin
 TBA15 + 5M Thrombin
[
] 
x1
0
-5
 (
d
eg
re
es
.c
m
2
.d
m
o
l-1
)
Wavelength (nm)
 
 
 
Figure 4.18 CD spectrum of TBA15. a) The sequence of TBA15; b) 5M TBA15 in thrombin binding buffer 
was measured at 4°C and 20°C. The spectrum shows positive bands at 293nm and 246nm and a negative 
band at 266nm; c) in the presence of different concentration of thrombin (0-5M), TBA15 shows the same 
characteristic peaks as in the absence of thrombin. 
 
The TBA29 primary sequence also contains repeated guanine bases (Figure 
4.19(a)) which can form G-quadruplex/duplex structure (Tasset et al., 1997). The CD 
spectrum of TBA29 is shown in Figure 4.19 (b) performed in TBA binding buffer at 4°C 
and 20°C. In the absence of thrombin, the intensity of bands formed at 4°C is higher than 
that at 20°C. The characteristic peaks showed a broad positive band at 290-295nm and a 
small positive band at 255nm and a negative band at 260nm at 4°C but this small peak at 
255nm disappeared at 20°C. The same pattern of characteristic peaks was displayed in 
the presence of 50mM KCl (Figure 4.20). This is probably due to the low temperature 
and high salt concentration stabilizing a secondary structure of DNA. Instead of the 
sharp peak at 295nm as shown in TBA15 CD spectrum, a broad band was observed from 
265-290nm and a shoulder at 295nm. This may suggest a mixture of an anti-parallel 
quadruplex structure and a duplex structure that is generally characterized by positive 
bands at 260-280nm (Kypr et al., 2009). The secondary structural change of TBA29 can 
be observed when TBA29 is titrated with various concentrations of thrombin. The CD 
spectra in Figure 4.19(c) show the shift of the positive peak from around 290nm to 
260nm and negative peaks around 230nm and 285nm.  
 
(b) (c) 
(a) 
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It is unclear whether this result is due to the anti-parallel G-quadruplex 
structure transforming to parallel one in the presence of thrombin or whether the 
duplex structure dominates the spectra possibly in a mixture of both structures. This 
might be related to the change in base stacking orientation where the positive CD 
spectrum at 295nm relates to alternating syn and anti glycosyl conformations while the 
positive band near 260nm arises from the stacking of quartets of the same strand 
polarity with all guanines adopting the anti- conformation (Gray et al., 2008). However, 
it needs to be kept in mind that the relationship between structure and CD spectrum is 
based on empirical analysis. Buffer condition, DNA sequences, and mainly base 
orientations are all affect the observed CD spectra (Rodger and Ismail, 2000). These 
considerations mean that conclusions based only on CD measurement, which used to 
determine the G-quadruplex structure, are likely to be ambiguous and therefore direct 
measurements of binding affinity need to be made. 
 
 AGTCCGTGGTAGGGCAGGTTGGGGTGACT 
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Figure 4.19 CD spectrum of TBA29. a) The sequence of TBA29; b) CD spectra of 5M of TBA29 in 
thrombin binding buffer measured at 4°C and 20°C; c) Titration of thrombin to 5M TBA29 shows positive 
bands at 260nm and 210nm. The dashed-green line in each graph represents the CD signature of TBA15 in 
thrombin binding buffer, which is measured at 20°C. The G-quadruplex structure of TBA15 is used as a 
standard for other samples.  
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Figure 4.20 TBA29 in buffer containing 20mM Tris-acetate, 140mM NaCl, 1mM MgCl2, 1mM CaCl2 and 
different concentrations of KCl. The pattern of CD spectrum of TBA29 in the presence of 50mM KCl is 
measured at 20°C and it is similar to the spectrum performed at 4°C. The dashed-green line represents a CD 
signature of G-quadruplex from the folding of TBA15 at 20°C.  
 
The other observation is that the dominant positive band of parallel quadruplex 
DNA shown at 260nm is similar to A-form DNA except that the peak at 210nm is positive 
instead of negative as it is in A-form DNA. Compared to the antiparallel-quadruplex 
structure, both quadruplex types have distinct characteristic peaks but share an 
additional characteristic positive peak at 210nm (Kypr et al., 2009). The peak at 210nm 
remains unchanged for both TBA15 and TBA29 and doesn’t appear in the CD spectrum 
of the starting DNA pool (Figure 4.21). Due to the fact that interpretation of CD spectra 
of G-quadruplexes has relied on empirical relationships with spectra of known or 
inferred G-quadruplex structure, such structures in solution vary with DNA sequences in 
that bases that are not involved in G-quadruplex make a contribution to the spectra as 
do the solution conditions (Burge et al., 2006). So in contrast to the proposed structure 
of TBA29 by Tasset et al. (1997) in which the TBA29 has intramolecular G-quadruplex 
structure, our finding from CD experiments gave a different interpretation and was not 
sufficient to draw any conclusion about its structure. However, as mentioned earlier, 
this study is beyond our scope here, where we would like to pre-determine whether or 
not we can select the thrombin binding aptamer from a single round of selection using 
the PLS method.  
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Figure 4.21 CD spectrum of a mixture of 5M starting pool and 5M thrombin in thrombin binding 
buffer. a) The sequence of a starting pool. The pool is N40 pool, which contains 40 random nucleotides 
flanking by constants region at both the 5’ and the 3’ end; b) The spectrum reveals unstructured DNA 
molecules in solution. The dashed-green line represents a CD signature of G-quadruplex from the folding of 
TBA15. The experiment is carried out at 20°C.  
 
 
4.8.3.2.3) CD Spectrum of Sequences found by Proximity Ligation Selection 
 To perform the PLS, TBA29 was modified by adding extensions to the 5’ and the 
3’ ends as described in the Section 2.4.1. This newly modified sequence named as 
TBA29plus was then characterized its ability to form a G-quadruplex structure using CD 
spectroscopy. The TBA15plus, a modified version of TBA15, was similarly characterized. 
Both samples were measured in thrombin binding buffer. As shown in Figure 4.22(b) 
and (c), TBA15plus did not show any significant G-quadruplex signature, mainly 
showing unstructured characteristic spectrum instead. Only a small shoulder can be 
seen near 295nm in the presence and absence of thrombin which may be contributed by 
a base stacking interaction.  
 
(a) 
(b) 
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Figure 4.22 CD spectra of TBA15plus in the presence and absence of thrombin. a) The sequence of 
TBA15plus; b) CD spectrum of the 5M of TBA15plus was diluted in thrombin binding buffer in the absence 
of thrombin. The experiment was performed at 4°C and 20°C; c) Titrating thrombin of various 
concentrations (0, 1, 3 and 5M) to 5M TBA15plus. The dashed-green line in each graph represents a CD 
signature of G-quadruplex from the folding of TBA15. The experiment is carried out at 20°C. 
 
 
Figure 4.23(b) and (c) shows the CD spectra of TBA29plus. In the absence of 
thrombin (Figure 4.23(b)) the CD spectrum of the TBA29plus displayed a broad positive 
band from 265nm to 285nm that is mainly characteristic of base-pairing. The position 
and amplitudes of the CD bands may differ markedly with sequence, as well as with 
different conformational properties (Gray et al., 1992; Kypr et al., 2009). Once thrombin 
was added at different concentrations (Figure 4.23(c)), the flat area disappeared and the 
positive peak around 265nm and 210nm appeared. Transformation of the secondary 
structure appeared in the same way as in native TBA29 (Figure 4.19(c)). The 
appearance of unstructured conformations may be due to the extensions at the 5’ and 
the 3’ ends which destabilize the quadruplex structure in TBA15 and quadruplex/duplex 
structure of TBA29. 
 
 
 
(a) 
(b) (c) 
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Figure 4.23 CD spectra of TBA29plus in the presence and absence of thrombin. a) The sequence of 
TBA29plus; b) 5M of TBA29plus was prepared in thrombin binding buffer. Without thrombin present, the 
CD spectrum was measured at 4°C and 20°C; c) Titrating thrombin of various concentrations (0, 1, 3 and 
5M) to 5M TBA29plus. The dashed-green line in each graph represents a CD signature of G-quadruplex 
from the folding of TBA15. The experiment is carried out at 20°C. 
 
 
 
The individual components of aptamer dimers which were the 2/19-5 
monomer2 and 4/19-7 monomer2 were analyzed by CD spectroscopy. As shown in 
Figure 4.24 and Figure 4.25, neither of the sequences showed a quadruplex 
conformation in the presence or absence of thrombin, although repeated guanine bases 
were found in the sequences. Assuming that the lack of G-quadruplex structures 
resulted from bases in the sequence forming other possible stable secondary structures, 
we then reduced the sequence to a minimal length to cover only the first and the last 
possible guanine in a G-quadruplex. The sequences, named as short.2/19-5 and 
short.4/19-7, are shown in Table 4.2 and in Figure 4.26(a) and (b). CD spectra of these 
short sequences are shown in Figure 4.26(c) and (d).  
 
 
 
(a) 
(b) (c) 
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Figure 4.24 CD spectra of 2/19-5 monomer2 in the presence and absence of thrombin. a) The 
sequence of 2/19-5 monomer2 which is obtained from the PLS between F pool and R pool; b) CD spectrum 
of 5M of 2/19-5 monomer2 in thrombin binding buffer in the absence of thrombin, performing at 4°C and 
20°C; c) Titrating thrombin of various concentrations (0, 1, 3 and 5M) to 5M 2/19-5 monomer2. The 
dashed-green line in each graph represents a CD signature of G-quadruplex from the folding of TBA15. The 
experiment is carried out at 20°C. 
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Figure 4.25 CD spectra 4/19-7 monomer2 in the presence and absence of thrombin. a) The sequence 
of 4/19-7 monomer2. This sequence is obtained from the PLS between TBA29plus and R pool; b) CD of 5M 
of 4/19-7 monomer2 in the absence of thrombin, measured at 4°C and 20°C; c) Titrating thrombin of 
various concentrations (0, 1, 3 and 5M) to 5M 4/19-7 monomer2. The dashed-green line in each graph 
represents a CD signature of G-quadruplex from the folding of TBA15. The experiment is carried out at 20°C. 
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Figure 4.26 Sequences and CD spectra of short.2/19-5 and short.4/19-7. a) The sequence of 
short.2/19-5 and; b) the sequence of short.4/19-7. These sequences are part of full length sequences 2/19-5 
and 4/19-7, respectively. The sequences are cut short to show only the repeated guanine; c) The CD 
spectrum of short.2/19-5 is shown to have characteristic peaks of G-quadruplex in the presence and 
absence of thrombin; d) There is no G-quadruplex signatures observed in short.4/19-7 neither with nor 
without thrombin. The dashed-green line in each graph represents a standard CD signature of G-quadruplex 
from the folding of TBA15.The experiment was performed in thrombin binding buffer at 20°C.  
 
As shown in Figure 4.26, although the CD spectrum of the short.2/19-5 did not 
display sharp peaks, it did contain characteristic G-quadruplex signatures while none of 
these signatures were observed in short.4/19-7. More in-depth studies on the binding 
behavior were necessary.  
 CD spectroscopy is a well-established method of choice for studying DNA-
conformational properties. However, using the information from the spectra alone or 
interpretation of CD spectral changes by following only single band or a single condition 
can lead to incorrect conclusions. The structural conclusions must be made with caution 
because one of the limitations of using CD in analyzing quadruplex structures in G-rich 
nucleic acid sequences is that interpretation relies only on the comparison with spectra 
of known or inferred G-quadruplex structures (Gray et al., 2008). That is to say the base 
composition, DNA concentration, as well as condition used in the study (temperature, 
pH, salts, buffer condition, stabilizer etc.) all influence the CD spectra (Dapic et al., 2003). 
It has been recommended that for more accurate conclusions, the CD changes must be 
(a) (b) 
(c) (d) 
Short.4/19-7 
GGACAATGAGGATGGAGGGGG 
Short.2/19-5 
AAGGGTCAGGTGGGGTCTAGG 
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measured under several conditions that give rise to particular DNA arrangements rather 
than from only a single spectrum taken under one set of conditions (Kypr et al., 2009).  
The information obtained from CD spectrum alone did not appear to provide a 
definitive answer to whether the selected molecules were duplex structures or whether 
or not the sequences bind to thrombin. To answer the second question, which is the 
more important aspect and related to our study, is to further analyze the binding 
behavior of those structures. Due to the fact related to naturally-found guanine-rich 
oligonucleotides (GROs), not all quadruplex structures exhibits anti-proliferative effects, 
yet the most accurate factor in predicting biological activity of GROs would be an ability 
to bind to their specific proteins (Gray et al., 2008). This is also true to our experiment 
where some of potential primary sequences did show a repeated guanine bases motif 
but didn’t display any specific secondary structure. The binding affinity then needed to 
be determined to answer our question whether the selected aptamers potentially bind 
to thrombin or not. In the next experiment, we tested the binding affinity of the selected 
ligated aptamers using SPR and ELONA methods. 
 
4.8.4 Binding Characteristic of Selected Proximity Ligated Thrombin Binding 
Aptamers 
 
4.8.4.1 Binding Affinity by ELONA  
ELONA has been adopted for use as a quick binding affinity screen as previously 
demonstrated in Chapter 3. In the following experiment, we used an ELONA procedure 
to measure the binding affinity of the selected aptamers derived from PLS to thrombin. 
The principle of ELONA has already been described in detail in Chapter 3. Here, we only 
briefly discussed the aspects relevant to thrombin.  
There are two different formats of ELONA used here according to the type of 
aptamer sequences. As summarized in Figure 1.1 (Chapter 1), the binding of a sequence 
that contains a biotin modification can be directly monitored by adding SA-HRP and 
TMB/H2O2 substrate. However, in the case where a sequence does not contain biotin 
modification, we then used a biotinylated probes which can hybridize to either the 5’ or 
the 3’ end of aptamer sequence. To assay the monomer sequence, the sequence of each 
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half of the proximity ligation product, either the 5’ probe or the 3’ probe can be used 
depending on which half of the sequence will be assayed.  The sequence of probes and 
methods in more detail were described in Section 2.8.1.3. To start the ELONA assay, 
100L of 80nM thrombin (8pmol or 0.3g total amount of thrombin) was added into 
each well and incubated overnight at 4°C. The subsequent preparation and detection 
was carried out as described in described in Section 2.8.1 and Section 3.5.2. 
 
4.8.4.1.1) Binding Affinity of TBA15 and TBA29 and Their Modified Forms 
As described previously, two assay formats were used. Because TBA15 and 
TBA29 contained biotin at the 5’ end, they were assayed directly by adding SA-HRP 
which interacted with the biotinylated moiety in the aptamers. TBA15plus, TBA29plus 
and the starting DNA pool did not carry any modification. In order to determine the Kd of 
these unmodified samples, the assay was then performed by adding the 5’ probe that 
can hybridize to the 5’ primer region before adding SA-HRP. Figure 4.27 illustrates the 
assay formats for the sequences that contain (a) biotinylated modification and (b) no 
modification. All possible ELONA assay formats are summarized in Figure 1.6 (Chapter 
1).  
 
 
 
Figure 4.27 Schematic diagram of ELONA assays. Protein targets are adsorbed onto microtiter plate. The 
assay format depends on an oligonucleotide of interest. The oligonucleotides in (a) is modified with biotin. 
This modified sequence can be directly measured by adding SA-HRP. Whilst the sequence in (b) doesn’t 
contain any modification, the assay can be performed by adding the biotinylated 5’ probe that can hybridize 
at the 5’ end of the sequence before adding SA-HRP. 
(a) 
(b) 
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Different concentrations of aptamer were used to determine the binding affinity. 
The concentration range was selected based on the reported Kd of each aptamer and 
preliminary results. Preliminary experiments were performed for each of aptamer due 
to the fact that the different formats of the assay might affect the binding affinity. The 
concentration of TBA15 was varied in the range of 0-600nM and TBA15plus was tested 
in 0-5M range. Whereas TBA29 concentration was varied up to 20nM and TBA29plus 
concentration range of 0-200nM were tested, all in a total volume of 100L.  
The signal was obtained by reading the absorbance at 450nm. TBA15 and TBA29 
were used as positive controls for this assay since the binding affinity of these two 
aptamers have been well reported using different methods (Bock et al., 1992; Tasset et 
al., 1997; Berezovski et al., 2003; Baldrich et al., 2005). As related to the result from CD 
experiment in which TBA15plus and TBA29plus did not clearly show the G-quadruplex 
structure (Figure 4.22 and Figure 4.23), they were then tested for their affinity. The 
binding curves of TBA15 and TBA15plus are shown in Figure 4.28. Whilst the graphs 
that shows the TBA29 and TBA29plus’ binding affinities are shown in Figure 4.29. The 
binding curve of each aptamer was fitted using the non-linear curve fitting program 
Origin 8.6 assuming a 1:1 binding isotherm. The dissociation constants are summarized 
in Table 4.3.  
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Figure 4.28 The binding curve of TBA15 and TBA15plus. a) The sequence of TBA15 and b) The sequence 
of TBA15plus; The binding curves of TBA15 (c) and TBA15plus (d) were obtained by ELONA or ELONA 
Probe method. The dissociation constant (Kd) of each aptamer against thrombin was calculated by fitting the 
curve with nonlinear curve fitting program, Origin 8.6. Each data point was performed in triplicate. 
 
 
The Kd for TBA15 (Figure 4.28(c)) was calculated to be 250nM and 284nM from 
two independent experiments. This value is far higher than that of previous reports 
suggesting a low affinity for thrombin when assayed by the ELONA method. The Kd value 
thus depends on the measurement method where, according to the literature, the Kd of 
TBA15 can be as low as 2.9nM using SPR (Baldrich et al., 2005) or reported to be as high 
as 240nM using NECEEM (Berezovski et al., 2003) and in the range of 25-200nM by a 
nitrocellulose retention assay (Bock et al., 1992; Tasset et al., 1997). In contrast 
TBA15plus (Figure 4.28(d)) which contained the same core sequence did not show any 
binding signal. The result of binding affinity measurements together with the 
unstructured CD pattern shown in Figure 4.22(b) of TBA15plus might reflect the effect 
of sequence extension. It has been claimed that the extension of the aptamer sequences 
can destabilize the aptamer 3D structure. It is important to carefully select the sequence 
for the extension (Müller et al., 2007; Kim et al., 2008). 
 
 
TBA15plus 
5’TCGTGGCGTAATATGGTTGGTGTGGTT
GGGATCTTGGACCCTGCGAA-3’ 
TBA15 
5’GGTTGGTGTGGTTGG3’ 
 
(a) 
(c) 
(b) 
(d) 
 
177 Proximity Ligation Selection and Bivalent Thrombin Binding Aptamers 
 
 
 
0 5 10 15 20
0.0
0.5
1.0
1.5
2.0
A
4
5
0
[Biotinylated TBA29] (nM)
0 50 100 150 200
0.0
0.5
1.0
1.5
2.0
2.5
A
4
5
0
[TBA29plus] (nM)
 
 
Figure 4.29 The binding curve of TBA29 and TBA29plus. a) The sequence of TBA29 and b) The sequence 
of TBA29plus; The binding curves of TBA29 (c) and TBA29plus (d) were obtained by ELONA or ELONA 
Probe method. The dissociation constant (Kd) of each aptamer against thrombin was calculated by fitting the 
curve with nonlinear curve fitting program, Origin 8.6. Each data point was performed in triplicate. 
 
For TBA29 (Figure 4.29(c)), the Kd was calculated to be 1.2nM and 1.3nM from 
two independent experiments. This binding constant was consistent to the approximate 
Kd of TBA29 which was 0.5-1nM as reported by Tasset et al. (1997). The ELONA probe 
was used to assay binding affinity of TBA29plus (Figure 4.29(d)) by adding the 5’ probe 
to track the binding sequence. The dissociation constant of TBA29plus was calculated to 
be 6.4nM and 8.0nM.  
The ELONA signal from TBA15 itself was quite low compared to the binding 
signal obtained from TBA29 and TBA29 plus. The explanation for this presumably due 
to the minimal binding of TBA15 to adsorbed thrombin because we cannot control the 
orientation of thrombin adsorbed onto the surface, so it was possible that only a certain 
orientation was favored during adsorption. The adsorption then hid the fibrinogen 
binding exosite and exposed the heparin binding exosite. Moreover, the lack of proper 
exposure of the biotin molecule that attached to the aptamer in target-aptamer complex 
may prevent the interaction with SA-HRP. Furthermore, adsorbed thrombin may 
undergo denaturation or structural rearrangement to some extent with loss of binding 
TBA29 
5’ AGTCCGTGGTAGGGCAGGTTGGGGTGACT -3’ 
TBA29plus 
5’AAGCATCCGCTGGTTGACCAGTCCGTGGTAGG 
GCAGGTTGGGGTGACTATTTGGGCTGCTC -3’ 
(a) 
(c) 
(b) 
(d) 
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ability. This seems less likely, however, since TBA29 and TBA29plus always gave high 
signals in a very reproducible manner.  
The starting pool was used as a negative control for the binding assay. A 
concentration range of 0-2.5M DNA was used in a total volume of 100L. Figure 4.30 
shows the binding curve of DNA starting pool to thrombin. The binding curve was fitted 
using the non-linear curve fitting program Origin 8.6 assuming a 1:1 binding isotherm. 
However, for the starting pool, there was no binding observed at any DNA 
concentration.  
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Figure 4.30 The binding curve DNA starting pool.  Binding curves were obtained by ELONA or ELONA 
probe method. The dissociation constant (Kd) of DNA starting pool against thrombin was calculated by 
fitting the curve with nonlinear curve fitting program, Origin 8.6. Each data point was performed in 
triplicate. 
 
 
 
 
 
Starting pool sequence 
5’ AAGCATCCGCTGGTTGAC-N40-GATCTTGGACCCTGCGAA -3’ 
(a) 
(b) 
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 4.8.4.1.2) Binding Affinity of Aptamer Monomer 
The first set of PLS was performed on two starting pools (F and R pool). One of 
the proximity-ligated aptamers was selected to test for its binding affinity against 
thrombin. In this experiment, we determined the Kd of the two monomers. The binding 
of monomer was performed using the ELONA probe method. Only 2/19-5.monomer1 
showed signal from binding, but the signal was linear in a dose-dependent manner that 
suggests low binding affinity (Figure 4.31). The second monomer did not have any 
binding ability. From this result, it might explain the possibility that only one sequence 
specifically binds to the target but not the other one. As in proximity ligation assay, 
target-independent, background ligation always occurs to some degree (Fredriksson et 
al., 2002; Kim et al., 2010). Another reason may be that the selection was performed in 
solution while the binding test was performed on the adsorbed protein which may 
resulted in the hiding of some part of protein structure as in the case of TBA15. 
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Figure 4.31 The binding curve of 2/19-5.monomer1. The binding did not reach saturation and displayed 
in dose-dependent manner which would suggest it is binding to the protein target with low binding affinity. 
  
 
2/19-5 monomer1 
5’AAGCATCCGCTGGTTGACACGCCCTCACGAAGGACGTTTT
GCGCTCAGGGATAAAACAAATTTGGGCTGCTC -3’ 
(a) 
(b) 
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The second set of PLS was performed using R pool and known aptamer, 
TBA29plus. This set was carried out for two purposes. Firstly, it acted as a positive 
control for cloning and sequencing. Secondly, to prove the hypothesis that by using a 
known aptamer in PLS, the second sequence can then be easily picked out from the 
whole pool. The sequencing showed the right orientation as we expected as 5’-
(TBA29plus)-linker-(R pool)-3’ in every sequence. After sequence analysis, we selected 
one sequence, ID 4/19-7 to assay its binding affinity against thrombin. The 4/19-
7.monomer2 was assayed for its binding ability. However this sequence did not show 
the binding even though the concentration of monomer was as high as 5M. This can be 
explained by only TBA29plus binding to thrombin. The binding of two monomers far 
apart or in the wrong orientation cannot be ligated.  
The short.2/19-5 was also tested for its binding affinity. However, this truncated 
sequence did not give any binding. Although the short sequence that was cut from 2/19-
5.monomer2 displayed characteristic peaks of G-quadruplex in CD spectrum (Figure 
4.26(a)), it did not exhibit binding affinity against thrombin. This might be explained as 
in the case of TBA29 selection by Tasset et al. (1997). The TBA29 was obtained from the 
isolation from two starting pools containing 30 and 60 nucleotides in random regions. 
Interestingly after 11 round of selection, it was found that all the clones selected 
contained 15-nucleotide core sequences with eight highly conserved guanine residues 
that can form a G-quadruplex structure. However, when the chosen sequences were 
trimmed down to only 15 nucleotides in length, they can bind to thrombin with low 
micromolar range affinity. Further characterization revealed that the additional 
elements from the 15-nucleotide core of truncated sequences (Figure 4.32) were a three 
nucleotide spacer to the 5’ and the 3’ end and four nucleotide base-pairs, these stem 
forming quadruplex/duplex structure thus play a role in the high affinity. Moreover, the 
preference of having guanine base at the first position after the core (at the 3’-spacer 
direction) is associated with high-binding affinity and also adenine nucleotide at 
position 4 in the G-quadruplex core can direct the aptamer to the heparin binding 
epitope (Tasset et al., 1997). Each part of a sequence more or less contributed to the 
binding efficiency. The truncated form thus should retain high-affinity with minimal 
length. 
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Figure 4.32 A schematic diagram of the quadruplex/druplex structure of TBA29. The core 15-mer G-
quadruplex is labeled with number. The duplex part also plays a role in the high binding affinity (Tasset et 
al., 1997). 
 
The objective at first for developing PLS is not only single round of selection, but 
also the higher binding affinity of proximity ligated product than that of monomer 
sequence because of an avidity effect. The full length of 2/19-5 and 4/19-7 (0-1M 
range) were assayed for their binding affinity using ELONA. However, there was no 
binding observed (no signal from A450 measurement) within the concentration range 
that was assayed, indicating the low affinity of aptamers to thrombin. This might be due 
to 1) the binding affinity of these sequences was a lot lower than that of the 
concentration range we use in ELONA, 2) the additional sequence of the full length 
aptamer destabilized the secondary structure of the whole molecule, even though half of 
the sequence can bind to the target, and 3) protein denaturation occurred during 
adsorption. The full length 2/19-5 and 4/19-7 were then assayed for binding by SPR 
instead. The dissociation constants of each aptamers, measured by ELONA method, are 
summarized in Table 4.3.  
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Table 4.3 Summary of the dissociation constant of selected proximity ligated 
thrombin binding aptamers using ELONA 
Aptamer name Sequence (5’  3’) Kd (nM)* 
Starting pool  AAGCATCCGCTGGTTGAC-N40-GATCTTGGACCCTGCGAA N 
TBA15 GGTTGGTGTGGTTGG 267 
TBA15plus TCGTGGCGTAATATGGTTGGTGTGGTTGGGATCTTGGACCCTGCGAA N 
TBA29 AGTCCGTGGTAGGGCAGGTTGGGGTGACT 1.2 
TBA29plus AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTAT
TTGGGCTGCTC 
7.2 
2/19-5 monomer 1 AAGCATCCGCTGGTTGACACGCCCTCACGAAGGACGTTTTGCGCTCAGGG
ATAAAACAAATTTGGGCTGCTC 
N 
2/19-5 monomer 2 TCGTGGCGTAATAAACCTTTGCAAGGGTCAGGTGGGGTCTAGGCTTATTA
GTGGGATCTTGGACCCTGCGAA 
N 
4/19-7 monomer 1 TBA29plus 7.2 
4/19-7 monomer 2 
ATTTGGGCTGCTCTCGTGGCGTAATACGGGTACATGCGGACAATGAGGAT
GGAGGGGGTGCACCACAGATCTTGGACCCTGCGAA N 
2/19-5 full length 
AAGCATCCGCTGGTTGACACGCCCTCACGAAGGACGTTTTGCGCTCAGGG
ATAAAACAAATTTGGGCTGCTCTCGTGGCGTAATAAACCTTTGCAAGGGT
CAGGTGGGGTCTAGGCTTATTAGTGGGATCTTGGACCCTGCGAA 
N 
4/19-7 full length 
AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTAT
TTGGGCTGCTCATTTGGGCTGCTCTCGTGGCGTAATACGGGTACATGCGG
ACAATGAGGATGGAGGGGGTGCACCACAGATCTTGGACCCTGCGAA 
N 
*N refers to ‘no observed binding signal’ while the number after each sequence represents the dissociation 
constant in the average value from two independent experiments. 
 
 
 
 
 
 
 
 
183 Proximity Ligation Selection and Bivalent Thrombin Binding Aptamers 
 4.8.4.2 Surface Plasmon Resonance (SPR) 
SPR is known as a label-free optical technique that determines the differential changes 
in mass on a surface that result in refractive index changes. The technique, which offers 
high sensitivity and versatility, has become a central tool for real-time interaction 
analysis. A briefly introduction to SPR is given below. 
 
 4.8.4.2.1) The Principle of SPR Measurement  
 A surface plasmon is an electron wave that propagates along the surface of a thin 
metal film (less than 100nm thick), typically silver or gold. Surface plasmon resonance 
(SPR) occurs under certain conditions when the surface plasmon waves are excited by 
photons from polarized light. The incident beam of the polarized light passes through a 
prism or diffraction grating (Figure 4.33(a)) to the back of the glass sensor chip and a 
fraction of the light energy, at a defined angle, can be absorbed by the electrons in the 
metal coating. When the momentum of incoming photons matches the plasmon, 
electrons resonate at the interface between the thin metal film and the external medium 
that have different refractive indices. The transfer of momentum from the photons to 
the excited surface plasmon reduces the reflected light intensity, which is seen as a dip 
in the curve of intensity against angle of incidence. Any change in refractive index of the 
external medium leads to a shift of the dip angle (Figure 4.33(b)). The SPR technique is, 
thus, sensitive to the changing environment close to surface of the metal. This technique 
has been applied for measuring changes in refractive index within 300nm of the metal 
surface when material is adsorbed. This allows molecular interactions to be monitored 
in real-time at the surface by detecting changes in the reflected light intensity as 
illustrated by a SPR sensorgram (Homola et al., 1999; Pattnaik, 2005). Real-time 
measurement allows determination of both ‘on’ (i.e. binding) and ‘off’ (i.e. dissociation) 
rate constants by flowing different concentration of analyte across the surface of the SPR 
chip. When equilibrium binding constants are measured, this can be achieved by 
measuring the change in SPR intensity as a function of concentration. 
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Figure 4.33 SPR flow cell cross section. (a) The cross section of flow cell (b) SPR intensity curve 
  
4.8.4.2.2) Surface Chemistry on the SPR Chip 
 SPR chips used in this experiment were made of a mixed self-assembled 
monolayer (SAM) of 10% hexa(ethylene glycol)-carboxylic acid ((EG)6COOH)-
terminated thiol and 90% tri(ethylene glycol) ((EG)3OH)-terminated thiol on gold 
coated glass slides (Reichert SR7000DC). The most common approach to the covalent 
attachment of proteins onto the surface involves converting surface carboxyl groups to 
an amine reactive-NHS ester via EDC/NHS chemistry. This ester then reacts with free 
amino groups (of typically lysine residues) of proteins. A schematic drawing of 
EDC/NHS activation of surface carboxylic acid groups is presented in Figure 4.34. SPR 
provides information on the DNA-protein interaction through which the binding is 
measured from the mass change at the SPR chip surface. The mass change corresponds 
to the change in the refractive index of the material at the SPR chip surface. This is 
measured in response units (RU) or micro refractive index units (RIU). 
 
(a) 
(b) 
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Figure 4.34 A typical immobilization procedure using EDC/NHS crosslinking reaction. Streptavidin 
(or other proteins) is immobilized on SAM-COOH surface. Immobilization is carried out through EDC/NHS 
coupling reaction. Amine-reactive surface reacts with primary amine of protein (lysine residues) forming 
covalent amide bond.  
 
 
4.8.4.2.3) Binding Affinity by SPR 
 In our experiment, the binding affinity of full length proximity ligated products 
(2/19-5 and 4/19-7) was carried out employing a Reichert SR7000DC instrument. The 
well established TBA15 was used as a validation of the system. The SPR chip was 
prepared as described in Section 2.8.2.1-2.8.2.3. The response curve from SPR showing 
steps including surface chemistry modification, streptavidin immobilization, surface 
blocking and aptamer immobilization is shown in Figure 4.35 using TBA15 
immobilization as an example. Firstly, to achieve immobilization of streptavidin, the 
surface functional group, was activated by transformation of the carboxylic acid groups 
into reactive N-hydroxysucinimidyl esters intermediate via EDC/NHS coupling 
chemistry. The primary amino group of lysine residues on streptavidin then reacted 
with the NHS esters to form covalent amide bonds (Figure 4.34). Regardless of size and 
protein concentration, the level of immobilization is a pH dependent process as reported 
by Lahiri et al. (1999). The experiments revealed that the optimum pH used during 
coupling should be approximately one unit below protein’s pI. Here in our experiment, 
we used 10mM sodium acetate buffer pH 5.0 as a coupling buffer for streptavidin which 
has a pI around 6. The immobilization of 1M streptavidin was performed on both left 
(L) and right (R) channels. Covalent attachment of streptavidin to the amine reactive-
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NHS ester gave a response change 1,800RIU obtained from average value from several 
experiments. Assuming that 1RIU is equivalent to an immobilized protein density of 
1pg/mm2 as described in the Reichert user guide, the amount of streptavidin was 
calculated to be roughly 1800pg/mm2 or a total streptavidin loading of 22.5ng or 
0.4pmol or 2.4x1011 molecules per channel.  
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Figure 4.35 Immobilization of streptavidin on a sensor chip. Reactive succinimide ester group was 
introduced to the surface via EDC/NHS coupling chemistry. Streptavidin which was diluted in 10mM sodium 
acetate (NaOAc) buffer pH 5.0 was then covalently linked to the surface on both channels. Surface blocking 
for any active residues was performed using 1M ethanolamine-HCl pH 8.5 that converted active –COOH 
group to –CONHCH2CH2OH group. Nonspecifically bound streptavidin was washed from the surface using 
10mM HCl before ligand injection. 10mM Phosphate buffer saline (PBS) was used as a running buffer for all 
chip preparation steps. 
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To immobilize an aptamer, the biotinylated sequences were loaded only on the 
left channel and kept the right channel as a reference. The immobilization occurred via 
the strong interaction between biotin and streptavidin. As shown in Figure 4.36, 
immobilized TBA15 gave a response around 350RIU which can calculated to be 
roughly about 1pmol of total TBA15 attached to streptavidin per channel. The ratio of 
TBA15 to streptavidin was equal to 2:1.  
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Figure 4.36 Immobilization of biotinylated aptamer on a streptavidin coated sensor chip. Biotinylated 
DNA aptamer was diluted to a range of 0.2M-1M in 10mM PBS. The immobilization of aptamer on a 
sensor chip was performed by injecting the ligand to the left channel at a flow rate of 10L/min for 25 min 
10mM PBS was flown through the right channel as it was kept as a reference with no DNA aptamer. The 
amount of DNA immobilized through biotin-streptavidin interaction was calculated from the raise of signal 
from the base line. TBA15 around 1pmol (or ~350RIU) was attached to the streptavidin surface on the left 
channel. There was no signal shift on the right channel since it was only buffer run through. 
 
To determine the Kd at equilibrium, various concentrations of the protein target 
in binding buffer were injected and the binding events were observed. The analysis of 
interactions was performed by flowing thrombin solution over the immobilized aptamer 
at a slow flow rate of 5L/min for 40 min.  For TBA15 binding assay, duplicate sample 
injection was performed at the 100nM of thrombin. An example of the binding 
sensorgram of different thrombin concentrations was shown in Figure 4.37(a). The data 
 
188 Proximity Ligation Selection and Bivalent Thrombin Binding Aptamers 
set of responses obtained can be fitted to a hyperbolic binding affinity curve as shown in 
Figure 4.37(b). The binding curve was fitted using the non-linear curve fitting program 
Origin 8.6 and assuming a 1:1 binding isotherm. 
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Figure 4.37 a) Sensorgram demonstrating the binding of TBA15 to thrombin. b) TBA15 binding 
curve. The Kd for TBA15 was calculated to be 53nM. 
 
(a) 
(b) 
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The binding curve of full length product from PLS, 2/19-5 and 4/19-7, are shown 
in Figure 4.38.  
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Figure 4.38 Determination of binding affinity of proximity ligated aptamers for thrombin using 
surface plasmon resonance. Data were obtained from the binding response from SPR and were fitted with 
nonlinear curve fitting using Origin 8.6 by assuming a 1:1 binding ratio. The sequence of full length 2/19-5 
is shown in (a) and for 4/19-7 is shown in (b). The Kd for 2/19-5 was calculated to be 1.6M (c) and the Kd 
for 4/19-7 was calculated to be 1.2M (d). 
 
As shown in Figure 4.37 and 4.38, using Origin 8.6, the equilibrium Kd value of 
TBA15 was calculated to be 53nM which is comparable to the previous reports. The Kd 
of full length proximity ligation product that obtained from F pool ligated with R pool 
(2/19-5) was calculated to be 1.6M and the sequence that contained one half of 
TBA29plus (4/19-7) has an affinity of 1.2M.  
Comparison of the two binding assay methods; ELONA did not give any signal 
when the dimers were assayed whereas by using the SPR, a signal was obtained from 
both samples even though the binding affinity was quite low (in the micromolar range). 
(a) 
(b) 
AAGCATCCGCTGGTTGACACGCCCTCACGAAGGACGTTTTGCGCTCAGGGATAAAACAAATTT
GGGCTGCTCTCGTGGCGTAATAAACCTTTGCAAGGGTCAGGTGGGGTCTAGGCTTATTAGTGG
GATCTTGGACCCTGCGAA 
 
AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCAT
TTGGGCTGCTCTCGTGGCGTAATACGGGTACATGCGGACAATGAGGATGGAGGGGGTGCACCA
CAGATCTTGGACCCTGCGAA 
(c) (d) 
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This can be explained by the different formats of the assay. In ELONA, the protein is 
attached onto a PS surface through passive adsorption and various concentrations of 
DNA aptamer were added and incubated with the adsorbed protein at a specific time 
before washing. The problems of adsorption may arise from disfavored orientations of 
the protein on the surface, surface induced denaturation and poor-immobilization 
efficiency, hence resulting in the loss of the binding site. These problems may prevent 
the access of ligand to its specific epitope on the protein. Alternatively, in SPR, the 
biotinylated aptamer sequences were immobilized on the streptavidin coated chip and 
various concentrations of protein solution were flowed over the surface at a flow rate of 
5L/min for at least 30 min in order to observe the equilibrium binding. The 
immobilization of the aptamer is generally more flexible, and occurs in a more 
controllable fashion than the protein. And due to the fact that the selection was 
performed in solution, aptamers freely select their preferable binding regions on the 
protein, which are quite similar in the binding assay format in SPR. On the other hand, 
during SELEX, the protein in solution is more accessible than when immobilized.  
 
4.9 Conclusions 
The PLS is a technique that we developed with an idea adopted from the PLA. By taking 
advantage of the local concentration derived from the protein-dependent ligation of two 
simultaneously bound aptamers, an avidity effect plays an important role in the binding 
efficiency. In this experiment, we chose thrombin as our control target. Because it is well 
known that thrombin contains two binding exosites and has two respective aptamers 
which were well characterized. Two sequences were obtained from each set of 
experiments were the 2/19-5 from F and R pool and the 4/19-7 from TBA29plus and R 
pool. None of the selected aptamers showed a G-quadruplex signature in CD spectrum 
even in the presence of thrombin. We then assayed the binding affinity of the ligated 
product and their monomers. The Kd from two independent ELONA experiments of 
TBA15, TBA29 and TBA29plus were 250-284nM, 1.2-1.3nM and 6.4-8.0nM, respectively. 
However, no binding signal was observed from any other constituted sequences neither 
monomer nor dimer aptamers. By using the SPR, we can then determine the Kd of 
aptamer dimers. The aptamer 2/19-5 and 4/19-7 have Kd 1.6M and 1.2M, 
respectively. 
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In the next chapter, we will describe the method optimization performed against 
another model target, lysozyme, and will describe how we can perform PLS as we 
carried out in this chapter. The advantages and disadvantages of the PLS method will 
also be discussed further.  
 
 
 
 Chapter 5 
Proximity Ligation Selection and 
Bivalent Lysozyme Aptamers 
 
 
  
 
 
 
The principle advantages of a combination of two known aptamers, forming a 
bifunctional aptamer, which can simultaneously recognize the target, have already been 
described in Chapter 4. The selection was carried out against human -thrombin, the 
protein molecule that is well known as having two aptamer binding epitopes. In this 
chapter, we will focus on PLS method optimization using hen-egg white lysozyme as a 
target. It has so far not been reported that it has two binding aptamers. The 
experimental design of PLS and its advantages and disadvantages will be described in 
more detail in the following section.  
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5.1 Introduction 
Lysozyme is a small hydrolytic enzyme (129 amino acids) that is abundant in egg white 
and human tears. It functions as a natural anti-bacterial agent because lysozyme 
hydrolyzes the (14) glycosidic bond between N-acetylmuramic acid (Mur2Ac or 
NAM) and N-acetylglucosamine (GlcNAc or NAG) of the peptidoglycan that forms the 
gram-positive bacterial cell walls. Once digested, the bacteria can no longer prevent 
cellular swelling from water osmosis and undergo lysis. The structure of lysozyme and 
its catalytic function are shown in Figure 5.1. 
Lysozyme is an easy target for aptamer selection because of its commercial 
availability, low cost and exceptional stability. It has previously been chosen as an initial 
target for the development of aptamer selections, biosensors and microarray platforms. 
The selection of RNA aptamers that bound hen-egg white lysozyme was reported by the 
Ellington lab using an automatic system (Cox and Ellington, 2001). The anti-lysozyme 
aptamer had a dissociation constant of 31nM and inhibited lysozyme catalytic activity. 
Although the original anti-lysozyme aptamer was selected from a random RNA pool 
(Cox and Ellington, 2001), it was further elaborated to develop biosensing platforms by 
several research groups (Rodriguez et al., 2005; Hansen et al., 2006; Cheng et al., 2007; 
Huang et al., 2009; Girardot et al., 2011; Rohrbach et al., 2012) who made the anti-
lysozyme aptamer out of DNA instead of RNA as in the original report. Moreover, only 
the random region was reverse transcribed instead of the whole length of the RNA 
aptamer. Later, to avoid the controversy of misuse of the anti-lysozyme RNA sequence, 
CE-SELEX was used to isolate a DNA aptamer that had a Kd around 3nM after five rounds 
of selection (Tran et al., 2010). It is known that RNA aptamer sequences cannot be 
substituted by their reverse transcribed DNA’s due to the fact that the binding of an 
aptamer relies on the formation of a three dimensional structure and the folding energy 
between the highly ordered-structure of RNA and DNA would result in a difference 
folding pattern (SantaLucia and Hicks, 2004). The binding of lysozyme, which has a net 
positive charge at neutral pH, can be partly enhanced by electrostatic interactions, with 
the negatively charged aptamers. However, the claims from those research groups that 
adopted the anti-lysozyme aptamer sequence from the Ellington group to use in a DNA 
form argued for a specific binding of the DNA aptamer to the lysozyme target rather 
than a simple electrostatic interaction (Rodriguez et al., 2005; Huang et al., 2009; Han et 
al., 2012; Rohrbach et al., 2012). 
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Figure 5.1 Lysozyme structure and function. a) A ribbon model of a hen-egg white lysozyme (PDB ID 
3LYM), showing Glu35 and Asp52 in the enzyme active site; b) Notably present in human tears and egg white, 
lysozyme hydrolyzes 14 glycosidic bond between N-acetylmuramic acid (Mur2Ac or NAM) and N-
acetylglucosamine (GlcNAc or NAG). This repeating disaccharide chain is crosslinked by short peptides (4-5 
amino acids), forming a layer of peptidoglycan, found in the bacterial cell wall.  
(a) 
(b) 
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5.2 Results and Discussion 
 
5.2.1 Preliminary Study on Proximity Ligation Selection  
A preliminary study of PLS was performed using a DNA pool that was given as a gift 
from the Ellington lab. This starting pool sequence contained 30 nucleotides (N30) is a 
central core flanked by constant regions required for PCR amplification. The sequence is 
as follows: 5’-GATAATACGACTCACTATAGGGAATGGATCCACATCTACGA-N30-GATCTTGGACCC 
TGCGAA. This original DNA template was designed to be transcribed to a starting RNA 
pool for in vitro aptamer selection. Thus, the DNA pool construct has the T7 promoter at 
the 5’ end (delineated in bold) which is necessary for transcription and the total length 
was 98 bases. Since we aimed to perform the in vitro selection for DNA aptamers, we 
removed the TATA box and carried out the amplification by using a forward primer 
excluding the T7 promoter. The PCR amplification was then performed using following 
primers: 5’-P-GGGAATGGATCCACATCTACGA-3’ and 5’-AAGCTTCGTCAAGTCTGCAGTGAA-3’ 
where ‘P’ denoted a phosphate group at the 5’-end of the forward primer. Hence, the 
new starting DNA pool was 80 bases in length. The general PLS strategy has already 
been shown in Figure 4.11 in Chapter 4 and the workflow in this preliminary study on 
PLS is illustrated in Figure 5.2.  
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Modified N30 Starting pool Target+
Independent binding of two sequences to target
Ligation of bound sequences
Separation of target with bound ligation product from unbound sequence
Release of ligation product and increase the copy number
Determination of corresponding size of the proximity 
ligation products
The original N30 Starting pool (Ellington Lab)
5’-GATAATACGACTCACTATAGGGAATGGATCCACATCTACGA-N30-GATCTTGGACCCTGCGAA
N30 pool sequence modification
5’-GGGAATGGATCCACATCTACGA-N30-GATCTTGGACCC TGCGAA
Sequence amplification and ssDNA preparation (Asymmetric PCR amplification) 
 
Figure 5.2 A diagram shows a workflow in the preliminary study on the proximity ligation selection. 
This preliminary study is focused on the N30 DNA pool preparation and the strategy to obtain ligated DNA 
products of expected size that is then determined using gel electrophoresis.   
 
 
 5.2.1.1 DNA Pool Amplification 
Before starting the experiment, as shown in Figure 5.2, the DNA pool needed to be 
amplified to generate enough starting material for in vitro selection. PCR amplification 
was performed in a thermocycler as described in Section 2.2.7 with minor modifications 
in that different primer pairs were used so as to set the annealing temperature at 50°C.  
As a general procedure for DNA pool amplification, the optimization of the 
number of PCR cycles was performed by removing an aliquot (200L) of the PCR 
mixture from a 40mL PCR master mix (excluding DNA polymerase). Then, 6L aliquots 
were drawn out every two PCR cycles for 30 cycles in total. The PCR product quality was 
then analyzed by gel electrophoresis as shown in Figure 5.3. Theoretically, the more PCR 
cycles, the higher the concentration of PCR products obtained, however, as can be seen 
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in Figure 5.3, the PCR product became smeared from higher molecular weight amplicons 
with increasing numbers of cycles and the primers ran out after cycle 4. This could be 
due to the product priming on another sequence when the concentration of primers was 
not high enough to compete. Even though the primers were well designed, it was 
difficult to completely eliminate the accumulation of larger PCR products. This can be 
explained by the heterogeneous nature of the random region (Crameri and Stemmer, 
1993; Musheev and Krylov, 2006). It was not helpful to decrease the template 
concentration because it would reduce the pool complexity (Pollard et al., 2000) but we 
should consider increasing the primer concentration instead.  
Amplification of the DNA pool requires a large PCR volume to maintain its 
complexity and to ensure that every molecule is amplified. A 40mL PCR master mix was 
distributed to 96-well PCR plates and only four PCR cycles were carried out. The dsDNA 
pool was concentrated by ethanol precipitation (Section 2.2.2) and purified by 10% 
(v/v) polyacrylamide gel to remove non-incorporated primers as described in Section 
2.2.6. The purified dsDNA pool was kept as small aliquots at -20°C. The concentration of 
the dsDNA pool calculated from its A260 was 526ng/L. This dsDNA N30 pool was then 
used as a template to generate ssDNA by asymmetric PCR.  
 
 
Figure 5.3 The PCR course of N30 DNA pool amplification. The 3% (w/v) agarose gel showed PCR 
amplification products from even cycles of amplification of the N30 pool. DNA size marker (L) was a 25 
base-pair step ladder which ran along with the PCR product. The number of cycles is depicted in each lane. 
The expected size of DNA product is indicated by the arrow. 
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5.2.1.2 Asymmetric PCR Amplification 
There have been several methods proposed so far in order to prepare a ssDNA pool for 
in vitro selection of DNA aptamers. Thermal DNA denaturation can be used to separate 
two complementary DNA strands. Once they are cooled down rapidly, most of the 
oligonucleotides fail to re-hybridize, and instead form internal secondary structures. 
However, this method has low efficiency where the presence of complementary DNA is 
able to disrupt aptamer selection in subsequence rounds. A biotinylated modification on 
one end, either the 3’ or the 5’, can be used where streptavidin-coated beads bind the 
biotinylated strand. The ssDNA product (the nonbiotinylated strand) can be released 
either using heat denaturation or alkaline elution as shown in Figure 2.4 (Espelund et 
al., 1990; Bowman and Palumbi, 1993). Several aptamer selection experiments have 
relied on this technique (Bock et al., 1992; Green et al., 1996; Murphy et al., 2003; 
Mosing et al., 2005; Sefah et al., 2010), however, there are concerns with contamination 
which would occur by streptavidin detaching from the beads and contamination with 
dsDNA that can rehybridize to its complementary stand (Paul et al., 2009; Wilson, 2011). 
Another method for isolating ssDNA uses the specificity of lambda () exonuclease. This 
enzyme possesses a 5’3’ exodeoxyribonuclease activity that selectively digests the 
phosphorylated strand of dsDNA and leaves non-phosphorylated strand free as shown 
in the diagram in Figure 2.5 (Chapter 2) (Sriprakash et al., 1975; Higuchi and Ochman, 
1989; Citartan et al., 2010). However in our case, the DNA contained a phosphate 
modification at the 5’ end that was subsequently used in proximity ligation selection so 
this method was not appropriate to prepare our ssDNA. We then tried asymmetric PCR 
amplification. This method is carried out in the presence of excess of one primer over 
the other. The replication that is initiated by one PCR primer is relatively inefficient and 
so the ssDNA synthesized from the other primer will accumulate at the end of the 
process (Ellington and Szostak, 1992; Conrad et al., 1996). However, it was reported 
that this protocol gave low efficiency in amplifying DNA (Yang et al., 2009).  
To improve the yield, two step PCR amplification is used (Huizenga and Szostak, 
1995). The first amplification is carried out using equal amounts of the primer pairs to 
generate enough dsDNA pool and the PCR product is then used as a template for the 
second asymmetric PCR using only one primer. Although it is a tedious process with two 
steps and the products need purification, use of asymmetric PCR amplification for 
preparing the starting pool offers the advantage of pool purification by gel 
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electrophoresis, where DNA molecules at or near full length are excised, as an 
extendable ssDNA for selection and subsequent amplification. We then performed the 
single primer PCR amplification using the template from cycle 4 of N30 DNA pool 
(Figure 5.3). Based on the cycle course of the asymmetric PCR (Figure 5.4), the 
amplification was carried out in 10mL scale for 12 cycles, followed by ethanol 
precipitation. The DNA was then purified using 10% (v/v) TBE-urea polyacrylamide gel. 
After gel purification and ethanol precipitation, ssDNA yielded 3.6nmol in total from the 
starting dsDNA template of 1nmol. To increase ssDNA yield, more cycles of PCR 
amplification should be performed. 
 
 
Figure 5.4 The asymmetric PCR course. The 10% (v/v) TBE-urea polyacrylamide gel showed ssDNA 
product of N30 pool from asymmetric PCR amplification which was drawn out every two cycles. The 
number of cycles is depicted in each lane. Bigger bands belonged to starting pool that contained the T7 
promoter. The 80 bases-DNA band was expected size of our amplified pool. The excess primer could be seen 
bottom of the gel. 
 
 
5.2.1.3 Proximity Ligation Selection Using the N30 Pool 
The PLA, first described by Fredriksson et al. (2002), was used to detect PDGF-BB as 
described in Section 4.4 (Chapter 4). We have adapted the method to use as an aptamer 
selection procedure and performed a PLS using lysozyme as our target protein. The PLS 
against lysozyme was carried out in lysozyme binding buffer containing 20mM Tris-HCl 
pH 7.5, 100mM NaCl and 5mM MgCl2. This binding buffer condition was used according 
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to the automated selection procedure of an anti-lysozyme RNA aptamer, as reported by 
the Ellington group (Cox and Ellington, 2001). The first PLS experiment was performed 
by following the general workflow in Figure 5.2. The experimental strategy is 
summarized in Figure 5.5. A small reaction volume was used as described in PLA 
(Fredriksson et al., 2002) in that the pre-incubation of the proximity probes and sample 
in the smallest possible volume should promote binding. The modifications that we 
made for our PLS included: 
 A low concentration of oligonucleotide connector was used in PLS as a 
parameter to drive a protein-dependent ligation. Whilst in PLA the 
oligonucleotide connector was added at high concentration where the co-
localized ends of proximity probes were joined but all free probes were 
hybridized with the oligonucleotide connector, which then inhibited the 
formation of non-specific ligation products. 
 A fixed ratio of lysozyme to DNA pool to the oligonucleotide connector was 
4500pmol: 450pmol: 4.5pmol (100: 10: 1). The high amount of lysozyme was 
used to ensure that all the possible binding molecules could be ligated and 
amplified. An avidity effect of the binding was what we expected rather than 
simple affinity. 
 Two-step PCR amplification was used. The first amplification was performed by 
adding PCR reaction mixture directly to the ligation mix and the amplification 
carried out for 5 PCR cycles. The reason to perform the first 5 PCR cycles was to 
prepare proximity ligated products in double stranded form. Then we could use 
a Microcon YM-100 membrane to partition the non-ligated DNA pool. The cut-off 
of YM-100 was 100kDa proteins, 300 bases ssDNA and 125 bp dsDNA. Our 
double stranded ligated DNA was 160 bp so they should be retained while the 
molecules smaller than the cut-off went through. The retentate was collected 
and used as a template for another 30 rounds of the second amplification. 
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Figure 5.5 Flowchart illustrating the first PLS experimental strategy. The control (no lysozyme) was 
performed along with the sample (containing lysozyme) reaction. After incubation for two hours, ligation 
and amplification reactions were carried out. In this protocol, ultracentrifugation was used to separate 
bound and ligated product from unbound/non-ligated sequences. The agarose gel on the right bottom 
shows the ligation product analysis. Lane 1 represents DNA marker. Lane 2 and lane 3 shows the PCR 
products of negative control and sample, respectively. The gel doesn’t show a clear ligated PCR product. 
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 From the agarose gel in Figure 5.5, we did not obtain any of the expected ligation 
product, which should appear at around 160 base-pair. This may result from 1) 
inappropriate ligation and amplification conditions where each step was performed 
without changing buffers, 2) as a rule of thumb for aptamer selection, the amount of 
pool should be higher than that of target to retain all possible sequences. Using high 
protein over DNA leads to non-specific binding, and 3) centrifugation could not 
completely remove DNA monomer. The degradation of N30 DNA pool that had been 
kept for several years would also affect the pool quality and complexity as we can notice 
from the smear on the gel (Figure 5.3). We then decided to use a new DNA starting pool 
and performed optimizations for the conditions used in the PLS.  
  
5.2.1.4 Proximity Ligation Selection: Optimization of Conditions 
From the preliminary study, lysozyme concentration, partitioning method and starting 
pool quality are of major consideration for PLS. For further experiment, the new random 
DNA pool was used. It was re-designed containing 40 nucleotides in the random region 
flanked by a new primer pair. The sequence is shown as followed: 5’-P-
AAGCATCCGCTGGTTGAC-N40-GATCTTGGACCCTGCGAA-3’. For this new DNA pool we 
performed optimization of many parameters as described in the following subsections. 
 
5.2.1.4.1) Lysozyme Concentration 
The first parameter that needed to be optimized was the lysozyme 
concentration. This is because a high concentration of protein target over DNA pool 
increases the likelihood of non-specific binding. The PLS was performed without 
partitioning and at a fixed amount of DNA pool (1nmol) and varying amounts of 
lysozyme. The workflow is shown in Figure 5.6.  
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Figure 5.6 PLS against various amount of lysozyme target. Lysozyme from 0.01nmol to 1nmol was 
incubated with 1nmol N40 DNA pool. The selection and ligation were performed in solution and the PCR 
amplification was carried out without partitioning. PCR product was analyzed on 3% (w/v) agarose gel. 
Lane 1 and 7 was DNA 25 bp step ladder, lane 2 to lane 6 were the reaction that contained 0nmol (control), 
0.01nmol, 0.1nmol, 1nmol lysozyme and template blank PCR amplification, respectively. Black arrows 
marked the expected ligated DNA products (~152 bp). Unfortunately, there was no band observed at this 
position.   
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After the ligation and heat inactivation of T4 DNA ligase, we noticed the reaction 
solution containing 1nmol of lysozyme became turbid and after centrifugation, there 
was a pellet at the bottom of the tube. For PCR amplification, we transferred each 
sample to new PCR thin wall tubes. The expected size of DNA after ligation should be 
around 152 base-pairs. As shown in Figure 5.6, the agarose gel analysis indicated that no 
ligation products were obtained in any sample. In the absence as well as the presence of 
0.01 and 0.1nmol lysozyme, only DNA monomers were amplified. An extra band 
appeared at a size of around 100 bp. This may due to priming by the oligonucleotide 
connector which contained part of the reverse primer sequence. In Lane 3, the 
disappearance of the DNA band may be due to the co-precipitate of DNA with lysozyme 
as described above. The primary conclusion from this experiment was that a 
partitioning step is necessary to remove unbound DNA pool. We then performed a 
repeat experiment to optimize lysozyme concentration along with two partitioning 
methods including membrane filtration and centrifugation.  
 
5.2.1.4.2) Partitioning Methods 
As mentioned in the first preliminary PLS experiment (Figure 5.5), the DNA 
monomers became the major products during the PCR amplification due to inefficient 
partitioning of aptamer monomers and dimers using the ultracentrifugation method. In 
the second PLS experiment (Figure 5.6), we omitted the partitioning step and we can 
only see the band of DNA monomer in each sample. This can be either: 1) we couldn’t 
obtain any ligation product or 2) DNA monomers are more favorable than dimers during 
PCR amplification. We assumed that if we can remove DNA monomer, then PCR 
amplification would favor replication of the aptamer dimers, which were a product of 
the ligation selection and likely to be present in much lower amounts than the 
monomer. We then introduced an alternative partitioning using nitrocellulose 
membrane adsorption. Two sets of experiments were performed. The experimental 
strategy in the incubation and ligation steps is similar to the workflow in Figure 5.6, 
except that two partitioning methods are applied. The workflow of this experiment is 
shown in Figure 5.7.     
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Figure 5.7 Comparison between two partitioning, centrifugation and membrane filtration. At a fix 
amount of DNA pool at 1nmol, the amount of lysozyme were varied from 0pmol (no lysozyme control) to 
10pmol. The selections were performed in 30L total volume of incubation and increased to 50L after 
adding ligation mixture. Ultracentrifugation and membrane filtration were used to partition DNA unbound 
monomer. The PCR amplification products from these two partitioning method were analyzed by 3% (w/v) 
agarose gel electrophoresis. The expected DNA ligation product (~152 bp) is marked by arrow and dashed 
line. 
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 According to the previous experiment and this experiment, the membrane 
centrifugation did not efficiently separate a monomer from dimer. Band intensities of 
the DNA dimer from centrifugation were less than those of the membrane filtration. This 
might be due to the preference of amplification of the DNA monomer over the dimer 
where centrifugation retained more DNA monomer than in the other method. 
Nontheless, as can be seen from the gel, the ligation products were present even in the 
absence of lysozyme. This protein-independent ligation also occurred in PLA 
(Fredriksson et al., 2002). For the subsequent experiments, we redesigned the selection 
strategy in order to decrease the effect of DNA monomer amplification and protein-
independent ligation and also to increase the specific DNA ligation products. We kept 
the starting pool at 1nmol for each experiment and used membrane filtration as the 
partitioning method.  
 
5.2.2 New Pool Design for Proximity Ligation Selection 
The preliminary experiment was designed to use a standard ssDNA pool with a slight 
modification. This pool contained a random region of a specific number of nucleotides 
flanked by the constant region for PCR amplification and also included the phosphate 
modification at the 5’ end to facilitate ligation during selection. Nitrocellulose membrane 
filtration was chosen as the partitioning method because we used unmodified protein 
target. The difficulty that arose from using this pool was the interference from DNA 
sequence monomers that co-amplified with the ligation products at an even better rate 
of amplification than that of the long sequences. After identifying this problem we 
redesigned two different N40 DNA pools as described in Section 2.4.1. The new starting 
pools were named as the forward pool (F pool) and the reverse pool (R pool). Each pool 
contained 40 random nucleotides flanked by different extension at both the 5’ end and 
the 3’ end. The forward (F) pool was extended at the 5’ end with forward primer and at 
the 3’ end with 13 additional nucleotides. The reverse (R) pool was flanked by reverse 
primer complementary sequence at the 3’ end and additional 13 nucleotides extension 
at the 5’ end. The R pool sequences were modified with a phosphate group at the 5’ end. 
Although the experimental strategy was similar, the PLS that used new F and R starting 
pools had an advantage over the one that used a standard starting pool in term of DNA 
dimer amplification efficiency. It is only the ligated DNA product that can be amplified 
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because it has a complete forward primer and reverse primer hybridization region from 
F pool and R pool, respectively. The F pool itself cannot be amplified and the R pool can 
be amplified at a linear rate. Figure 5.8 shows the comparison between the use of a 
standard pool and the new pool for PLS.  
 
 
 
Figure 5.8 Comparison of two pools used in the PLS. Preliminary study was carried out using standard 
pool. After PLS and amplification, aptamer monomers were dominant (a). In contrast, selection using F and 
R pool gave aptamers dimer as a majority (b).   
 
We assumed that if we performed experiments using these new N40 mixed 
pools, we can reduce the problems obtained during amplification. The working principle 
of PLS for further experiments using the new N40 mixed pools is shown in Figure 5.9.  
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Figure 5.9 Schematics of the working principles of proximity ligation selection using two different 
pools, named Forward (F) and Reverse (R) pools. In the presence of target, two aptamers from each pool 
would be able to bind simultaneously to their target. And only if those pairs are in an appropriate 
orientation in which the 3’ terminal of the F pool is sufficiently close to the 5’ phosphate of the R pool, two 
DNA sequences can then ligate. The optimizations are performed in the incubation and ligation steps. The 
analysis of ligation product is carried out using gel electrophoresis.  
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5.2.3 PLS Method: The Optimization Using New Mixed Pools 
With the new F and R pools, we first optimized the amount of lysozyme. According to the 
preliminary study, the amount of lysozyme was varied as a ratio of the DNA pool at 1:1, 
0.1:1, 0.01:1 and 0.001:1 at a fixed amount of DNA (F and R pool mixture) of 1nmol. The 
negative control was performed in the absence of lysozyme and in the absence of the 
mixed pool. The incubation and ligation was performed as described previously except 
that the amount of oligonucleotide connector was kept at 0.1nmol in a total reaction 
volume of 20L. According to the amplification property of the new DNA pool (Figure 
5.8), we expected to have less DNA monomer than dimer and thus we should gain more 
of the proximity ligation products. We then omitted the partitioning step and performed 
the PCR amplification, by following the PCR course for 30 cycles. The PCR products were 
analyzed by 3% (w/v) agarose gel electrophoresis as shown in Figure 5.10. 
 
 
Figure 5.10 PLS without partitioning step. The PLS was performed by using 1nmol mix pool incubating 
with different amount of lysozyme. The partitioning step was omitted since we assumed that there would be 
less DNA monomer can be amplified. The smeared bands can be seen on the gel, which are due to a high 
concentration of DNA template for PCR amplification. 
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Although we expected to have less DNA monomer than dimer, from the gel 
analysis in Figure 5.10, there are no differences in the gel pattern in the absence and 
presence of lysozyme. We noticed smeared bands presented in each sample. This might 
be because of too high template concentration during amplification. As described in the 
previous experiment using the normal starting pool, partitioning was a critical step and 
this was also applied to our new mixed pools. We then applied membrane filtration to 
partition unbound DNA from complexed and performed PCR amplification. The gel 
analysis of PCR product is shown in Figure 5.11. 
 
 
Figure 5.11 The PLS with membrane filtration partitioning step. The PLS was performed by using 
1nmol mix pool incubating with 1nmol lysozyme. The partitioning step was performed after the ligation 
step. A protein-independent ligation also occurred and became the main problem of the PLS. 
 
The gel analysis in Figure 5.11 showed less smearing when applied membrane 
filtration to partition unbound DNA from complexed. However, protein-independent 
ligation became a problem instead. As can be seen from the gel (Figure 5.11) in the 
presence of 1nmol lysozyme and in the absence of lysozyme, there is no different in the 
band pattern. The ligation product (~152 bp) is found in both negative control and 
sample experiment. To minimize the protein-independent ligation, various parameters 
were optimized by performing the same PLS as described above, including the 
membrane filtration step but carried out in the absence of lysozyme (negative 
experiment). We then determined the ligation time and the amount of T4 DNA ligase 
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and oligonucleotide connector. In each parameter, we chose conditions that gave less or 
no ligated PCR product band. For example, when we varied the amount of T4 DNA ligase, 
the maximum amount that did not generate ligation product (or very little) at 10 PCR 
cycles was 0.05U. We then used 0.05U of theT4 DNA ligase in subsequent experiments. 
The amount of lysozyme used in PLS was also optimized under selected conditions. The 
flowchart of this optimization experiment is shown in Figure 5.12.  
 
 
 
Figure 5.12 Flowchart of PLS condition (negative experiment) optimization. The optimization includes 
ligation time, amount of T4 DNA ligase, amount of oligonucleotide connector and amount of lysozyme. Most 
experiments were carried out in the absence of lysozyme except the last experiment where amount of 
lysozyme was varied. After each experiment, the PCR product was analyzed on 3% (w/v) agarose gel 
electrophoresis.  
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Gel electrophoresis was used to determine the PCR products obtained from each 
experiment. The first negative experiment was performed on ligation time and in the 
absence of lysozyme. Fixed parameters included 1nmol mixed pools, 1U of T4 DNA 
ligase and 1pmol of oligonucleotide connector. Ligation time was varied from 0 min 
(pre-heat sample) to 5 min. Figure 5.13 illustrates the gel analysis of PCR product 
obtained from samples that carried out at different ligation time. 
 
~152 bp
~152 bp
 
Figure 5.13 Optimization the proximity ligation selection condition using the negative experiment: 
ligation time. In the absence of lysozyme, the DNA mixed pools were incubated with T4 DNA ligase. The 
ligation time was varied from 0 min to 5 min. The blank experiments were carried out in 1) the absence T4 
DNA ligase; 2) the absence of DNA mixed pools; and 3) the absence of PCR template during amplification. 
The number under each well represents the PCR cycles (0, 5 and 10 cycles). 
 
From Figure 5.13, the ligation product was observed after incubating the ligation 
reaction at room temperature for 1 min. To ensure the ligation would occur, we then 
decided to keep the ligation time at 5 min for further experiments since there was no 
different in the ligation product at any incubation time scale. There is no band observed 
in the blank experiments (no ligase, no mixed pools and PCR template blank 
experiments). The next parameter that needed to be optimized was the amount of T4 
DNA ligase. Too much ligase is unnecessary and would lead to higher non-specific 
ligation. Figure 5.14 shows the gel analysis of PCR product obtained from samples that 
carried out at different amount of T4 DNA ligase from 0.001U to 1U.  
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Figure 5.14 Optimization the proximity ligation selection condition using the negative experiment: 
amount of T4 DNA ligase. In the absence of lysozyme, the DNA mixed pools were incubated for 5 min with 
different amount of T4 DNA ligase. The amount of T4 DNA ligase was varied from 0.001U to 1U. The blank 
experiments were carried out in 1) the absence T4 DNA ligase; 2) the absence of DNA mixed pools; and 3) 
the absence of PCR template during amplification. The number under each well represents the PCR cycles 
(0, 5 and 10 cycles). 
 
 From Figure 5.14, in the absence of lysozyme, the maximum amount of T4 DNA 
ligase that first observed the ligation product was 0.05U. This is, in fact, the minimum 
amount of T4 DNA ligase that can function but generates less interference from non-
specific ligation product. When the amount of T4 DNA ligase increased, we then 
observed more ligation product, as the product bands were more intense. There is no 
band observed in the blank experiments (no ligase, no mixed pools and PCR template 
blank experiments). In the next negative experiment, the amount of oligonucleotide 
connector was varied from 0.001nmol to 0.5nmol (0.05nM-25nM). Although it was 
reported in the proximity ligation assay (Fredriksson et al., 2002) that the 
oligonucleotide connector was used at high concentration (400nM) to push the ligation 
reaction of co-localized ends of proximity ligation probes. In our PLS experiment, we 
considered the concentration of oligonucleotide connector as one of the stringent 
conditions for the selection so that we kept the concentration of oligonucleotide 
connector at low concentration. Figure 5.15 shows the gel analysis of samples that were 
incubated with different concentrations of oligonucleotide connector.  
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Figure 5.15 Optimization the proximity ligation selection condition using the negative experiment: 
amount of oligonucleotide connector. In the absence of lysozyme, the DNA mixed pools were incubated 
for 5 min with 0.05U of T4 DNA ligase and different amount of oligonucleotide connector. The amount of 
oligonucleotide connector was varied from 0.001nmol to 0.5nmol. The blank experiments were carried out 
in 1) the absence T4 DNA ligase; 2) the absence of DNA mixed pools; 3) the absence of oligonucleotide 
connector; 4) the presence of non-related short nucleotide; and 5) the absence of PCR template during 
amplification. The number under each well represents the PCR cycles (0, 5 and 10 cycles). 
 
 In the absence of lysozyme, the amount of oligonucleotide connector that gave 
no ligation signal (Figure 5.15) is 0.001nmol. The next experiment was performed by 
varying the amount of lysozyme from 0.001nmol to 1nmol (0.05nM–0.05M). The fixed 
parameters that obtained from previous experiment were used, including 1nmol mixed 
pools, 0.001pmol oligonucleotide connector and 0.05U T4 DNA ligase. The incubation 
time for ligation reaction was 5 min. The PCR products were analyzed on gel 
electrophoresis as shown in Figure 5.16. The ligation product was observed when using 
1nmol of lysozyme but not found at 0.001nmol of lysozyme. The ligation product band 
intensity at 0.1nmol and 0.5nmol lysozyme was similar. We then fixed the amount of 
lysozyme at 0.1nmol, which then give the ratio of DNA to protein at 10:1 for further 
experiments.  
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Figure 5.16 The proximity ligation selection using the optimized conditions obtained from negative 
experiments. The DNA mixed pools were incubated for 5 min with 0.05U of T4 DNA ligase and 0.001pmol 
oligonucleotide connector in the presence of different amount of lysozyme. The blank experiments were 
carried out in 1) the absence lysozyme; 2) the absence of DNA mixed pools; 3) the absence of T4 DNA ligase; 
and 4) the absence of PCR template during amplification. Arrows indicate the ligation product bands. The 
number under each well represents the PCR cycles (0, 5 and 10 cycles). 
 
 Although we optimized the ligation condition, the lysozyme-independent 
ligation was still a problem. We then considered another factor, according to the study 
of Kim et al. (2010). They proposed a solution for target-independent ligation in PLA by 
using an asymmetric oligonucleotide connector. The oligonucleotide connector can 
hybridize unequally to the two extension ends of the proximity aptamer probes and the 
hybridization was weaker on one side. Thus, in the absence of target, the background-
ligation was significantly reduced. The shorter the oligonucleotide connector, the lower 
background ligation would be, but it also needed to be kept in mind that too short an 
oligonucleotide connector could affect the ligation efficiency for the protein-dependent 
reaction. The standard oligonucleotide connector contained 20 bases (C20), hybridized 
to 10 bases of each aptamer end. The asymmetric oligonucleotide connector that we 
used contained 16 bases and was called Cv3’16. The sequence of asymmetric 
 216 Proximity Ligation Selection and Bivalent Lysozyme Aptamers 
oligonucleotide connector is 5'-ATATACGCCACGAGAGCAGTTT-3'. The first half of 
oligonucleotide connector (purple highlight) is the region that hybridizes to R pool and 
the sequence with green highlight hybridizes to six bases on the 3’ extension end of F-
pool. We tested the ligation efficiency of Cv3’16 at various concentrations. The result 
showed that at 0.001nmol Cv3’16, a ligation band appeared in the presence of 0.1nmol 
lysozyme but not in the absence of lysozyme (Figure 5.17). 
 
 
Figure 5.17 Asymmetric oligonucleotide connector, Cv3’16. Various concentrations of Cv3’16 were 
tested. Non-protein dependent ligation was observed when using 0.01nmol and 0.1nmol of asymmetric 
oligonucleotide connector. The optimal amount of Cv3’16 was 0.001nmol in total volume of 30L after 
adding ligation mixture containing 0.05U ligase. At this amount of oligonucleotide connector, there was a 
ligation product observed in the presence of lysozyme but not in the absence of lysozyme. 
 
The condition up to this point for PLS was that 1nmol of mixed pool (0.5nmol F 
pool and 0.5nmol R pool) was incubated with 0.1nmol lysozyme in a total volume of 
20L. The incubation was performed for 2 hrs at room temperature. Then the ligation 
mixture containing 0.001pmol Cv3’16, 0.05U T4 DNA ligase were added to perform the 
ligation reaction at room temperature for 5 min. Heat inactivation the T4 DNA ligase 
also denatured lysozyme, thus before membrane filtration, we added new lysozyme to 
the solution and continued the incubation process for another 30 min. After filtration, 
Ligation product 
Ligation product 
Aptamer monomer 
Aptamer monomer 
PCR course 
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the membrane was washed with 1 lysozyme binding buffer ten times to remove non-
specific binding. The aptamers that bound to lysozyme and were retained on the 
membrane were then extracted using hot water and were used as a template for PCR 
amplification. The control experiment performed in parallel was carried out in the 
absence of lysozyme. Both control and sample experiment were then analyzed using gel 
electrophoresis and the difference in the number of PCR cycles from the two sets were 
determined. We repeated the optimum condition as described with minor modifications 
that were 1) the incubation of mixed pool with lysozyme was carried out in 100L 
binding buffer, and 2) the amplification was performed in two steps. To minimize the 
loss of bound sequences, the entire eluted pool was amplified in the 1st PCR for 10 cycles 
at a 1mL scale. Then in the 2nd PCR amplification, product from the 1st PCR was divided 
into aliquots serving as a template to perform a PCR. However, we again faced the 
inconsistence of the process where the DNA dimers were also shown in the ‘no 
lysozyme’ control in the second PCR amplification as shown in Figure 5.18. Further 
method modifications were performed in the subsequent section.  
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Figure 5.18 The 2nd PCR amplification product from modified PLS. The DNA product from the 1st PCR 
was used as a template for the 2nd PCR amplification. 10 % (v/v) polyacrylamide gel electrophoresis was 
used for analysis the PCR product. There were no dimer bands (only monomers) presenting in the 1st PCR 
but, once performed the 2nd PCR amplification, the dimer bands appeared in both the presence and absence 
of lysozme.  
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5.2.4 New Modified PLS for Lysozyme  
To develop more efficient PLS, we then modified the selection method in which instead 
of performing the ligation in solution, we then carried out this process after partitioning. 
Target-aptamer complexes were formed in 100L binding buffer, and then the 
complexes were separated by membrane filtration and washed five times. After 
washing, we then added the ligation mixture, and performed the ligation reaction. This 
process was different from previous PLS in that the ligation was performed in solution 
before partitioning. This would lead to a large amount of oligonucleotides coming close 
in such a small reaction volume and ligated even in the absence of a connector (Kuhn 
and Frank-Kamenetskii, 2005). 
The ssDNA pool used in this experiment was described in Section 2.4.1. The F 
pool and the R pool were processed through the heating and cooling cycle before the 
incubation step with lysozyme was performed. Similar to other proteins we used in our 
experiments, the unmodified lysozyme-DNA complexes were simply separated from the 
unbound ssDNA using nitrocellulose membrane filtration. Washing five times after 
filtration pushed towards the survival of strong binders that oriented in the right order. 
The ligation proceeded afterwards giving an opportunity for two high affinity aptamers 
which locally bound in close proximity to join to each other by the activity of T4 DNA 
ligase. As a result, the ligation process was expected to succeed by giving only a few 
dimer products. It was necessary to ensure that the aptamer dimer we aimed for was 
not just from a nonspecific binding and nonspecific ligation. Firstly a negative control 
was required. We performed a negative control with no protein in parallel with the 
protein sample set. Secondly a quality check was performed using gel electrophoresis. 
We can primarily observe whether or not we obtained DNA product of the expected size. 
The starting F and R pools are 71 bases in length. The dimerization would give DNA size 
around 142-144 base-pairs after amplification. The details of selection are described in 
Section 2.6.1. Here in this section the proof-of-principle results obtained from the PLS of 
ligated aptamer in the presence and absence of lysozyme were analyzed on 10% (v/v) 
polyacrylamide gel electrophoresis as shown in Figure 5.19.  
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* Quality check of the product from the 1st PCR amplification 
** PCR cycle course of the 2nd PCR amplification 
 
Figure 5.19 Proximity ligation DNA products in the presence and absence of lysozyme. The selections 
were performed in parallel. Amplification was carried out twice. The first amplification was kept as a 
template for the second PCR amplification that performed as a cycle course. The appearance of ligated 
bands was compared. The DNA dimers were presented in the first PCR amplification in the presence of 
0.1nmol lysozyme (a). Without lysozyme (b), the band of protein-independent ligation appeared at PCR 
cycle 8 of the second amplification.  
 
Two independent experiments were performed in order to ensure that the 
process gave a reproducible result in terms of DNA product size and the number of PCR 
cycles after which DNA bands appear. In the repeated experiment, the gel 
electrophoresis revealed the same pattern of bands on the gel in the presence and 
absence of the lysozyme target. The selection strategy in detail was already explained in 
the selection of proximity ligated aptamer against thrombin in Chapter 4. The second 
(a) 
(b) 
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PCR reaction mixture contained 10% (v/v) of DNA template from the first amplification. 
The amplification was carried out so that the presence of ligated product could be 
monitored according to the proportional relationship between the number of thermal 
cycles and the amount of ligated products. Then, the PCR course was followed every two 
cycles until cycle 16. In the presence of lysozyme, the aptamer dimer DNA band 
appeared from the first PCR amplification cycle. The DNA band in the second 
amplification of protein-independent ligation in the absence of target can be able to see 
from the gel from the PCR cycle 6. The same band intensity appeared in the PCR cycle 2 
in the ‘with sample’ experiment and in the PCR cycle 10 in the absence of protein. 
Several PCR cycle differences comparing between the sample and ‘no protein’ control 
experiment suggested successful selection and protein-dependent ligation.  
 
5.2.5 Proximity Ligation Sequence Analysis 
The DNA products from the first PCR amplification were purified as inserted sequences 
for cloning. There were 50 clones randomly picked out for sequencing and only 37 
clones showed the correct orientation and a clear sequencing chromatogram. The 
sequences were compared using ClustalW2 program tool (http://www.ebi.ac.uk) for 
multiple alignment analysis. The sequence alignment is shown in Figure 5.20. The 
complete sequences including primer regions are shown in Appendix D. The Genebee 
program (http://www.genebee.msu.su) was used to identify common motifs within the 
selected regions and illustrated in Figure 5.21 as a graphical supermotif alignment 
generated by WebLogo program (http://weblogo.berkeley.edu/logo.cgi).  
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Local supermotif 1  
           ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
LPLS-4 (1) TTGAGAGTGAATCTATCGTGACGTACTGAACCGAATAAAGAATTTGGGCTGCTCTCGTGG 
LPLS-37(1) TTGAGAGTGAATCTATCGTGACGTACTGAACCGAATAAAGAATTTGGGCTGCTCTCGTGG 
        
 
            +++++++++++++++++++++++++++++++++++++++++++++++ 
LPLS-4 (61) CGTAATATCATCTCGCGAGTAATGGTTATAAGTCGCTCCTCATAGTG 
LPLS-37(61) CGTAATATCATCTCGCGAGTAATGGTTATAAGTCGCTCCTCATAGTG 
                    
 
Local supermotif 2 
           ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
LPLS-25(1) TAACTATCCCCCTGCAACCGAGTATTTCCTTCACGTTAGGTATTTGGGCTGCTCTCGTGG 
LPLS-45(1) TAACTATCCCCCTGCAACCGAGTATTTCCTTCACGTTAGGTATTTGGGCTGCTCTCGTGG 
         
 
            ++++++++++++++++++++++++++++++++++++++++++++++ 
LPLS-25(61) CGTATATCGAGTTAGCGTCGACCTCTTATGAGCCGCACTGTGATCT 
LPLS-45(61) CGTATATCGAGTTAGCGTCGACCTCTTATGAGCCGCACTGTGATCT 
                    
 
Local supermotif 3 
                  +     +++++++++++++++++++++++++++   +  ++++ +++  +++ +   
LPLS-29   (30)ctgatcccggAATTTGGGCTGCTCTCGTGGCGTAATAACCTTCTCCGCCAACTCTGatat 
LPLS-34   (31)tatctaatacAATTTGGGCTGCTCTCGTGGCGTAATATGATAATCCGACAATCCTGcttc 
                        
 
Figure 5.21 Supermotif alignment and Logos for ligated aptamers against lysozyme. Supermotif 1 and 
2 are the only two repeated sequences found among 50 randomly picked clones. The underline sequences 
are a constant region. 
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From the alignment, no individual sequence predominated and only two 
sequences occurred twice among 37 clones so these two aptamer sequences were 
selected for further characterization. The sequences of selected aptamers were shown in 
Table 5.1. 
 
Table 5.1 Selected anti-lysozyme aptamers from proximity ligation selection 
Clone 
number 
Aptamer sequences* 
 
LPLS-4 and 37 
 
AAGCATCCGCTGGTTGACTTGAGAGTGAATCTATCGTGACGTACTGAACCGAATAAAGAATTTGGGCTGCTCT
CGTGGCGTAATATCATCTCGCGAGTAATGGTTATAAGTCGCTCCTCATAGTGGATCTTGGACCCTGCGAA 
 
 
LPLS-25 and 45 
 
AAGCATCCGCTGGTTGACTAACTATCCCCCTGCAACCGAGTATTTCCTTCACGTTAGGTATTTGGGCTGCTCT
CGTGGCGTATATCGAGTTAGCGTCGACCTCTTATGAGCCGCACTGTGATCTGATCTTGGACCCTGCGAA 
* The italic characters represent the primer regions that flank the random regions shown in bold. The 
highlight shades the hybridization region with oligonucleotide connector that facilitates the orientation and 
ligation of the two sequences.  
 
 
5.2.6 Binding Affinity Determination of Proximity Ligated Lysozyme Aptamer 
As described in previous chapters, the binding affinity of selected aptamers was 
measured using the ELONA and the SPR assay. In the following section, two sequences 
selected using the PLS method were assayed for their binding ability to the lysozyme. 
The ELONA was used to determine the binding of the dimers and monomers of 
proximity ligated lysozyme aptamers as well as a reported lysozyme aptamer. Then SPR 
was used to confirm the binding of the aptamer dimer. The principles and the discussion 
of the determination aptamer binding affinity can be found in Section 3.5.2, Section 3.5.4 
and Section 4.8.4. 
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5.2.6.1 Anti-Lysozyme Aptamer Binding Affinity Assay  
We first started the experiment by determining the optimum amount of protein to be 
added to the well of microtiter plates. Lysozyme is a small and highly basic molecule 
with molecular weight 14kDa and an isoelectric point (pI) around 11. We diluted stock 
lysozyme to a desired concentration and performed the immobilization in 10mM 
sodium bicarbonate buffer pH 9.0. Preliminary studies were performed by preparing 
plates containing two different amounts of lysozyme, 10pmol and 20pmol, and using a 
biotinylated anti-lysozyme DNA aptamer as a reporter probe through the binding 
affinity assay in order to ascertain the optimum amount of lysozyme needed to be added 
to each well. The sequence of the anti-lysozyme aptamer was 5’-ATCTACGAATTCATCAGG 
GCTAAAGAGTGCAGAGTTACTTAG-3’.  
After tracking the amount of biotinylated anti-lysozyme aptamer that formed the 
complex with immobilized lysozyme, it was found that the plate that contained 20pmol 
of lysozyme showed lower signal in ELONA than that of the plate containing 10pmol 
which can be explained in terms of the hook effect and the efficiency of the adsorption 
on hydrophobic polystyrene surface as described earlier (Section 3.5.2). We then 
decided to use 10pmol of lysozyme (144ng) to prepare the plates for ELONA assay 
throughout the lysozyme experiments.  
After preparing the lysozyme plates, various concentrations of biotinylated anti-
lysozyme aptamer were added to each well and after incubating, blocking and washing 
steps, the amount of complex was measure by adding SA-HRP and HRP substrate 
(TMB/H2O2). The binding curve is shown in Figure 5.22. The Kd value was calculated to 
be 45nM by fitting the curve with non-linear curve fit software Origin 8.6, assuming a 
1:1 binding isotherm. The reported Kd of the original RNA anti-lysozyme aptamer was 
31nM and 65nM for non-modified and biotinylated modified lysozyme, respectively 
(Cox and Ellington, 2001). The Kd on other reports on the DNA version of the same 
sequence range from 48nM and 610nM depend on the assay methods (Cheng et al., 
2007; Girardot et al., 2011).  
 
 
 
 225 Proximity Ligation Selection and Bivalent Lysozyme Aptamers 
(a) Anti-lysozyme aptamer 
  ATCTACGAATTCATCAGGGCTAAAGAGTGCAGAGTTACTTAG 
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Figure 5.22 The Kd of biotinylated anti-lysozyme aptamer with lysoyzme was 45nM. a) the sequence of 
anti-lysozyme aptamer; b) 10pmol of lysozyme was coated on microtiter plate wells. Various concentrations 
of anti-lysozyme DNA aptamer were added to each wells and the binding signal was assayed using ELONA. 
 
 5.2.6.2 Full Length LPLS-4 and LPLS-25 Aptamer Binding Affinity Assay 
Two aptamers which were selected from the PLS of two pools with the lysozyme target 
were subjected to a binding affinity test. By using ELONA, 0-100nM aptamer dimers 
were added to each well of the lysozyme coated plates. The binding curves were shown 
in Figure 5.23. In the range of the aptamer dimer used, it appeared that there was no 
binding signal obtained from LPLS-25, which would suggest a very low binding affinity 
for lysozyme. For LPLS-4, a low signal but saturation curve was observed. The calculated 
Kd from the binding curve, assuming a 1:1 binding isotherm, was 9nM. The low 
saturating curve may be understood as the steric blockage of the complex that may 
interfere in the binding of another aptamer as well as limiting the access of aptamer to 
the protein binding site. Considering the size of molecule, lysozyme (around 14.4kDa) is 
almost three times smaller than the aptamer dimer (around 47kDa), the binding on 
immobilized target might not occur as freely as in solution. 
(b) 
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(a) LPLS-4  
AAGCATCCGCTGGTTGACTTGAGAGTGAATCTATCGTGACGTACTGAACCGAATAAAGAATTTGGGCTGCTCTCGT
GGCGTAATATCATCTCGCGAGTAATGGTTATAAGTCGCTCCTCATAGTGGATCTTGGACCCTGCGAA 
 
(b) LPLS-25 
AAGCATCCGCTGGTTGACTAACTATCCCCCTGCAACCGAGTATTTCCTTCACGTTAGGTATTTGGGCTGCTCTCGT
GGCGTATATCGAGTTAGCGTCGACCTCTTATGAGCCGCACTGTGATCTGATCTTGGACCCTGCGAA 
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Figure 5.23 The binding curve of full length of aptamer dimers, a) LPLS-4; and b) LPLS-25 using 
ELONA. The random region of each sequence is shown in bold. c) No binding observed from LPLS-25. The Kd 
of LPLS-4 to the immobilized lysozyme was calculated to be 9nM. 
 
 
 
 
 
 
(c) 
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 The binding of LPLS-4 was confirmed using the SPR. The binding occurred in 
different format by immobilizing the aptamer onto a SA-SPR chip and lysozyme at 
different concentrations were freely flowed above the surface-bound aptamer. The SPR 
chip was prepared as described in Section 2.8.2.1-2.8.2.3. Briefly, 1M of SA was flowed 
over the EDC/NHS activated SPR chip, giving a response on both channels of around 
1600RIU. The amount of SA was calculated to be roughly 1600pg/mm2 over the total 
surface area of 12.5mm2 per channel. The total amount of SA was 20ng or 0.38pmol or 
2.3x1011 molecules per channel. Then, 0.2M of biotinylated LPLS-4 in 10mM PBS was 
injected to only the left channel and run at 10L/min for 25 min. The interaction 
between SA and biotin generated the SPR response of around 880RIU. This number 
was calculated to be equal to 11ng or 0.2pmol or 1.2x1011 molecules of LPLS-4 per 
channel. The molar ratio of aptamer to SA was around 2:1 which was reproducible in 
every experiment. Although the SA has four binding sites for biotin, the electrostatic 
repulsion between the adjacent aptamer resulted in the maximum binding of only two 
aptamers. The sensorgram of binding response was shown in Figure 5.24(a). Each 
sensorgram line represented the differential response between the left and the right 
channel at each concentration of lysozyme. The curve fitting of these data is shown in 
Figure 5.24(b). The Kd was calculated to be 8.7M which was several times higher than 
the constant we obtained from the ELONA method and suggested low binding ability of 
the aptamer dimer. It is quite commonly reported in the literature that different assay 
formats yield quite different apparent affinities. 
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Figure 5.24 a) The binding sensorgram of various concentration of lysozyme to LPLS-4 aptamer 
dimer; b) The binding curve plot between the SPR response (RIU) and the lysozyme concentration. 
The Kd calculated from the binding curve was 8.7M.  
 
5.2.6.3 LPLS-4.1 and LPLS-4.2 Binding Affinity Assay 
Unlike the PLS performed on thrombin, no binding affinity was found in any of the 
selected dimers. The LPLS-4 aptamer showed some sign of binding ability; although the 
Kd obtained from two assays were different (9nM by ELONA and 8.7M by SPR). The 
dimer was comprised of two monomer sequences from F and R pool, which we named 
LPLS-4.1 and LPLS-4.2, respectively. We split the dimer and determined the Kd of these 
two monomers using the ELONA probe assay. The binding curves were fitted to a 
(b) 
(a) 
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hyperbolic curve, assuming a 1:1 binding isotherm. The Kd of LPLS-4.1 was 51.5nM as 
shown in Figure 5.25(a) and the Kd of the second monomer was 35.5nM as shown in 
Figure 5.25(b). The difference in saturating absorbance between the two monomers can 
possibly be explained in terms of binding site accessibility. In the thrombin-PLS case, 
there was no binding observed for any dimers and monomers except TBA29plus. 
Different aptamers can fold differently and so have different fits to their binding sites. 
The immobilization of LPLS-4 through SA-biotin interaction on the SPR chip surface may 
inhibit the formation of its proper structure. The Kd obtained from SPR was high, 
suggesting a low binding affinity, which was different from the result obtained from 
ELONA. In the ELONA method, we assume that the aptamer molecule can freely fold into 
a favored structure once it meets the target and thus can perform binding better than in 
the SPR.  
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Figure 5.25 The binding curve of aptamer monomer (LPLS-4 monomer) using ELONA. The sequence of 
each half is shown on top of each graph. The random region is shown in bold. The constant region includes a 
primer hybridization region (italic) and the oligonucleotide connector hybridization region (highlighted). 
The Kd was calculated to be 51.5nM for LPLS-4.1 (a) and 35.5nM for LPLS-4.2 (b). 
 
 
 
 
(a) LPLS-4.1 (monomer 1) 
AAGCATCCGCTGGTTGACTTGAGAGTGAATCTATCG
TGACGTACTGAACCGAATAAAGAATTTGGGCTGCTC 
(b) LPLS-4.2 (monomer 2) 
TCGTGGCGTAATATCATCTCGCGAGTAATGGTTATA
AGTCGCTCCTCATAGTGGATCTTGGACCCTGCGAA 
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We previously reviewed the potential of the simultaneous binding of a ligand to 
multiple sites of the same target molecule in Section 4.4. This multivalent interaction has 
been reported to increase binding affinity based on its avidity compared with 
corresponding monomers (Fredriksson et al., 2002; Pai et al., 2005; Söderberg et al., 
2006; Jarvius et al., 2007; Gustafsdottir et al., 2008; Fredrikson et al., 2008). The simple 
example that can give a clear picture is the cooperative interaction of antigen and an 
antibody such as IgM. IgM is a low affinity ligand but it mostly presents as a pentamer 
that contains 10 binding sites therefore it has a high avidity. How an avidity function is 
that if one interaction dissociates, the others will remain associated and thus enhances a 
re-association process. In terms of aptamer, the advantage of aptamer dimerization was 
reviewed in Section 4.5. The dimerization enhances the effective local concentration and 
thus improved the binding ability of aptamer to its target.  
In our study, we performed a binding assay of each of monomer component to 
confirm whether the ligated aptamer does have a better binding affinity. By comparing 
aptamer that was assayed by the same ELONA assay format, the Kd of LPLS-4 was 9nM 
while the Kd of the monomers were 51.5nM and 35.5nM. Theoretically, avidity is a 
multiple of the individual affinity constants. Our dimer has a better binding affinity but 
this is not as good as the simple theory suggests. The possible reason for this might be 
related to the folding of the newly ligated aptamer. We used Mfold software (Zuker, 
2003) to predict the possible secondary structures of the selected aptamer. Structure 
prediction is expressed as an energy minimization through thermodynamic parameters. 
The folding was set to perform at 25°C in the presence of 140mM Na+ and 1mM Mg++ in 
binding buffer. There is only one possible Mfold structure of the LPLS-4 aptamer display 
in Figure 5.26. The Gibb’s free energies were shown to be -12.66kcal/mol. Although the 
secondary structure prediction does neglect of tertiary interactions that stabilize 
compact three dimensional structures of sequences (SantaLucia and Hicks, 2004), the 
unique fold of the sequence may suggest a high structural stability. The folding of LPLS-
4.1 has a similar loop size and loop position but LPLS-4.2 folds differently. This folding 
after ligation may destabilize the optimum structure of the monomer and affect the 
binding efficiency.    
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Figure 5.26 The Mfold structures of LPLS-4 and its monomer. The ligated LPLS-4 has a unique folding 
(ΔG = -12.66kcal/mol). The predicted secondary structure of its monomer displayed two possible folding 
patterns of LPLS-4.1 and a single fold of LPLS-4.2. Loop size and loop position of LPLS-4.1 is similar to the 
structure in the dimer but the unique fold of LPLS-4.2 is difference from part of the dimer.   
        
 
 
LPLS-4.1 
LPLS-4.2 
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5.2.6.4 Negative Control Experiment of Binding Affinity Assay 
A nonspecific binding between proteins and nucleic acids commonly occurs through 
electrostatic forces. At physiological pH, lysozyme carries a net positively charge that 
can easily interact with negatively charged DNA molecules. This property makes 
lysozyme an easy target for aptamer selection, however there is a risk of selecting 
nonspecific binders because of the electrostatic interactions. We therefore performed 
two negative control experiments that assayed the binding of ssDNA pool (Figure 5.27) 
and a non-related sequence, TBA29 (Figure 5.28), to lysozyme coated on PS plate. 
ELONA probe was used for the assay. The binding signals were observed, and can be 
possibly due to complementary charge interactions. The signal obtained from the 
binding of TBA29 was higher than the pool. This may explain by higher structural 
variations in starting pool sequences than that of a certain structure of TBA29, which 
would then affect the homogeneous pattern of opposite charged interactions. 
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Figure 5.27 The binding curve of pool and lysozyme. Various concentrations of DNA starting pool were 
added to microtiter plate well coated with lysozyme. The Kd was calculated to be 307nM. The curve showed 
nonspecific binding affinity because the absorbance signal obtained from the reaction of HRP was rather 
low, below 0.1 absorbance unit.  
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Figure 5.28 The binding curve of non-related anti-lysozyme aptamer and lysozyme. Various 
concentrations of TBA29 were added to microtiter plate well coated with lysozyme. The curve showed 
nonspecific binding with the calculated Kd of 311nM. The binding is likely to be mainly from electrostatic 
interactions between opposite charge residues.  
 
 
5.3 Conclusions 
The PLS method was adapted from PLA described by Fredriksson et al. (2002). The 
principle of the PLA is very interesting as the assay provides a higher sensitivity 
obtained from a dual and proximate recognition of probe pairs. The classic example of 
the cooperative interaction is the binding between antigen and antibody. There are also 
several studies that reviewed the potential of multivalent interactions (Fredriksson et 
al., 2002; Pai et al., 2005; Söderberg et al., 2006; Jarvius et al., 2007; Gustafsdottir et al., 
2008; Fredrikson et al., 2008).  
We have developed the PLS based on the PLA strategy. Several protocol 
modifications were carried out in order to select aptamer dimers. Although we did not 
succeed in generating aptamer dimers that had higher affinity than monomers, there are 
several steps in the procedure that could be improved. First, a shorter pool length can be 
used to reduce a difficulty in long sequences amplification and ssDNA generation. 
Second, introducing a few selection rounds and negative selections would increase the 
number of specific dimer aptamers and decrease the amount of membrane bound 
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oligonucleotides. Third, next generation sequencing would help to determine the 
repeated sequences in the pool at low enrichment (Cho et al., 2010). If the PLS is 
success, it would have advantage over the other aptamer selections as the PLS is 
potentially simple and fast.  
  
Chapter 6 
Concluding Remarks and Future 
Work 
 
 
 
The most widely used in vitro selection method to produce nucleic acid aptamers is 
SELEX and it has been demonstrated many times to produce nucleotide-based 
recognition molecules, which can have affinities comparable to monoclonal antibodies, 
and in addition have an ease of synthesis, flexibility and stability. In the first results 
chapter of this thesis, we described selection of aptamers against AChE using a SELEX 
(Chapter 3). Pool enrichment was observed during 15 rounds of selection and the 
aptamer, R15/19, was shown to bind to AChE with a dissociation constant in the pM 
range, but it did not inhibit AChE activity. This would suggest that the aptamer did not 
bind at, or close to the active site of AChE. The application of this R15/19 was then 
explored as a mediator that facilitated AChE immobilization.  
Immobilization of AChE in a site-directed manner was achieved by first 
modifying the surface with streptavidin in order to subsequently assemble the R15/19 
aptamer, which then captured AChE. There was a roughly 4-fold improvement in the 
activity of the immobilized AChE via aptamer capture compared to the direct adsorption 
method (Figure 3.17). In summary, the use of this aptamer as a mediator for a new 
immobilization strategy improved the retention of activity of AChE on the surface 
compared to adsorption. There are a number of reasons that support this role for 
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aptamers. Firstly, the binding affinity is comparable to that of the affinity tags for 
proteins that have been widely used (Takakura et al., 2010; Le et al., 2011). Secondly, no 
additional modification of protein is required. In addition, the reversible denaturation 
property of nucleic acids makes this immobilization approach valuable in sensing 
devices, where we can easily replace the enzyme attached on the aptamer-mediated 
surface by fresh enzyme.  
 Although we successfully selected an aptamer that bound AChE, the entire 
selection process was time-consuming and tedious. Several alternatives as described in 
Section 1.6 (Chapter 1) have been developed to overcome disadvantages of each 
method. For example, the CE-SELEX has been introduced to improve the efficiency of 
partition, allowing the high speed and great resolving power of CE-based separation. 
The number of selection rounds thus reduces significantly. Automated SELEX is another 
example of the effort to perform a faster selection and to work on several samples in 
parallel. The automated selection has been developed by Cox et al. (1998) and was used 
to select anti-lysozyme aptamer (Cox and Ellington, 2001) and anti-aminoglycoside 
aptamers (Goertz et al., 2004). Later, to improve the efficiency of aptamer identification, 
the quality control step was included and performed as a semi-automated selection 
(Eulberg et al., 2005; Wochner et al., 2007). The other example is the development of the 
quantitative selection of aptamers through sequencing (QSAS) by pairing microfluidic-
SELEX (M-SELEX) with high-throughput DNA sequencing (Cho et al., 2010). The QSAS 
significantly improves the selection speed as well as data analysis as this method 
overcomes the limitations of the expense, tedious work in cloning and sequencing 
individual clones and it would very suitable for analysis of the low abundance aptamer 
pools as in PLS-aptamers. The choice of selection method, in practical, depends on 
resources in a lab, scope of the project as well as the budget available.  
We here proposed an alternative selection method that was simple and required 
only a single round of selection. The method called proximity ligation selection (PLS) 
was adopted from the proximity ligation assay (PLA), which is a sensitive method for 
determining protein concentration and protein localization. The combination of two 
known aptamers has already been reported to improve functionality over the monomer; 
therefore the aptamer generated through PLS would possibly include the advantage of 
being a dimer that bound tightly to the target molecule through avidity interactions. 
Two targets, thrombin (Chapter 4) and lysozyme (Chapter 5), were chosen as a model 
 
237 Concluding Remarks and Future Work 
for PLS development. Lysozyme was used in method optimization as it was 
commercially available at low cost and was an easy target for selection due to its 
positively charge in physiological buffer. Several factors were studied including starting 
pool design, DNA to lysozyme ratio, ligation condition and partitioning method. 
Preliminary studies on PLS were performed using a single starting pool and omitted the 
partitioning steps. However, many problems occurred, for example the DNA monomers 
became major amplification products.  
 In the newly developed PLS, instead of using one starting pool, two DNA pools, 
the F and the R pools, have been used. These new pools were designed to have unique 
sequences at the connection region between the two oligonucleotides. The F pool and R 
pool contained only one primer hybridization region at the 5’ end and the 3’ end, 
respectively. This pool designs facilitated the amplification of only the DNA dimer 
(ligated DNA products). The general PLS process, which can be completed within 5 hrs, 
includes 6 steps which are: 
 Binding of mix pools to target through incubation  
 Partitioning of unbound oligonucleotides using nitrocellulose membrane 
filtration 
 Performing ligation reaction 
 Washing non-specific binders either ligated or non-ligated sequences 
 Eluting of specifically bound PLS product 
 Amplifying the PLS product (the 1st and the 2nd PCR amplification) 
The quality control of PLS product was carried out using gel electrophoresis 
where the expected protein-dependent ligation aptamers should have twice the size of 
the starting pools. To some degree, protein-independent ligation can occur. This 
suggested that it was necessary to perform the PLS in the absence of lysozyme and use 
this as an indicator for PCR amplification conditions of the PLS product in sample 
reactions by comparing the number of PCR cycles needed in the presence and absence of 
proteins to reach a defined band intensity. At the chosen conditions, we observed that 
the successive ligated sequences in the presence of lysozyme can be seen after the 1st 
amplification cycle, whereas in the absence of lysozyme, eight PCR cycles of 
amplification in the 2nd PCR was needed for the protein-independent ligation product to 
be observed on the gel. After cloning and sequencing steps, the characterization of 
 
238 Concluding Remarks and Future Work 
binding affinity of an individual aptamer was performed using the ELONA method, 
which offers a quick and simple assay. The Kd of PLS anti-lysozyme aptamers was found 
to be in the M range by SPR. 
Thrombin was the other chosen target as it has a pair of aptamers (TBAs) that 
are among the best characterized. By following the PLS process described above using 
1) the F and the R pool and 2) TBA29plus and the R pool, two PLS product sizes were 
obtained. There were no significant common sequence motif shared among aptamer 
pools, thus we further chose PLS-aptamer dimers based on their primary sequences 
which likely to have four interspersed GG features. Splitting the selected sequences into 
monomers and investigating their folding ability into G-quadruplex structures showed 
that none of them gave CD signatures of a G-quadruplex structure. Although the 
conclusion made based on CD measurement showed no G-quadruplex structure which 
are common for TBAs, it can be misleading to just consider the CD spectrum and 
therefore the direct measurement of binding affinity was performed. Unfortunately, 
there were no binding signals observed from any other sequence neither monomer nor 
dimer in aptamer assays by ELONA. Using the SPR, the Kd of aptamer dimers were 
measured and the Kd of aptamer 2/19-5 and 4/19-7 were in the M range.  
So far we have not successfully obtained high avidity binding aptamers through 
PLS in a single round. We could however generate protein-dependent ligation aptamers 
through our PLS protocol in a higher amounts than that occurred by protein-
independent ligation. There are several factors that limit our current PLS protocol. 
Firstly, this single round of selection is prone to generate the protein-independent 
ligation. This would raise the issue of how to choose the right candidates among artifacts 
and true binders. Secondly, two monomers that bind to target may loss their binding 
property once they are ligated due to a new three dimensional structure of the ligated 
sequence. Thirdly, it is not only important to develop a fast selection method but also to 
speed up the analysis process (e.g. replacing cloning and sequencing by next generation 
sequencing). A new selection strategy has been designed including a few more rounds of 
selection as shown in a flow chart in Figure 6.1. 
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Figure 6.1 A new selection strategy for high avidity aptamers. More rounds of selection are applied. A 
ligation is performed among the binders (not from the starting pool). DNA dimer pool is then used as a new 
starting pool for more selection that aims for high binding avidity aptamers. 
 
This newly proposed strategy may not speed up the selection process but high 
avidity aptamers are possibly obtained using this protocol. Several rounds of pre-
selection before ligation can also be carried out to increase the enrichment of the 
binders. In addition, the selection can be modified by adding a negative selection steps. 
This step would reduce the amount of non-specific binding sequences.  
To achieve the selection, another important factor that needs to be considered is 
the nature of the starting pool. From our previous PLS trial, to avoid the interference 
from DNA sequence monomers that co-amplified with the ligation products, we used F 
and R pools that can be amplified only in the ligation form (Figure 5.8). A starting pool 
that can be used with the new protocol should be amplifiable either in the monomer or 
dimer format. To support this idea, starting pools are re-designing as shown in the 
schematic diagram in Figure 6.2.  
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Figure 6.2 New starting pools which are designed for the aptamer ligation selection. The short 
monomer pools and dimer (ligation pool) can be amplified using different set of primer pair. This can 
reduce the co-amplification of monomer molecules after ligation process. 
 
Nonetheless, one limitation of using long DNA sequences is the difficulty in 
ssDNA production since the price of the synthesis of DNA over 100 bases is expensive 
and what we observed when we performed our own ssDNA preparation was that the 
ligated sequences tended to form secondary structures leading to aggregates and 
becoming retained in the wells during polyacrylamide gel purification. In some cases, a 
formamide gel needs to be used instead of a urea gel. The shorter random pool might be 
used in the PLS case. Although the short random pool has less complexity than the 
longer one, the PLS, by generating a longer product, may compensate for this.  
Alternatively, to improve the binding ability of the selected oligonucleotides, 
error-prone PCR (Bittker et al., 2002) can be used to generate a small diverse pool out of 
the first PLS-pool. This pool will compose oligonucleotides that potentially have the 
desired binding property and oligonucleotides that have weaker binding abilities are 
later removed through stringent washing. Affinity maturation selection using a PLS pool 
for a second round of selection will therefore generate a successive PLS aptamer 
selection in two rounds. The whole process should not take longer than a few days. And 
if by any chance multiple pools (having different primer pair set) are used, multiple 
selections can be performed in parallel.   
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Appendix A 
Sequences of Anti-AChE Aptamers from Round 15 
 
This appendix shows the complete sequences of the inserted sequences of anti-AChE 
aptamers from Round 15. The random regions are shown in bold, flanking by constant 
primer regions, which are shown in italic. The sequence alignment is illustrated in 
Chapter 3 (Figure 3.7). 
Table A Sequences of anti-AChE aptamers from Round 15 
Name Sequence 
R15-1 AaGCATcCGctgGTTGACATGCCCCacCCCTTgcACGACGTaGACATTCGTCTTTTTGAGATCTTGGA
CCCTGC 
R15-2 AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-3 aAGCATCCGCTGGttgaCCCCACCCACTCTACTGATGCGCTTACTGCTCCCACCCCTATGATCTTGGA
CCCTGC 
R15-4 AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-5 AAGCATCCGCTGGTTGACCCCACCCACTCTACTGATGCGCTTACTGCTCCCACCCCTATGATCTTGGA
CCCTGC 
R15-6 AAGCATCCGCTGGTTGACAACGGGTGCCCGGTCGTGTGGGGGTTGACTGTAGCTCTGGCAGACGTAGT
GTGAAGGTACCCGCTATTGGGATCTTGGACCCTGCGAA 
R15-7 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-8 
AAGCATCCGCTGGTTGACCGCGCCGCACCACCACTTGGACCCGCTCCCGTTCGTTCGGAGATCTTGGA
CCCTGCGA 
R15-9 
AAGCATCCGCTGGTTGACGGCCCGGCCCAACCTATCCTCGTAACTACCTCCAGGCCCCTCGatCTTGG
AC 
R15-10 
AAGCATCCGCTGGTTGACGATGCCCGAgtCCTGTTgGTTCTTGCCACCCGCCACCGTTCGATCTTGGA
CCCTGCGAT 
R15-11 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-12 
ATCCGCTGGTTGACCCCACCCACTCTACTGATGCGCTTACTGCTCCCGCCCCTATGATCTTGGACCCT
GCGAA 
R15-13 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-14 
AAGCATCCGCTGGTTGACCGCATACCTCTCCAATCTCCGTTTACTGCACCTAATCACCTGATCTTGGA
C 
R15-15 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-16 
AAGCATCCGCTGGTTGACAAAGGAGTGCGTGCGACGTGTAGTGTGTGGGGGGTGTGTTGGATCTTGGA
CCCTGCGAA 
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Table A (continue) Sequences of anti-AChE aptamers from Round 15 
Name Sequence 
R15-18 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-19 AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-20 AAGCATCCGCTgGttGactGTAGCTCTGGCAGACGTAGTGTGAAGGTACCTGCTGTTGGGATCTTGGA
CCCTGCGAA 
R15-21 AAGCATCCGCTGGTTGACGGCCGGCCCAACCTATCCTCGTAACTACCTCCAGGCCCCTCGATCTTGGA
CCCTGCGAA 
R15-22 AAGCATCCGCTGGTTGACGGCCGGCCCAACCTATCCTCGTAACTACCTCCAGGCCCCTCGATCTTGGA
CCCTG 
R15-23 AAGCATCCGCTGGTTGACTCCGCCCATTTGTCTCAGCAACACGCTGTACGTTACGAACTGATCTTGGA
CCTTGCAA 
R15-24 
AAGCATCCGctgGtTgacCCCACCCACTCTACTGATGCGCTTACTGCTCCCACCCCTATGATCTTGGA
CCCTGC 
R15-25 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-26 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-27 
AAGCATCCGCTGGTTGACAGTGCACCGGTCGAAACCCTTATGCCGAACGAGTGGTAGCCGATCTTGGA
CCCTGCGAA 
R15-29 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-30 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-31 
AAGCATCCGCTGGttGACCCcgtAgtACCCTCCCACCTCCTGATCCGctgGTTGACCAAGCCCCCCCT
TCGGCTCTTCTGTTGTTTACGCTCCAAGCGATCTTGGACCCTGCGAA 
R15-32 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-33 
AAGCATCCGctgGttGACCGTTTTCACAATCTAGTTTGGGGTATTATAACCAGCGGGCTGATCTTGGA
CCCtgCGAA 
R15-34 
AAGCATCCGCTGGTTGACGAACCATCCCACGCAGGCCCACCATTTGTCCCTTTCTCCTCGATCTTGGA
CC 
R15-35 
AAGCATCCGctgGTTGACGAAGGCCCCATTCTCTGAGCCCCTTAGCTTGGCCGCCCGCtgATCTTGGA
CCCTGCGAA 
R15-36 
AaGCATCCGCTGGttGaCCGAATTGCCCCATTCGCCGGCTTCCCTTCCCGCAGGCCTCAGATCTTGGA
CCCtgCGAA 
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Table A (continue) Sequences of anti-AChE aptamers from Round 15 
 
Name Sequence 
R15-37 
AAGCATCCGCTGGTTGACGGCCGGCCCAACCTATCCTCGTAACTACCTCCAGGCCCCTCGATCTTGGA
CCCTGCGAA 
R15-38 AGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGAC
CCTGCGAA 
R15-39 AAGCATCCGCTGGTTGACATGCCCCACCCCTTGCACGACGTAGACATTCGTCTTTTTGAGATCTTGGA
CCCTGC 
R15-40 AAGCATCCGCTGGTTGACGGCCCCATCCCTAACTGAAGTCCCATCCGTAGCCCCGTGATGATCTTGGA
CCCTGCGAA 
R15-41 AAGCATCCACTGGTTGACTTTCTTCTACGCATTGACTCCCTCTCCACCCTCATCGGCTTGATCTTGGA
CCCTGCGAA 
R15-42 AAGCATCCGCTGGTTGACTCCGGGGTGGGACGCCGGGCCTCGTCCGGGAGAGCGCGTTAGATCTTGGA
C 
R15-43 
AAGCATCCGCTGGTTGACGCACTCAAGCCTACAAACGCGCCCCCACTGTACGCACACATGATCTTGGA
CCCTGCGAA 
R15-44 
AAGCATCCGctgGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-45 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTGGGATCTTGGA
CCCTGCGAA 
R15-46 
AAGCATCCGCTGGTTGACTGTAGCTCTGGCAGACGTAGTGTGAAGGTACCAGCTATTGTGATCTTGGA
CCCTGCGAA 
R15-47 
AAGCATCCGCTGGTTGACCCCTTCTTTTCTCACACCCTTTGCGCCTCACCACCCTTTGAGATCTTGGA
CCCTGCGAA 
R15-48 
AAGCATCCGCTGGTTGACCACGCCATGCACAGGAAGCGTTTTGACGGTGGCTCTTGGCTGATCTTGGA
CCCTGCGAA 
R15-49 
AAGCATCCGCTGGTTGACTGTGGCTCTGGCAGACGTAGTGTGAAGGTACCCGCTATTTGGATCTTGGA
CCCTGCGAA 
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Initial Rate Velocity Curve of AChE Activity in the Presence and Absence                              
of Aptamer Pools 
 
AChE activity and AChE inhibition assays are performed by followed its initial rate 
velocity using Ellman’s colorimetric method. The rate of AChE activity is linear and can 
be fitted with linear fit function in Origin 8.6 program.  
The linear equation is y = mx + b, where the constant ‘m’ determines the slope 
and the constant ‘b’ defines y-intercept. The fitted curve equation is shown next to the 
graph. The AChE activity is calculated from the slope (Section 2.7.2.1). Each graph 
illustrates, in comparison, the initial rate velocity of the AChE in the absence and 
presence of aptamer pool.  
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Figure B.1 AChE activity in the absence of aptamer pool () and in the presence of starting DNA pool 
() 
 
 
 
263 Appendices 
Appendix B (continue) 
Initial Rate Velocity Curve of AChE Activity in the Presence and Absence                              
of Aptamer Pools 
0 50 100 150 200 250 300
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
y= 0.00396x + 0.35878
 AChE + Round 4 DNA pool
AChE + no aptamerA
4
1
2
Time (Sec)
y = 0.00394x + 0.35509
 
Figure B.2 AChE activity in the absence of aptamer pool () and in the presence of round 4 DNA pool 
() 
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Figure B.3 AChE activity in the absence of aptamer pool () and in the presence of round 7 DNA pool 
() 
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Figure B.4 AChE activity in the absence of aptamer pool () and in the presence of round 10 DNA 
pool () 
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Figure B.5 AChE activity in the absence of aptamer pool () and in the presence of round 15 DNA 
pool () 
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Figure B.6 AChE activity in the absence of aptamer pool () and in the presence of 40nM R15/19 
DNA () 
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Figure B.7 AChE activity in the absence of aptamer pool () and in the presence of 100nM R15/19 
DNA () 
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Figure B.8 AChE activity in the absence of aptamer pool () and in the presence of 200nM R15/19 
DNA () 
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Sequences of Proximity Ligation Selection Product: Selection against Thrombin  
 
This appendix shows the complete sequences of the inserted sequences of anti-
thrombin aptamers obtained from proximity ligation selection (PLS). Table C.1 shows 
the sequences from control experiment between TBA29plus and R-pool. The constant 
regions, which are primer binding sites and connector oligonucleotide binding site, are 
shown in italic. The TBA29plus sequence is underlined and the random region from R-
pool is shown in bold. Table C.2 shows the proximity ligation product from PLS between 
F-pool and R-pool. Two random regions are shown in bold and constant regions are 
shown in italic. The sequence alignment is illustrated in Chapter 4 (Figure 4.13 and 
Figure 4.15). 
 
Table C.1 The proximity ligation product from PLS between TBA29plus and R-pool 
against human -thrombin 
Name Sequence 
4/19-1 
AAGCATCCGCTGGTTGACCaGTCCgTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATATCCTGTGCACTTCGACGTAGTGTAAGGGCGACTCGACATGTGATCTTGGACCcTGCGAA 
4/19-2 AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATATAATTTTGATGCCCACATACTCACGCCGCCTGCATTTAGGAGATCTTGGACCCTGCGAA 
4/19-4 AAGCATCCGCTGGTTGACcaGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATAGCAGCACAGGTTAGGTAGTCTTAAACCACAGGCGTCCgTCTGATCTTGGACCCTGCGAA 
4/19-5 AAGCATCCGCTgGTTGACcaGTCCGTGgtAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATAAGGGTGGATATCACCAACATAAACGTGTATGGTTCGGACCaGATCTTGGACCcTGCGAA 
4/19-6 AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATAGGGCGATAGTGCGGCGGATCAGACTTTGCAGTCAGACGATAGATCTTGGACCCTGCGAA 
4/19-7 AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATACGGGTACATGCGGACAATGAGGATGGAGGGGGTGCACCACAGATCTTGGACCCTGCGAA 
4/19-8 
AAGCATCCGCTGGttGaccaGTCCgTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATATTGTTAGGCATCTATAATTTGGGAGAGGCCCTATATCGGCGGATCTTGGACCcTGCGAA 
4/19-9 
AAGCATCCGCTGGTTGACcaGTCCgTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATACCCGCAGGTGATGTATTGAATGTCGCACAAATAGCGGATGCGATCTTGGACCcTGCGAA 
4/19-10 
AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGAGTGACTATTTGGGCTGCTCTCGTGGC
GTAATATTCGTGGTTGGAAGGAGCCCATTTAATCTGCACCGAGAAATGATCTTGGACCCTGCGAA 
4/19-11 
AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCATGGC
GTAATATCTCTGCAACCCGTTACCAAACCCCATCTCGGTAGAGACGTGATCTTGGACCCTGCGAA 
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Table C.1 (continue) The proximity ligation product from PLS between TBA29plus 
and R-pool against human -thrombin 
Name Sequence 
4/19-13 
AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATAGAGCATGATGTATCAGCGTACACCCCGTGCCCACCGCGGTGGATCTTGGACCCTGCGAA 
4/19-14 
AAGCATCCGCTGGTTGACTAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATAACTGGAGGGCCAAACCGACGTACTCCCAATTCTCCCCAACGATCTTGGACCCTGCGAA 
4/19-15 
AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATAGTCTATTAATCCTGAAGGCATCTGAAAGGTGAGTTTGGCAAGATCTTGGACCCTGCGAA 
4/19-16 
AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATATAAGTACAGTAAACGCTCACCCGATCTTGTTCCTTCCAATTGATCTTGGACCCTGCGAA 
4/19-17 
AAGCATCCGCTgGTTGACcaGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATATGATAACGAGCTGGGGAAACCCGCCCCAGGCCACGTGCCAAGATCTTGGACCcTGCGAA 
4/19-18 
AAGCATCCGCTGGTTGACCAGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATATTTCTGAGGCTGTGGACATTCCTCGACAACCACGGGAAAATGATCTTGGACCCTGCGAA 
4/19-20 
AAGCATCCGCTgGTTGACCaGTCCGTGGTAGGGCAGGTTGGGGTGACTATTTGGGCTGCTCTCGTGGC
GTAATATTCCCTGGGAGAGCAGACCCGGTCAATTAGAGGCGTTGAAGGATCTTGGACCcTGCGAA 
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Table C.2 The proximity ligation product from PLS between F-pool and R-pool 
against human -thrombin 
Name Sequence 
2/19-1 
AAGCATCCGCTgGtTGACAGGGCTTAAGGTCCAACTTGCGTGTATACAGGTAGGTACCCATTTGGGC
TGCTCTCGTGGCGTAATATTCTATGGACGGTCATTTTCCTCCAAGTTGTTTCCGACctCGATCTTGG
ACCcTGCGAA 
2/19-2 
AAGCATCCGCTGGTTGACCCGTTCGCGCAATGTCATGGACACGACACGTTTTTAACCCCATTTGGG
CTGCTCTCGTGGCGTAATAACTTAATTTTTGCATAATAGACAGATTCTACAGTTCATCCTGATCTT
GGACCCTGCGAA 
2/19-3 
AAGCATCCGCTGGTTGAcGAACCCCATCTGAATCATTGTGTTTACCGGAAAGAAACACCATTTGGG
CTGCTCTCGTGGCGTAATAGGGTACTGGAAACACGCCATATCActAAGAAATTGGACTTTGATCTT
GGACCCTGCGAA 
2/19-5 
AAGCATCCGCTGGTTGACACGCCCTCACGAAGGACGTTTTGCGCTCAGGGATAAAACAAATTTGGG
CTGCTCTCGTGGCGTAATAAACCTTTGCAAGGGTCAGGTGGGGTCTAGGCTTATTAGTGGGATCTT
GGACCCTGCGAA 
2/19-6 
AAGCATCCGCTGGTTGACCGCATAACTGAGTCGGGTAATAGGAGTGATGAGTGTTAGTAATTTGGG
CTGCTCTCGTGGCGTAATACGATCCTCCTTAGAGGTGGCAAAGCGGGGTTTTCGTGCCAAGATCTT
GGACCCTGCGAA 
2/19-8 
AAGCATCCGCTgGTTGACATAGACCTTGcCACGCCgTCGCTCTGGGGACGATCTAAgtAATTTGGG
CTGCTCTCGTGGCGTAATAACCTTGGGACCTTTCGTGTAATCTTATAATCCCGGTACTTTGATCTT
GGACCcTGCGAA 
2/19-9 
AAGCATCCGCTGGTTGAcGGGTTGATTTGGATGCGTTGATCGGTGATCCTGTATAATACATTTGGG
CTGCTCTCGTGGCGTAATAGTAATAGAACTGCTGGATATCTCAAAACTCGGTCAACAGCTGATCTT
GGACCCTGCGAA 
2/19-10 
AAGCATCCGCTGGTTgaCCAGGagAAAATAAACGTACTCTTATACGTTTCTCGAATATAATTTGGG
CTGCTCTCGTGGCGTAATACGATTTCACGCGTCCCCTATCATTTAGAAATGTCGACGACGGATCTT
GGACCCTGCGAA 
2/19-11 
AAGCATCCGCTGGTTGACACATCGCATACTGACGCGCCGATACCGAAGCTATTCCGTCTATTTGGG
CTGCTCTCGTGGCGTAATATCGAACTCGCACTGGAAGAACCACGTATAATTAAGTGGTACGATCTT
GGACCcTGCGAA 
2/19-12 
AAGCATCCGCTGGTTGacGCCtTGTGTAAGTCAGGGACGAGGTCTACGTCGATGATCGTATTTGGG
CTGCTCTCGTGGCGTAATAAAGAGTTCGAATCATGCACCgTCAGTACACAGAGACGTGACGATCTT
GGACCCTGCGAA 
2/19-13 
AAGCATCCGCTgGTTGACGCCaGATTGCCACGGCATTCCCCCGGGCATTACTCATAAGCATTTGGG
CTGCTCTCGTGGCGTAATAATCATCTTGTGCATTCCCTCGTTTGTAGACCGGTTGGCATGGATCTT
GGACCctGCGAA 
2/19-14 
AAGCATCCGCTGGTTGACCTCGCCTCGTCCTCTCACGTATGCAGGCGCGGACGCGGCAAATTTGGG
CTGCTCTCGTGGCGTAATAACCGAGCAGGGCAAGACTTTCTTCTATTAGTCAGCCTTTCTGATCTT
GGACCcTGCGAA 
2/19-15  
 
AAGCATCCGCTgGTTGaCACGAAGttaATGCCATGACATCTAAGGACTGGAGATTTGTTATTTGGG
CTGCTCTCGTGGCGTAATAAAGTGCGCAGGGTATTCTCTAGTGTTGCTACTTCACAAATGGATCTT
GGACCcTGCGAA 
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Table C.2 (continue) The proximity ligation product from PLS between F-pool and 
R-pool against human -thrombin 
Name Sequence 
2/19-16 
AAGCATCCGCTGGTTGACCAAATTGAATCTCTTGGTCCACAGATAGCTGCAAACTGATCATTTGGG
CTGCTCTCGTGGCGTAATATATCTCTTTTACCTCAACACAAAGTGTGGCTAGAGCGCCCAGATCTT
GGACCCTGCGAA 
2/19-17 
AAGCATCCGCTgGTTGaCGTGAAGGTACGAGACACCCGAATCTTTTGTCGGTATATTACATTTGGG
CTGCTCTCGTGGCGTAATATTATTCGGGTGAAGAGGCCCAGCAAAGCCCTTTTAGTCCCTGATCTT
GGACCCTGCGAA 
2/19-18 
AAGCATCCGCTGGTTGACcaGGAGAAAATAAACGTACTCTTATACGTTTCTCGAATATAATTTGGG
CTGCTCTCGTGGCGTAATACGATTTCACGCGTCCCCTATCATTTAGAAATGTCGACGACGGATCTT
GGACCCTGCGAA 
2/19-19 
AAGCATCCGCTGGTTGACTTGGGCGTATCCAATATGCTCTATAGGGCAATTTTCAGAGAATTTGGG
CTGCTCTCGTGGCGTAATAAGCAGGGCATCGTTTCAAAACCTTCGGTGGCAGTCGGGCGTGATCTT
GGACCCTGCGAA 
2/19-20 
AAGCATCCGCTGGTTGAcgGctTTtTatGTActGacaaTAGacatctGTtGCTaatcGGATTTGGG
CTGCTCTCGTGGCGTAATAaTGTGTtacCTtGATCCCTGGAGTCTGTTTGGGACGCGGTCGATCTT
GGACCCTGCGAA 
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This appendix shows the complete sequences of the inserted sequences of anti-lysozyme 
aptamers obtained from PLS method. Table D shows the proximity ligation product from 
PLS between F-pool and R-pool against lysozyme. Two random regions are shown in 
bold and constant regions are shown in italic. The sequence alignment is illustrated in 
Chapter 5 (Figure 5.20). 
 
Table D The proximity ligation product from PLS between F-pool and R-pool 
against lysozyme 
Name Sequence 
LPLS-1 
AAGCATCCGCTGGTTGACCATAATCGAAGATGACACTACACGGGTTTATTGAAGTACACATTTGGGCT
GCTCTCGTGGCGTAATATTCCTGTTCAACAAACGAGAACCCTGACGTGTTTATAGGCGATCTTGGACC
CTGCGAA  
LPLS-2 
AAGCATCCGCTGGTTGACACTAGACCTTATGCCACGGGAATGGAGACACACCTCTAAACATTTGGGCT
GCTCTCGTGGCGTAATACGGGGTTGGCTCTGACATGTCTATCTATTATAGGTCGCGCGATCTTGGACC
CTGCGAA 
LPLS-4 
AAGCATCCGCTGGttGAcTTGAgagtGAATctaTCGtgAcgtactGAACcgaaTAAaGAATTTGGGCT
GCTCTCGTGGCGTAATAtcatctcgcgaGTAATgGtTatAagtcgctCCTCatagtgGATCTTGGACC
CTGCGAA 
LPLS-5 
AAGCATCCGCTGGTTGACCCTCGTTTGTCTGCCAGATCGCAGCTGGGTACACGGAACATATTTGGGCT
GCTCTCGTGGCGTAATATGTAGGGATATCTGGACAATACTGTCCACCGGTTTATTTTGATCTTGGACC
CTGCGAA 
LPLS-6 
AAGCATCCGCTGGTTGACACCGTGATAGCAAAGCTGTTCTTACCTATCCTTGGTCTTGCATTTGGGCT
GCTCTCGTGGCGTAATAAACGTTATGTTACGGGGGCCCAGGCTACGTCTTTACCAGCGATCTTGGACC
CTGCGAA  
LPLS-8 
AAGCATCCGCTGGtTGaCAAggtgGGGTAACGGTGCATCTCCCGCAACTGCTCTCCgtgATTTGGGCT
GCTCTCGTGGCGTAATAGTTCCTAGTGCTCGTGTGTTACGTATCAGCCTTATAACCTGATCTTGGACC
CTGCGAA 
LPLS-9 
AAGCATCCGctGGttgaCAAGTTTATaAACAACTCTTCTATCCTGGGCTATTTTCAAACATTTGGGCT
GCTCTCGTGGCGTAATAGCAAGTTACTCGAAATTCTACAGgtgTATGATGTAATCATGATCTTGGACC
CTGCGAA 
LPS-10 
AAGCATCCGCTGGTTGACTCAGCACTCTACTCTTGGCCTGTTTGTTGCTAAAGGCGATTATTTGGGCT
GCTCTCGTGGCGTAATAATTAATTGTCACGGGCGCAACCATGCAACAGGATGGCACCGATCTTGGACC
CTGCGAA  
LPLS-13 
AAGCATCCGCTGGtTGACGACTCCCGGAGTTCATATGGTCTCGGATAAGATCTCGGCGCATTTGGGCT
GCTCTCGTGGCGTAATATAGGAGCCCTAATGCCAGAAGAAAGAAACGATATAGTATGGATCTTGGACC
CTGCGAA 
LPLS-15 
AAGCATCCGCTGGTtgaCAGTCCACGTCGTTTGGGTACAGAGATTCATTAGAGTTTGTTATTTGGGCT
GCTCTCGTGGCGTAATACCTTTCGTATTCTGGTTGTTCATACCCTTATAACGACGAAGATCTTGGACC
CTGCGAA 
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Table D (continue) The proximity ligation product from PLS between F-pool and 
R-pool against lysozyme 
Name Sequence 
LPLS-16 
AAGCATCCGCTGGTTGACGGCGATTTCAGTACGTGCTTCCTAGGCATCGGGATAATGCAATTTGGGCT
GCTCTCGTGGCGTAATATGCTAAGCCTGGCACGCCGTTTTATTGAAATCCCGTCGTCGATCTTGGACC
CTGCGAA 
LPLS-17 
AAGCATCCGCTGGTTGACAAGTAGACGGGCCCCCGCTTTGACATGTCGAACGCTACGGTATTTGGGCT
GCTCTCGTGGCGTAATAACGTTGTGTTGGCCATCTTAGCAAACTACATAATTTTCGCGATCTTGGACC
CTGCGAA 
LPLS-18 
AAGCATCCGCTGGTTGACTATACCCCTGGCATTCCAGCAGAAGACGCGTTAGTACACGAATTTGGGCT
GCTCTCGTGGCGTAATATTATAGTGTGGTGCTTTTATAAGACGTGTGGAGGCGTAATGATCTTGGACC
CTGCGAA  
LPLS-19 
AAGCATCCGCTGGTTGACCCGCTCGCGTTCGAAGAAGGACGTCCGCTGGAAGTTTTGTGATTTGGGCT
GCTCTCGTGGCGTAATATTAGCAAATTACTTTCAGCTGTGTCGTGGGGCACAACAAGGATCTTGGACC
CTGCGAA  
LPLS-20 
AAGCATCCGctgGtTGaCTGCCCtgATTACGCgtACTATATGCCGTCAACGTTTCTGGAATTTGGGCT
GCTCTCGTGGCGTAATAGTTCTTTTCTAGCACACAACACACATGTGAACTAATGTCTGATCTTGGACC
CTGCGAA  
LPLS-22 
AAGCATCCGCTGGTTGACGTGTGTTTGTGGGAAAACGGGCCAGTCGAATAGCCGAGACAATTTGGGCT
GCTCTCGTGGCGTAATACTAACCAACCTGCACTGTATACATACGTCTTTTGTGCACAGATCTTGGACC
CTGCGAA 
LPLS-23 
AAGCATCCGCTGGTTGACTCGATGAGGGCAATTCGTTAATTAGATACCTACGAATTTTATTTGGGCTG
CTCTCGTGGCGTAATAGAAAAATTGTGGAGCGGTCTTGGAGCGGTACAGGCAAAAGGATCTTGGACCC
TGCGAA 
LPLS-24 
AAGCATCCGCTGGTTGACCTTCAATTACGTTCCAACAAAATTCGGCAGGTCACTACGATATTTGGGCT
GCTCTCGTGGCGTAATATCTCAATCATTTTCTGGCTTATGCGGTAGCATACACCAAAGATCTTGGACC
CTGCGAA 
LPLS-25 
AAGCATCCGCTGGTTGACTAACTATCCCCCTGCAACCGAGTATTTCCTTCACGTTAGGTATTTGGGCT
GCTCTCGTGGCGTATATCGAGTTAGCGTCGACCTCTTATGAGCCGCACTGTGATCTGATCTTGGACCC
TGCGAA  
LPLS-27 
AAGCATCCGctGGttgacTATTCGATGAATGGAGAAGACTAGTTTGCCAACGCTCACACATTTGGGCT
GCTCTCGTGGCGTAATAAGGGGAAAGTCATTATAATGATCGACGTAACAATTTTCTGATCTTGGACCC
TGCGAA 
LPLS-29 
AAGCATCCGCTGGtTGACTGAATACTCGCTCAACAGCGTTATAGctACCTGATCCCGGAATTTGGGCT
GCTCTCGTGGCGTAATAACCTTCTCCGCCAACTCTGATATAGGTTTCATAATTGGTTGATCTTGGACC
CTGCGAA 
LPLS-31 
AAGCATCCGCTGGTTGACGCCCGGTTAAACAGGCATCTATGGTCGCATATGCAGAGGTGATTTGGGCT
GCTCTCGTGGCGTAATAGTGATTATTCGTGGTCGCTGATTCGTGAACTTCTATTTTAGATCTTGGACC
CTGCGAA  
LPLS-32 
AAGCATCCGCTGGtTGACGACATCATTGTATTTCTCATCACTGATACATTACTATCTCCATTTGGGCT
GCTCTCGTGGCGTAATACAAAGCACAAATTTCAGTTCATCACGCACACTAGGTTGATGATCTTGGACC
CTGCGAA 
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Table D (continue) The proximity ligation product from PLS between F-pool and 
R-pool against lysozyme 
Name Sequence 
LPLS-33 
AAGCATCCGCTGGTTGACGATCAATGCCATTTTCATTAATCCTACCCTACAGATAAGGCATTTGGGCT
GCTCTCGTGGCGTAATACCTCAAAAGATTCTTTAACCCCATCCGCTCTAGAAATGCCGATCTTGGACC
CTGCGAA  
LPLS-34 
AAGCATCCGCTGGTTGACGTGACATATAAGCCGGGGATTATAGGATTTTATCTAATACAATTTGGGCT
GCTCTCGTGGCGTAATATGATAATCCGACAATCCTGCTTCTCTCAACCACGATGCTTGATCTTGGACC
CTGCGAA 
LPLS-37 
AAGCATCCGCTGGTTGACTTGAGAGTGAATCTATCGTGACGTACTGAACCGAATAAAGAATTTGGGCT
GCTCTCGTGGCGTAATATCATCTCGCGAGTAATGGTTATAAGTCGCTCCTCATAGTGGATCTTGGACC
CTGCGAA 
LPLS-38 
AAGCATCCGCTGGtTGACTagnaatcaAgTATCATGACGAGCCCAACACACACCGcaggATTTGGGCT
GCTCTCGTGGCGTAATACGGATATGATGAACGATGTCCTACCCATGCGGtgAAATATGATCTTGGACC
CTGCGAA 
LPLS-39 
AAGCATCCGCTGGTTGACCTTGGATCCTGTTTGATGTCCTCCGTTCACTCCGGGCTTGCATTTGGGCT
GCTCTCGTGGCGTAATACATGGCGATTAGAAGTGCGAGCGAAAACAGACAAGGGTGTGATCTTGGACC
CTGCGAA 
LPLS-40 
AAGCATCCGCTGGTTGACACTCTGATTCACGCCATATGACAGGAGTGTATTTTAATTTCATTTGGGCT
GCTCTCGTGGCGTAATATAAGGTCCGCATCACGAAGTTTTGGTGTGATTAGTGCAGGGATCTTGGACC
CTGCGAA 
LPLS-41 
AAGCATCCGCTGGTTGACACCGGCCGACATCAGCAGCATTATTCGCGTGGGTATAATTGATTTGGGCT
GCTCTCGTGGCGTAATATACAGAGGAAAGAGAACTAAAGGGCGGTTTTGATTAACAGGATCTTGGACC
CTGCGAA 
LPLS-42 
AAGCATCCGCTGGTTGACGGCAAATATGCACTAGCCTCGAGAATAAACCACCTGACAATATTTGGGCT
GCTCTCGTGGCGTAATACCGCAGATCGGCGTGCGGAATCTACCCAATATTTACGTAAGATCTTGGACC
CTGCGAA 
LPLS-43 
AAGCATCCGCTGGTTGACAAGGATTTGGTTTCAGCTCAACCTGTCAGGTGCTGTCTCGCATTTGGGCT
GCTCTCGTGGCGTAATATGGGGAAATGGTTATTCTATGCTGTGTTGTCAACGGCTGATCTTGGACCCT
GCGAA  
LPLS-45 
AAGCATCCGCTGGTTGACTAACTATCCCCCTGCAACCGAGTATTTCCTTCACGTTAGGTATTTGGGCT
GCTCTCGTGGCGTATATCGAGTTAGCGTCGACCTCTTATGAGCCGCACTGTGATCTGATCTTGGACCC
TGCGAA 
LPLS-46 
AAGCATCCGCTGGTTGACACATATATTACGGTTGACGATGTCACGTGGAACCTCATCACATTTGGGCT
GCTCTCGTGGCGTAATATATTTCTGTTATGCGGAGACCGCGATTTAACCGCACCTACGATCTTGGACC
CTGCGAA 
LPLS-47 
AAGCATCCGCTGGttgaCGTACATCCGGCGCTCCGACGTATAGTAACGCCTCGACTGAGATTTGGGCT
GCTCTCGTGGCGTAATATAACATCACTAGTATCCATGGGGTCAGGTTACTGCGGGGTGATCTTGGACC
CTGCGAA 
 
 
 
 
 
 
274 Appendices 
Appendix D (continue) 
Sequences of Proximity Ligation Selection Product: Selection against Lysozyme 
 
Table D (continue) The proximity ligation product from PLS between F-pool and 
R-pool against lysozyme 
Name Sequence 
LPLS-48 
AAGCATCCGCTGGTTGACGTCATTGAAGAGCGACCGTGTGATGAGACAGATTATCTACTATTTGGGCT
GCTCTCGTGGCGTAATATATTGAGAGTTTCTTGCTTCACCGCATCGAATGACCCCAAGATCTTGGACC
CTGCGAA 
LPLS-49 
AAGCATCCGCTGGTTGACACCGAAATTTTACACTCCGCTAACTCTTCTTAATCTGTTTCATTTGGGCT
GCTCTCGTGGCGTAATATTTCGACAGGAACACACCGTTCAAGGTTACCGGATATATTGATCTTGGACC
CTGCGAA 
LPLS-50 
AAGCATCCGCTGGTTGACCCTGAGACGGGGGCAGAAGGATTGGATCATATATCACATTAATTTGGGCT
GCTCTCGTGGCGTAATAGTGGCACAGTTTGATCTAACCGTGGGCATTTGAAAAGTCAGATCTTGGACC
CTGCGAA 
 
 
 
 
 
 
